Supplement to

Thorax

The Journal of the British Thoracic Society

VOLUME 52

President: K PROWSE

Executive Editors: J R Britton and A J Knox
Associate Editors: N C Barnes, P A Corris, M W Elliott, J A Fleetham, N M Foley, B G Higgins, N Høiby, S A Lewis, D F Rogers, P D Sly, D P Strachan, W S Walker, R J D Winter
Technical Editor: Elizabeth Stockman
Editorial Assistant: Hilary Hughes

Advisory Board

S H Abman *USA*
J H Alpers *Australia*
N Ambrosino *Italy*
J N Baraniuk *USA*
P J Barnes *UK*
E D Bateman *South Africa*
R Beasley *New Zealand*
L Brochard *France*
A S Buist *USA*
P S Burge *UK*
D B Coultas *USA*
S-E Dahlen *Sweden*
P-P B Ernst, *Canada*
D M Geddes *UK*
P Goldstraw *UK*
C Haslett *UK*
J C Hogg *Canada*
G J Laurent *UK*
F D Martinez *USA*
K S Naunheim *USA*
S Nava *Italy*
A J Peacock *UK*
C Persson *Sweden*
G Rizzato *Italy*
R M Rudd *UK*
C M Smith *USA*
M J Tobin *USA*
S T Weiss *USA*
A Wells *New Zealand*
M Woodhead *UK*
Editor, *BMJ*

BMJ Publishing Group

VOLUME 52 · AUTHOR INDEX

Key: A = Abstract: (E) = Editorial: (L) = Letter

Aalbers R, 662
Abbott J, 656, Suppl. 6. A45
Abdelkafi S, 492
Abdul-Manap R, Suppl. 6. A73
Abraham DJ, Suppl. 6. A20
Abramovich DR, Suppl. 6. A24
Abramson M, Suppl. 6. A2, A47
Abramson MJ, 816
Adams JE, Suppl. 6. A44
Addo Yobo EOD, 161
Addrizzo-Harris DJ, 303
Adler LM, Suppl. 6. A57
Adu H, 665 (L)
Ahmedzai S, Suppl. 2. S75
Aiken TC, Suppl. 6. A45
Akamine S, 120, Suppl. 6. A60
Akira M, 333
Akkermans MA, 981
Al-Dabbagh M, Suppl. 6. A39
Al-kutoubi A, 301
Al-Majed S, 362
Al-Shamma MRR, 1056
Alexander AG, Suppl. 6. A75
Alexander D, Suppl. 6. A61
Ali FR, Suppl. 6. A66
Ali N, Suppl. 6. A4
Alkner U, 964
Allen MB, Suppl. 6. A57, A72, A74
Alton E, Suppl. 6. A83
Alton EWFW, Suppl. 6. A3, A27, A43, A83
Alvarez-Granda L, 659
Alverola V, Suppl. 6. A27
Ambrosino N, 249
Amendola M, 494 (L)
Anderson HR, 618, 958, 1003
Anderson K, 399 (L), Suppl. 6. A78
Anderson PB, Suppl. 6. A39
Anderson SD, 59
Andersson M, 964
Andreani S, 284
Anees W, Suppl. 6. A8
Angus RM, Suppl. 6. A5, A17, A28
Anning PB, Suppl. 6. A30
Ansari S, Suppl. 6. A35
Anthonisen NR, 667 (E)
Antó JM, 235, 669 (E)
Antoine M, 643
Arbeeny C, 849
Archer S, 105 (E)
Archibald E, 680
Armstrong L, 442, Suppl. 6. A20
Armstrong R, Suppl. 6. A40
Arnold AG, 579, 805, Suppl. 6. A73
Aronoffsky L, Suppl. 6. A47
Asafo-Agyei AP, 161
Ashley J, Suppl. 6. A5
Askew J, Suppl. 6. A72
Association of Respiratory Technicians & Physiologists Executive Committee, Suppl. 6. A29
Atkinson RW, 958
Attali V, 582
Audit Subcommittee of the Standards of Care Committee, Suppl. 6. A17
Avila JJ, Suppl. 6. A21
Ayres J, Suppl. 6. A58
Ayres JG, 588 (L), Suppl. 6. A33, A40, A41
Ayrey RB, 1040
Azima H, Suppl. 6. A6
Aziz I, Suppl. 6. A50
Azzan L, Suppl. 6. A29

Baarends EM, 780, 981
Bacharova L, 760
Baguley E, Suppl. 6. A73
Bailey DL, 900
Bailey M, Suppl. 6. A2
Baker CS, Suppl. 6. A55
Baker R, Suppl. 6. A2
Baker RM, Suppl. 6. A45
Baker T, Suppl. 6. A34
Bakke PS, 276
Balasubramaniam R, 528
Baldini E, Suppl. 6. A21
Baldwin DR, Suppl. 6. A28, A31
Balfour R, Suppl. 6. A3
Balikó Z, 375
Bamford TL, 551
Barbera JA, 120
Barbour C, 72, Suppl. 6. A12
Barker DJP, 895
Barnes NC, 447, 519, 523, Suppl. 6. A75
Barnes PJ, 372, 540, 1051, Suppl. 6. A15, A18, A59
Barry PW, 585 (L), Suppl. 2. S31, S78, Suppl. 6. A22, A82
Barton DE, 96
Barumandzadeh T, 760
Basran G, Suppl. 6. A58
Bates J, Suppl. 6. A4
Baudouin SV, 401 (E), Suppl. 3. S9
Bauerfeind S, 377
Bautovich GJ, 900
Baxter-Jones ADG, Suppl. 6. A45
Bayley D, Suppl. 6. A13, A16, A48
Beasley R, 750 (L), Suppl. 6. A7, A40
Beccaria M, Suppl. 6. A15
Beckles M, 98
Bee D, Suppl. 6. A60
Beeching NJ, Suppl. 6. A34, A35
Begley P, Suppl. 6. A9
Bellia V, 731
Bellis MA, Suppl. 6. A34, A35
Belvisi MG, 933 (E)
Benaim D, 714
Benbow EW, 397 (L)
Benditte H, 545
Bennett JA, 458
Bennett LS, 103 (E), Suppl. 6. A9
Benson MK, 203 (L)
Bentham G, 218
Beresford E, Suppl. 6. A1, A58
Bernhard W, 723
Bersten AD, 171, 195
Berthaud P, Suppl. 6. A27
Bertrand J-P, 1045
Besson PF, Suppl. 6. A27
Bestall JC, Suppl. 6. A6, A10, A36
Bhowmik A, Suppl. 6. A14, A15, A26, A36
Biasin C, 969
Biernacki W, Suppl. 6. A11
Bilton D, Suppl. 6. A4, A84
Bisanti L, 760
Biville F, Suppl. 6. A26
Black CM, 1051, Suppl. 6. A20, A21, A63, A64
Boldy DAR, 837 (L)
Bolliger CT, 400 (L), 664 (L)
Bonazza L, 969
Bone MF, Suppl. 6. A1
Bonmarchand G, 690
Bonsignore G, 731
Bonucchi ME, Suppl. 6. A21
Boogaerts M, 465
Boran A, 28
Bosschaerts T, 492
Bosshammer J, 318
Bott J, Suppl. 6. A11, A43
Botto A, 45
Boudreau AC, 648
Bougas K, 299
Boukedes S, Suppl. 6. A16, A49
Bourke SJ, 746, Suppl. 6. A45
Boutin C, 836 (L)
Boyd G, Suppl. 6. A1, A70, A76
Brackenbury ET, 834
Bradbury S, Suppl. 6. A72
Bradding P, Suppl. 6. A1
Bradford B, Suppl. 6. A68
Bradshaw LM, Suppl. 6. A40
Braithwaite RA, Suppl. 6. A41
Brand PLP, 634
Brander PE, 829
Braude S, 1016
Brazier JE, 879
Bredin CP, Suppl. 6. A85
Brewin A, Suppl. 2. S102
Bright P, 28
Brisgand D, Suppl. 6. A27
Britton J, 1021 (E), 1023 (E), Suppl. 6. A8
Britton JR, 904
Britton MG, Suppl. 6. A1
Bromly CL, Suppl. 6. A2, A58
Bron A, 662
Bronsky E, 1030
Brooks S, Suppl. 6. A46
Brophy C, Suppl. 6. A10, A33, A77
Brown A, Suppl. 6. A63
Brown BH, Suppl. 6. A79
Brown D, Suppl. 6. A30, A31
Brown DM, Suppl. 6. A55
Brown JS, 203 (L)
Brown K, 166, Suppl. 6. A24
Brown NM, 927
Brown S, 281
Browne K, 507
Browning J, Suppl. 6. A3
Bruckdorfer KR, 628
Brunet A, 492
Brusasco V, Suppl. 6. A58
Bruschi C, 249
Brutsche M, 329, 836 (L)
BTS Research Committee, Suppl. 6. A12
Bucknall CE, Suppl. 6. A17
Bulpa P, 369
Bunce M, Suppl. 6. A64
Burdet L, 130, 751 (L)
Burge A, 994
Burge PS, Suppl. 6. A5, 28, A74
Burgess C, 750 (L)
Burghuber OC, 1014
Burney P, 397 (L), Suppl. 6. A7, A38
Burney PGJ, Suppl. 6. A6, A18
Burrell H, 853
Bury Th, 187
Bush A, 472, 697, Suppl. 6. A23, A42
Busse WW, 45
Busst CA, 697
Bustamante-Ruiz A, 659
Butland BK, 618
Butterfield AK, Suppl. 6. A29
Buurman WA, 338
Bye PTP, 900
Byrne P, 425
Byrnes CA, 697

Cabero-Perez MJ, 659
Cailes JB, 1051
Caine N, 755 (E)
Calder C, Suppl. 6. A18
Callaghan S, Suppl. 6. A17
Calverley PMA, 843 (E), 998, Suppl. 6. A5, A18, A37, A75
Calvin J, Suppl. 6. A16
Cameron CHS, 399 (L)
Campbell E, Suppl. 6. A13, A16, A48, A49
Campbell IA, 98, Suppl. 6. A35, A77
Campbell M, Suppl. 6. A16, A49
Carey IM, 628
Carpagnano F, Suppl. 6. A26
Carpentier A, 714
Carr V, Suppl. 6. A10, A37
Carratalà J, 745
Carroll N, Suppl. 6. A18
Carswell AJ, Suppl. 6. A39
Carswell F, Suppl. 6. A39
Carter R, Suppl. 6. A78
Castanheira P, Suppl. 6. A33
Cater JI, 766, Suppl. 6. A41
Catterall JR, 109, Suppl. 6. A1, A9
Cayton R, Suppl. 6. A8
Chacko RT, Suppl. 6. A66
Chacon RA, 718
Chadwick M, Suppl. 6. A34
Chadwick S, Suppl. 6. A3
Chadwick SL, Suppl. 6. A43
Chakravorty I, Suppl. 6. A8
Chalmers GW, 625
Chalmers JC, 38
Chan TYK, 265
Chanarin N, Suppl. 6. A7
Chang AB, 770
Chang W, Suppl. 6. A16
Chang Y-L, 810
Chapman K, 535
Charlett A, 1060
Charoenratanakul S, 394
Cheeseman P, 181
Chege JK, 586 (L)
Chen J-C, 810
Chen Y, Suppl. 6. A29
Cheng A, Suppl. 6. A2
Cheng S, Suppl. 6. A3, A83
Chevrolet J-C, 369
Chevron V, 690
Chikobvu D, Suppl. 6. A7, A38
Chinn S, Suppl. 6. A7, A38
Chirico S, 628
Choudhary N, Suppl. 6. A59
Christie GL, 953
Christie PE, 940
Christopher DJ, Suppl. 6. A66
Chrystyn H, 586 (L), Suppl. 6. A70, A82
Chuchalin A, Suppl. 6. A56
Chung KF, 1019 (E)
Churg A, 303
Chyrstyn H, Suppl. 6. A82
Ciamarra I, 775
Cibella F, 731
Cigolari S, Suppl. 6. A27
Cipriani A, 76
Clague HW, Suppl. 6. A27
Clark BJ, 586 (L)
Clark DJ, 55, 686, 849, 1036
Clark RA, 153, 766, Suppl. 6. A41
Clarke IC, Suppl. 6. A57
Clarke JR, 587 (L)
Clarke SW, 176
Clayton RA, 453
Clelland L, 929
Cliff IJ, Suppl. 6. A28
Clough JB, Suppl. 6. A24
Coakley R, 818, Suppl. 6. A13
Cockcroft DW, 845
Cohen D, Suppl. 6. A72
Coker RK, 294
Cole P, Suppl. 6. A67
Cole PJ, 260
Collier C, 680
Collier D, Suppl. 6. A22
Collier I, Suppl. 6. A78
COMPACT 2 Study Group, Suppl. 6. A57
Compton CH, 519
Confalonieri M, 249
Congleton J, 397 (L), Suppl. 6. A11
Connolly MJ, Suppl. 6. A75
Convery R, Suppl. 6. A42
Convery RP, 746, Suppl. 6. A4, A42, A43, A58, A68
Conway SP, 987, Suppl. 2. S64
Cook A, Suppl. 6. A41
Cook DG, 628, 905, 1003, 1081
Cook HT, 588 (L)
Cooper A, Suppl. 6. A1, A17, A46, A58
Cooper B, Suppl. 6. A8
Cooper BG, Suppl. 6. A29
Copenhagen City Heart Study Group, 287
Coppens P, 714
Cordier JF, 190
Corhay JL, 187
Corlett SA, Suppl. 6. A70, A82
Corne JM, 380
Corrigan CJ, 593 (E)
Corrin B, 399 (L), 507
Corris P, Suppl. 4. S1–24
Corris PA, 718, Suppl. 6. A53
Corsten MJ, 702
Costello C, Suppl. 6. A17
Costello JF, 513, Suppl. 6. A51
Costello R, 818
Costello RW, Suppl. 6. A50
Cottell DC, Suppl. 6. A54
Couetil JP, 714
Covi M, Suppl. 6. A21
Cowan JO, Suppl. 6. A1
Cowen ME, 579
Cowley A, Suppl. 6. A12
Cowley AJ, Suppl. 6. A22, A79, A80
Cowperthwaite C, Suppl. 6. A42, A68
Cox G, Suppl. 6. A74
Crane J, 750 (L), Suppl. 6. A40

Cremona G, 120
Crimi N, 775
Crivellari MT, 76
Crombie IK, 766, Suppl. 6. A41
Crompton GK, Suppl. 6. A58
Crosby J, Suppl. 6. A12
Crowther SD, Suppl. 6. A51
Crozier A, Suppl. 6. A61
Cullinan P, Suppl. 6. A41
Cunningham D, 831
Currie DC, Suppl. 2. S72
Curzen N, 105 (E)
Custovic A, 161, Suppl. 6. A3, A39
Cuttitta G, 731

Dagg KD, 453, 625
Dahlén B, 342
Dahlén S-E, 342
Danel P, Suppl. 6. A26, A27
Daniels J, Suppl. 6. A8
Daniil Z, Suppl. 6. A63, A65
Darbyshire JH, 1060
D'arcy EM, 502
Dark JH, 718, Suppl. 6. A53
Darke K, Suppl. 6. A23, A28, A75
Darwin R, Suppl. 6. A39
Daudenthun I, 690
Davies CWH, 1095, Suppl. 6. A67
Davies J, Suppl. 6. A3, A54
Davies L, Suppl. 6. A5, A28
Davies PDO, 398 (L), Suppl. 6. A34, A35
Davies RE, Suppl. 6. A44
Davies RJ, Suppl. 6. A14, A15, A58
Davies RJO, 72, 416, 1099 (L), Suppl. 6. A9, A67
Davis C, Suppl. 2. S75
Davis CF, Suppl. 6. A63
Davis M, Suppl. 6. A54
Davison A, 203 (L)
Dawson JK, Suppl. 6. A64
De Bruin PF, 472
De Giacomo T, 289
de Graaf-in't Veld C, 143
de Graaff CS, 535
de Lena M, Suppl. 6. A26
de Marneffe M, 492
de Muralt B, 130
De Rose V, 76
De Vaster J-M, 492
De Vuyst P, 1097
Dean A, Suppl. 6. A83
Deary IJ, 114
Deegan P, Suppl. 6. A8
Deegan PC, 403 (E), Suppl. 6. A31
Dekan G, 1014
Delgado FM, Suppl. 6. A26
Delgado-Rodriguez M, 659
Demedts M, 465
Denby F, Suppl. 6. A78
Dennis M, 519
Dennis SM, Suppl. 6. A18, A59
Dent RG, Suppl. 6. A68
Dentener MA, 338
Denyer J, Suppl. 6. A83
Deray G, 582
Derenne J-P, 582
Devalia JL, Suppl. 6. A14, A15
Devereux G, Suppl. 6. A9
Devine J, Suppl. 6. A70
Devlin MM, Suppl. 6. A50
Dewar A, Suppl. 6. A83
Dezateux C, Suppl. 6. A24
Dharmage SC, Suppl. 6. A2
Diaz de Atauri MJ, 120
Dickson P, 816
Dimitriou G, Suppl. 6. A19
Dinarevic S, 697
Dirksen A, Suppl. 6. A16, A48, A49
Diss TC, 888
Dixon K, 281
Djukanovic R, 662
Dobson L, Suppl. 6. A10, A37
Docherty CC, Suppl. 6. A62
Dodd M, Suppl. 6. A84
Dodd ME, 291, 656, Suppl. 2. S69, Suppl. 6. A5, A44, A45
Doherty L, Suppl. 6. A85
Doherty MJ, 998, Suppl. 6. A25, A68, A76
Dolovich J, 929
Donaldson GC, Suppl. 6. A6, A26, A36
Donaldson K, 796, Suppl. 6. A30, A31, A52, A54, A55, A56
Donnell D, Suppl. 6. A58
Donnelly SC, Suppl. 6. A30
Donnolly B, Suppl. 6. A32
Douglas AS, 398 (L)
Douglas JG, 67, 953, Suppl. 6. A18
Douglas NJ, 114, 1068, Suppl. 6. A9
Douglass JA, Suppl. 3. S22
Douillard JY, Suppl. 6. A26, A27
Dowd M, Suppl. 6. A22
Dowlati A, 187
Dowson LJ, Suppl. 6. A74
Doyle IR, 195
Drake WM, 301
Driscoll BR, Suppl. 6. A2
Drobniewski F, Suppl. 6. A33, A34
Drost EM, Suppl. 6. A30
D'Souza W, Suppl. 6. A40
du Bois RM, 92, 265, 888, 1051, Suppl. 3. S47, Suppl. 6. A11, A20, A21, A63, A64, A65
Dubail D, 492
Duiverman EJ, 739
Duncan-Skingle F, 397 (L)
Dundas I, Suppl. 6. A24
Dunne B, 395
Duran-Tauleria E, Suppl. 6. A7
Duranti R, 355, 494 (L)
Durham S, Suppl. 6. A3
Durham SR, 447
Dyche T, Suppl. 6. A83
Dyer CAE, Suppl. 6. A75

EASE Study Group, Suppl. 6. A45
East London COPD Collaborative Group, Suppl. 6. A6
Ebden P, Suppl. 6. A72
Economou G, Suppl. 6. A44
Edenborough FP, Suppl. 6. A44
Edwards BJ, Suppl. 6. A26
Edwards JG, Suppl. 6. A66
Edwards RHT, Suppl. 6. A18
Edwards S, Suppl. 6. A77
Efthimiadis A, 929
Egan J, 671 (E)
Egan JJ, Suppl. 6. A44
Egbagbe E, 239
Ehrlich RI, 748
Eichler H-G, 736
Eichler I, 397 (L)
Eivindson A, Suppl. 6. A58
El-Araud KA, 586 (L)
El-Khushman H, Suppl. 6. A50
El Oakley R, 813
Elborn JS, 98, Suppl. 6. A4, A41, A44, A84
Elkin SL, 301, Suppl. 6. A43, A77
Elliott MW, Suppl. 6. A11, A25
Ellis D, Suppl. 4. S1–24
Elvin K, 422
Emberlin J, 680
Emerton D, 665 (L)
Emery CJ, Suppl. 6. A59, A60, A61
Engelman HM, 114
Engleman HM, Suppl. 6. A9
Epton MJ, 528
Eraut CD, 203 (L)
Eriksson S, 244
Erjefält JS, 213, 569, 1010
Estenne M, 643
Etheridge C, Suppl. 6. A83
Etherington C, 987
European Community Respiratory Health Survey, Suppl. 6. A40
Evans AH, Suppl. 6. A28
Evans C, Suppl. 6. A6
Evans CC, 305 (L)
Evans CM, Suppl. 6. A50
Evans DJ, 372
Evans DW, 136
Evans E, Suppl. 6. A72
Evans G, Suppl. 6. A9
Evans M, Suppl. 6. A35
Evans S, Suppl. 6. A67
Evans T, Suppl. 6. A19, A36
Evans TW, Suppl. 3. S16, Suppl. 6. A29, A30, A55, A56, A61, A81

Fairfax AJ, Suppl. 6. A26
Fall CHD, 895
Fanning G, Suppl. 6. A64
Fanning GC, Suppl. 6. A64
Farley R, Suppl. 6. A3
Farooqi IS, Suppl. 6. A8
Farrell PJ, 888
Faull CM, 298
Faux S, Suppl. 6. A54
Faux SP, Suppl. 6. A55
Fawehimni A, Suppl. 6. A70
Fayolle P, 714
Feldner-Busztin M, 1014
Fennerty AG, 229
Fergus M, Suppl. 6. A54
Ferguson KA, 362
Ferguson WP, Suppl. 6. A34
Ferrari M, 969
Ferrier RK, Suppl. 6. A53
Feyerabend C, 766, Suppl. 6. A41
Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society, 38
Field WN, Suppl. 6. A28
Filshie J, 831
Finch SP, 1068
Finlay G, 425
Finlay GA, 502
Finlay WH, Suppl. 6. A82
Fischer AR, 1074
Fisher AJ, Suppl. 6. A53
Fisher C, Suppl. 6. A31
Fishwick D, 22, Suppl. 6. A40
Fitting J-W, 130, 751 (L)
FitzGerald MX, 425, 502, Suppl. 6. A17, A21, A54
Flaishman I, 289
Flannery EM, Suppl. 6. A1
Fleetham JA, 255, 362
Fletcher AM, 22
Fletcher M, Suppl. 6. A24
Flint A, 490
Florey CduV, Suppl. 6. A38
Flower CHR, Suppl. 6. A64
Foley N, Suppl. 4. S1–24
Foley NM, Suppl. 6. A75
Foley PJ, Suppl. 6. A21, A64
Forbes AB, 816
Forsling ML, 84
Foster G, Suppl. 6. A6, A36
Fountain DW, 528
Foweraker J, Suppl. 6. A4
Francis H, 22
Francis J, Suppl. 6. A42
Fraser KL, 99
Frederico JA, 702
Frette C, 1045
Freud E, 487
Frey JG, 329
Friend JAR, 67, 953, Suppl. 6. A18
Frost CD, Suppl. 6. A18
Frost D, Suppl. 6. A34
Fryer AD, Suppl. 6. A50
Fuhlbrigge A, Suppl. 3. S58
Fujimoto K, 33
Fukumura M, 1024
Fuller RW, 590 (E)
Furness L, Suppl. 6. A35

Gabazza EC, 563
Gabbay E, Suppl. 6. A53
Gabrio BJ, Suppl. 6. A81
Gallagher M, Suppl. 6. A4, A42
Gannon PFG, 28
Garcia-Fuentes M, 659
Garnham R, Suppl. 6. A10, A36
Garrelds IM, 143
Garrett JE, 205 (E), 750 (L)
Garrod R, Suppl. 6. A6, A10, A36
Gaya H, Suppl. 6. A4
Geddes DM, 915, Suppl. 6. A3, A27, A43, A83
Geelhoed GC, 757 (E)
George CFP, 648
George PJM, 107 (E)
George S, Suppl. 6. A41
Georgiou P, 519
Germain S, 836 (L)
Gerth van Wijk R, 143
Gevenois PA, 1097
Ghanem M, Suppl. 6. A27
Ghi KM, Suppl. 6. A4
Gibson GJ, 102 (L), 718, Suppl. 6. A28
Gilchrist FC, Suppl. 6. A64
Gilham C, Suppl. 6. A34
Gill G, Suppl. 6. A39, A43
Gill GW, Suppl. 6. A39
Girard F, 582
Giraud GD, 185
Girault C, 690
Gleeson FV, 416, 581, 1099 (L), Suppl. 6. A67
Gleich GJ, Suppl. 6. A50
Glendenning GA, 975
Glick PL, 209 (E)
Glynn P, Suppl. 6. A13
Go LT, 586 (L)
Goddard J, Suppl. 6. A46
Godden DJ, 67, 953
Golco G, 76
Goldman J, Suppl. 6. A10, A37
Goldman MH, 987
Goldstraw P, 664 (L), 813
Gompertz S, Suppl. 6. A72
Gonzalez AM, Suppl. 6. A60, A61
Gonzalez-Lamuño D, 659
Goodchild M, Suppl. 6. A4
Goodman KE, 766, Suppl. 6. A41
Goodship THJ, Suppl. 6. A28
Gordon SB, Suppl. 6. A13
Gore JM, Suppl. 6. A10, A33, A77
Górecka D, 674
Gorini M, 355
Gorzelak K, 674
Goss S, Suppl. 6. A33
Gottlieb JE, 102 (L)
Götz I, 397 (L)
Götz M, 397 (L)
Govan JR, Suppl. 6. A84
Goyal M, Suppl. 6. A33
Grace-Parker J, Suppl. 6. A33, A34
Graham DR, Suppl. 6. A64
Graham P, 528
Grassi GG, 76
Greaves M, Suppl. 4. S1–24
Green DJ, 853
Green M, 831, Suppl. 6. A19, A29, A73, A74, A80
Green RM, Suppl. 6. A39
Greene T, 805
Greening AP, Suppl. 6. A54, A84
Greenough A, 181, Suppl. 6. A19
Greenstone MA, Suppl. 6. A10, A25, A33, A68, A76, A77
Gregory GA, 96
Greiff L, 964
Griffiths J, Suppl. 6. A2
Grigg J, Suppl. 6. A24
Grimwood K, 557
Groeneveld ABJ, 866
Grosman H, 99
Gross WL, 377
Grossman R, 535
Grousset A, 714
Grover M, Suppl. 6. A75
Grozovski S, 487
Gruppo IDA, Suppl. 6. A15
Gudowius P, 318
Guerreiro D, 1030
Guhlmann A, 438
Guigay J, 398 (L)
Guillem V, Suppl. 6. A27
Guite H, 397 (L)
Guleria R, Suppl. 6. A19, A29, A80
Gutteridge JMC, Suppl. 6. A29, A55, A56

Haahtela T, 157
Hack CE, 866
Hadcroft J, Suppl. 6. A28
Haidarnejad H, Suppl. 6. A9
Hainz R, 1014
Haites NE, 953
Haleens S, Suppl. 6. A63
Hales S, Suppl. 6. A40
Hall G, Suppl. 6. A48
Hall R, Suppl. 4. S1–24, Suppl. 6. A7, A36, A38
Halldorsdottir H, 964
Halstead JC, Suppl. 6. A32
Halvorsen OJ, 276
Hamad AM, Suppl. 6. A52
Hamilton AL, 348
Hamilton L, Suppl. 6. A55
Hancox RJ, Suppl. 6. A1
Hanratty C, Suppl. 6. A67
Hansell DM, 260, 265, Suppl. 6. A81
Hara H, 333
Hardaker P, 680
Hargreave FE, 498 (E), 929
Harkawat R, Suppl. 6. A72
Harman E, 1030
Harper R, 879
Harrap SB, 816
Harré ESM, 1040
Harris J, Suppl. 6. A11
Harris ML, Suppl. 6. A19, A80
Harris ND, Suppl. 6. A79
Harrison B, Suppl. 6. A7, A38
Harrison BDW, Suppl. 6. A1, A46, A58
Harrison NK, 588 (L)
Harrison R, Suppl. 6. A40
Harrison S, Suppl. 6. A11
Hart LA, Suppl. 6. A15
Harvey I, Suppl. 6. A11
Harvey IC, 528
Harvey J, 575
Harvey JE, 927, Suppl. 6. A32
Haslam PL, Suppl. 6. A55
Haslett C, 742, Suppl. 6. A30, A54
Haward RA, 1018 (L)

Hawksworth R, 407
Haworth CS, Suppl. 6. A44, A45
Haworth SG, Suppl. 6. A62
Hayashi S, 12
Hayes J, 425
Hayllar KM, 313
Hayward AC, Suppl. 6. A33
Healy PE, 528
Heather S, Suppl. 6. A23
Hedley J, 528
Hedrich HJ, 723
Hegele RG, 12
Heitz M, 664 (L)
Helenius IJ, 157
Helms PJ, 953, Suppl. 6. A24, A45
Hemming AL, 900
Hendeles L, 1030
Hendrick DJ, 399 (L), 746, Suppl. 3. S2, Suppl. 6. A2, A45, A58, A72
Hendry J, Suppl. 6. A84
Henry M, Suppl. 6. A17
Herbert J, Suppl. 6. A34
Herbison GP, Suppl. 6. A1
Heriot AG, 488
Hernigou A, 714
Hetzel MR, Suppl. 6. A31
Hibbert M, 1016
Hickey B, Suppl. 6. A50
Higenbottam TW, 120, Suppl. 3. S68, Suppl. 6. A39, A60, A61
Higgins BG, 200
Higham MA, 861, 975, Suppl. 6. A62
Highcock MP, Suppl. 6. A38
Hill A, 994, Suppl. 6. A13, A16, A48
Hill AT, Suppl. 6. A49
Hill JB, 1030
Hill K, Suppl. 6. A67
Hill KM, Suppl. 6. A71
Hill S, Suppl. 6. A13
Hill SL, Suppl. 6. A6, A26, A48, A75
Hillery E, Suppl. 6. A83
Hind CRK, 400 (L), Suppl. 3. S2
Hindell A, Suppl. 6. A11
Hirai S, 577
Hirani N, Suppl. 6. A30
Hirani NA, 17
Hnizdo E, 271
Ho LP, Suppl. 6. A84
Hodson M, 397 (L)
Hodson ME, 313, Suppl. 6. A3, A4, A41, A43, A85
Hodson TF, Suppl. 6. A39
Hoekstra MO, 398 (L)
Hofstra WB, 739
Hogg JC, 12
Holberg CJ, 946
Holden WE, 185
Holgate ST, 380, 662, 919, Suppl. 6. A7
Holland E, Suppl. 6. A52
Holm BA, 209 (E)
Holt PG, 1 (E), 786, 837 (L)
Honda T, 33
Honeybourne D, 709, Suppl. 6. A17, A29, A47
Hooper F, Suppl. 6. A46
Hooper J, Suppl. 6. A85
Hopkin JM, 654, Suppl. 6. A8
Hopkinson LC, Suppl. 6. A2
Hoskins G, 153
Howard P, 879
Howarth C, Suppl. 6. A5
Howarth PH, 310 (E)
Howell JBL, Suppl. 3. S30
Howland K, 519
Htut T, Suppl. 6. A39
Hubbard R, 496 (E)
Hudson E, 281
Hughes JMB, Suppl. 6. A49
Hughes P, 201, 831
Hughes PD, Suppl. 6. A74
Hull J, 557
Hull R, Suppl. 4. S1–24
Hunt L, Suppl. 6. A39
Hunter C, Suppl. 6. A15
Huovinen E, 49
Hussain IR, Suppl. 6. A14
Hussell T, Suppl. 6. A83
Hutchings H, Suppl. 6. A72
Hyland RH, 99

Iandelli I, 355
Iceton G, Suppl. 6. A32
Ihre E, 342
Iida K, 431
Ind PW, 839 (E), 861, 975, Suppl. 6. A50, A57
Innes JA, Suppl. 6. A76, A78, A84
Innes NJ, Suppl. 6. A1, A46, A58
Irish C, Suppl. 6. A34
Irvine L, 766, Suppl. 6. A41
Isolde Study Group, Suppl. 6. A5
Israel E, 1074
Israel H, 102 (L)
Ito M, 837 (L)

Jack S, Suppl. 6. A23, A28
Jack, Sir David, 665 (L)
Jacob M-P, 1045
Jacoby DB, Suppl. 6. A50
Jaffe A, Suppl. 6. A3
Jaffé A, Suppl. 6. A42
Jagoe RT, Suppl. 6. A28
James PD, Suppl. 6. A32
Jamieson AH, Suppl. 6. A58
Jamieson S, Suppl. 6. A34, A35
Janssen JP, 836 (L)
Jardine E, Suppl. 6. A23
Järvinen V, 829
Jarvis D, Suppl. 6. A7, A38, A40
Jefferson D, Suppl. 6. A19
Jeffery P, Suppl. 6. A3
Jenkins RJ, 975
Jick H, 612
Johns DP, 551
Johnson A, Suppl. 6. A69
Johnson L, Suppl. 6. A80
Johnson MK, Suppl. 6. A5
Johnson MM, Suppl. 6. A26
Johnson PH, Suppl. 6. A22, A79, A80
Johnson SA, 298
Johnson SR, Suppl. 6. A52, A65
Johnston GD, Suppl. 6. A67
Johnston IDA, 38, Suppl. 6. A32, A74
Johnston SL, Suppl. 6. A7, A14
Jolliet P, 369
Jolly E, Suppl. 6. A34
Jones AM, Suppl. 6. A65
Jones AP, 218
Jones AT, Suppl. 3. S16, Suppl. 6. A81
Jones EM, 927
Jones N, Suppl. 6. A8
Jones NMB, 879
Jones PW, Suppl. 6. A6, A10, A36
Jones RD, Suppl. 6. A59
Jones RN, 306 (L)
Jones S, Suppl. 6. A10, A37
Jonkers RE, 305 (L)
Jordan D, Suppl. 6. A47
Josty D, Suppl. 6. A29
Jourdan KB, Suppl. 6. A61
Judd D, Suppl. 6. A83
Jungerwirth S, 1074

Kaan PM, 12
Kadota J, 431
Kahlon R, Suppl. 6. A26
Kamitani A, 816
Kaprio J, 49
Karamanoukian HL, 209 (E)
Kastner J, 736
Katayama Y, 120
Kato H, 577
Katsoulis K, 299
Katsouyanni K, 760
Kauffmann F, 1045
Kawakami K, 431
Kay AB, 447
Kay PH, 753 (E)
Kazerooni EA, 490
Keane MP, 490, 818
Keaney NP, Suppl. 6. A27
Keatings VM, 372
Kelestimur H, 84
Kelly C, 305 (L)
Kelly SJ, Suppl. 6. A13
Kemhadjian EL, Suppl. 6. A57
Kemp M, Suppl. 6. A85
Kendrick AH, Suppl. 2. S92, S102, Suppl. 6. A9, A76, A78, A79
Kenny J, Suppl. 6. A64
Kenyon CJ, Suppl. 6. A53
Keogan M, Suppl. 6. A84
Kerstjens HAM, 820
Ketchell I, Suppl. 6. A39
Khair O, Suppl. 6. A8
Khan Y, 472
Kharitonov SA, 540, 1051, Suppl. 6. A15
Kiely JL, 395
Kilgallen IA, 411
Kimpen JLL, 634
King GG, 136
King M, 900
Kinnear W, Suppl. 6. A8, A12, A19, A22, A32, A71
Kinnear WJM, Suppl. 6. A22, A74, A79, A80
Kitson C, Suppl. 6. A83
Klempman S, 271
Klepetko W, 545
Knoop C, 643
Knox AJ, 1023 (E), Suppl. 6. A51, A52, A65
Kobayashi H, 563
Kobayashi T, 563
Koch P, 849
Kogevinas M, 235
Kohno S, 431
Koide K, 1024
Kok-Jensen A, Suppl. 6. A48, A49
Kolbe J, 750 (L)
Kolek V, Suppl. 6. A26
Kon OM, 447, Suppl. 3. S47, Suppl. 6. A63
Kondo S, 837 (L)
Kontrus M, 545
Koopmans RP, 305 (L)
Kopylev I, Suppl. 6. A56
Koskenvuo M, 49
Koston S, Suppl. 6. A17
Kotzerke J, 438
Koyama H, 915
Kritzinger M, 545
Kruk H, Suppl. 6. A32
Kubo K, 33
Kuethe MC, 739
Kumar D, 1060
Kumaran K, 895
Kumlin M, 342
Kumwenda J, Suppl. 6. A43
Kundu S, 45
Kyroussis D, Suppl. 6. A74

Lachanis S, 299
Ladas G, 664 (L)
Laframboise GG, 702
Lahrmann H, 545
Lamb NJ, Suppl. 6. A55
Lambert M, Suppl. 6. A1, A46, A58
Lammers J-WJ, 586 (L)
Lampronti G, 969
Lane DJ, Suppl. 6. A78
Lane SJ, 407, 940
Lanes S, 750 (L)
Lange P, 287
Langford BA, Suppl. 6. A9
Lant AF, Suppl. 6. A85
Larriba JL, Suppl. 6. A26
Larriba JLG, Suppl. 6. A27
Larsson B-M, 638
Larsson K, 638
Laubscher B, Suppl. 6. A19
Laude EA, Suppl. 6. A60
Laurent GJ, 294
Laurent P, 1045
Laverty J, Suppl. 6. A72
Le Chevalier T, Suppl. 6. A27
Leach RM, 84
Ledson MJ, Suppl. 6. A4, A42, A43, A68
Lee J-M, 810
Lee M, Suppl. 6. A13
Lee TH, 407, 940, Suppl. 6. A59
Lee Y-C, 810
Leeming J, Suppl. 6. A76
Legge JS, 67, 953, Suppl. 6. A18
Leigh PN, Suppl. 6. A19, A73
Leitch DN, Suppl. 6. A2, A58, A72
Leroy J, 690
Leslie P, Suppl. 6. A67
Leung B, Suppl. 6. A6
Lévy P, 872
Lewis RA, 605
Lewis S, Suppl. 6. A40
Lewis SA, 853
Leyland M, Suppl. 6. A33
Li A, 654
Li D, Suppl. 6. A3
Li J, 561
Li X, Suppl. 6. A50
Li XY, Suppl. 6. A30
Liakakos P, 551
Lidman C, 422
Lilford RJ, 588 (L)
Lillo E, 276
Lim WS, 837 (L), Suppl. 6. A31
Lindop GBM, Suppl. 6. A53
Linton K, 111
Lipworth BJ, 55, 305 (L), 476, 608, 686, 849, 1036, Suppl. 6. A50, A57
Liu Y, 561
Ljungström I, 422
Lo Cascio V, 969
Loasuthi K, 394
Lohela P, 829
Lomas DA, 755 (E), Suppl. 6. A16, A84
Lombard M, 313
Lombardi E, 946
Long L, Suppl. 6. A62
Loper M, 1074
Lopez A, 831
Lopez-Vidriero MT, 176
Loughney E, 200
Loukides S, 299
Love LL, 362
Loveless MO, 185
Lovelock F, Suppl. 6. A8
Lowe AA, 255, 362
Lowry K, Suppl. 6. A67
Lucas M, Suppl. 6. A78
Luczynska C, Suppl. 6. A7, A38
Luczynska CM, Suppl. 6. A6
Luh S-P, 810
Luisetti M, Suppl. 6. A15
Lukacs KV, Suppl. 6. A27
Lundgren B, 422
Lundgren JD, 422
Lung Volume Reduction Surgery Trial Project Team, 755 (E)
Luo YM, Suppl. 6. A80
Luppi F, Suppl. 6. A21
Lyall RA, Suppl. 6. A19, A73, A80
Lympany P, Suppl. 6. A21
Lympany PA, 92, Suppl. 6. A64
Lynch MP, Suppl. 6. A64

Ma Y, 561
McArdle N, Suppl. 6. A9
McAulay L, Suppl. 6. A70
McAuley D, Suppl. 6. A67
McCabe C, Suppl. 6. A44
McCabe M, 395
McCarthy OR, 802
McCaughen J, Suppl. 6. A41
McCloskey M, Suppl. 6. A41, A44
McCoach JS, Suppl. 6. A74
McColl J, 223
McCruden EAB, 1056
Macdonald M, Suppl. 6. A76
Macdonald W, Suppl. 6. A67
Macdonald WBG, 757 (E)
McFarland LC, 686
Macfarlane JT, 17, 403 (E), Suppl. 6. A12, A31
McFarlane LC, 608
McGavin CR, 201
McGill G, 229
McGinn BJ, 625
McGivern DV, Suppl. 6. A66
MacGowan AP, 927
McGrath DS, Suppl. 6. A85
McGrath M, Suppl. 6. A71
McGrory M, Suppl. 6. A70
McIntyre P, Suppl. 6. A68
Mackarel AJ, Suppl. 6. A54
Mackay T, Suppl. 6. A9
MacKay TW, 1068
Mackenzie JF, Suppl. 6. A62
McKeogh D, 425
Mackinlay CI, 1095
McLachlan CR, Suppl. 6. A1
McLean M, Suppl. 6. A46
Maclean MR, Suppl. 6. A61, A62, A63
McLeod K, 1056
Macleod KJ, 625
McLoughlin P, 425
McMahon KJ, 502, Suppl. 6. A54
McMahon R, 96
McNally R, Suppl. 6. A81
McNally RA, Suppl. 6. A81
MacNee W, 565, Suppl. 6. A27, A30, A52, A54, A55, A56
McNicholas WT, 395
McQueen J, Suppl. 6. A53
McShane E, Suppl. 6. A17
McSharry C, 625, 1056
Maddison J, 656
Madge P, 223
Madgwick RG, Suppl. 6. A28, A78
Madsen F, Suppl. 6. A16, A49
Magee JG, Suppl. 6. A34
Magnussen IJ, 276
Magri S, 775
Mahadeva R, Suppl. 6. A16, A64, A84
Maher ER, 96
Mahony JB, 929
Main MJC, Suppl. 6. A24
Malcolm RM, 746
Malmberg PO, 638
Malo JL, 535
Mancini M, 355
Mangiapan G, 398 (L)
Manhire A, Suppl. 6. A31

Maniar JK, 587 (L)
Manvell M, Suppl. 6. A83
Mark D, Suppl. 6. A40
Marriott C, Suppl. 6. A67
Marriott H, Suppl. 6. A60
Marriott HM, Suppl. 6. A60
Marron A, 745
Marshall BG, 588 (L)
Marshall M, Suppl. 6. A66
Martin CJ, 229
Martin GR, Suppl. 6. A20
Martin IR, 528, 1040
Martin N, Suppl. 6. A69
Martin SE, 114
Martinez A, Suppl. 6. A27
Martinez FD, 946
Martinez FJ, 490
Mascaró J, 745
Masel P, Suppl. 6. A72
Maslanka W, 853
Mason NP, Suppl. 6. A22
Massi G, Suppl. 6. A15
Massie RJ, 1099 (L)
Massobrio M, Suppl. 6. A15
Masterson JB, 502
Mastruzzo C, 775
Matonhodze M, Suppl. 6. A7, A26, A38
Matsubara Y, 431
Matzinger F, 702
Maxwell JD, 398 (L)
Mayaud C, 398 (L)
Maynard RL, 958
Maziak W, 494 (L)
Meadows K, 805
Meaney JFM, 490
Meeker D, Suppl. 6. A3
Meghjee SPL, Suppl. 6. A66, A73
Meier CR, 612
Meigh RE, Suppl. 6. A76
Meighan-Davies J, Suppl. 6. A46
Melgren G, 276
Melor S, Suppl. 6. A73
Mélot C, 643
Menchicchi FM, Suppl. 6. A15
Meyboom-de Jong B, 535
Mildenhall S, Suppl. 6. A46
Miles J, Suppl. 6. A7, A37
Millar AB, 442, Suppl. 6. A20, A32
Miller A, Suppl. 4. S1–24, Suppl. 6. A83
Miller RF, Suppl. 2. S60
Milleron B, 398 (L)
Milner AD, 595 (E)
Milnes P, Suppl. 6. A79
Misuri G, 355
Miszkiel KA, 260
Mitchell CG, 796
Mitchell D, 198
Mitchell DM, 301, 587 (L), Suppl. 3. S2
Mitchell EA, 207 (E)
Mitchell JA, 933 (E), Suppl. 6. A61
Miura H, 577
Miyamoto K, 255
Moghissi K, 281
Mohamed S, 59
Monie RDH, 229
Monnier A, Suppl. 6. A27
Moog F, 438
Moorcroft AJ, 291, 656, Suppl. 6. A5, A45
Moore AJ, Suppl. 6. A29
Moore-Gillon J, Suppl. 6. A34
Morehead RS, 392
Moretti M, 176
Morgan MDL, Suppl. 6. A1
Morgan WE, 834
Morgan WJ, 946
Morice AH, 111, Suppl. 6. A43, A46, A57, A59, A63, A73, A79
Morley J, Suppl. 6. A51
Morrell N, Suppl. 6. A62
Morrell NW, Suppl. 6. A53, A62
Morris MJ, Suppl. 6. A28, A78
Mortimore IL, 1068
Morton I, Suppl. 6. A63
Moscara G, Suppl. 6. A21
Moss SJ, Suppl. 6. A43
Moudgil H, Suppl. 6. A17, A47
Mowatt A, Suppl. 6. A47
Moxham J, 828, Suppl. 6. A19, A29, A73, A74, A80
Muers MF, 1018 (L), Suppl. 2. S25, S104, Suppl. 6. A67, A71
Mukhopadhyay S, 398 (L)
Mulier B, Suppl. 6. A27, A52, A56
Müller Ch, 1014
Mulloy EMT, 411
Mulvey DA, Suppl. 6. A74
Mumby S, Suppl. 6. A55, A56
Munday CJ, Suppl. 6. A26
Muñoz A, 235
Murray J, 271
Muscolino G, 284
Myers JD, 861, Suppl. 6. A50, A57

Nacci P, 969
Naik S, 181
Nakhosteen JA, 407
Nasser SM, 940
Nava S, 249
Ndudzo A, Suppl. 6. A7, A38
Neijens HJ, 739
Neil P, Suppl. 6. A7, A38
Neill SO, Suppl. 6. A13
Nemery B, 465
Neumann CS, 709
Neville RG, 153
Newhouse MT, 585 (L)
Newman S, Suppl. 6. A83
Newson R, 680
Nicholas S, 1060
Nicholas TE, 195
Nicholson AG, 888
Nicholson KG, 190
Nicolaides KH, 181
Nightingale JA, Suppl. 6. A15
Nikander K, Suppl. 6. A83
Ninane V, 492
Niven RMcL, 22
Nixon L, Suppl. 6. A84
Noble M, Suppl. 6. A46
Noble TJ, Suppl. 6. A79
Nolan J, Suppl. 6. A11
Noormohamed FH, Suppl. 6. A85

Oakley RE, Suppl. 6. A27
O'Brien C, Suppl. 6. A6
O'Byrne PM, 348
O'Callaghan C, 585 (L), Suppl. 2. S31, S78, Suppl. 6. A82
O'Callaghan J, Suppl. 6. A85
O'Connor BJ, 372, 591 (E)
O'Connor CM, 502, Suppl. 6. A17, A21, A54
Odell PF, 702
O'Doherty MJ, Suppl. 2. S56, S60
O'Donnell DM, Suppl. 6. A21
O'Driscoll BR, Suppl. 2. S49, Suppl. 6. A31, A65
O'Driscoll R, Suppl. 6. A32
O'Grady EA, 998
O'Hehir RE, Suppl. 3. S22
O'Hickey SP, 28, Suppl. 6. A33
Okubo T, 125
Oldham LA, 22
Olding A, Suppl. 6. A46
Oliver SM, Suppl. 6. A77
Olivieri M, 969
Olsson H, Suppl. 6. A58
Olver RE, 398 (L)
O'Neill SJ, 411, 818
Ono T, 362
Openshaw P, Suppl. 6. A83
Ormerod LP, 802, Suppl. 6. A35
Orpe V, Suppl. 6. A19
Orsida B, 322, Suppl. 6. A50
Orte C, Suppl. 6. A62
O'Shaughnessy TC, 519
O'Shea L, Suppl. 6. A85
Osman IM, Suppl. 6. A18
Osman LM, 67
Osmond C, 895
O'Toole SJ, 209 (E)
Owen C, Suppl. 6. A16
Owen JL, Suppl. 6. A25
Owen MJ, Suppl. 6. A23, A37
Özbek MM, 255

Pabst R, 1078
Packe GE, Suppl. 6. A36, A66
Packer R, Suppl. 6. A78
Page CP, 924, Suppl. 6. A51
Page KR, Suppl. 6. A24
Pahdi HS, Suppl. 6. A3
Palmberg L, 638
Panagou P, 299
PANDA 3 Clinical Study Group, Suppl. 6. A57
Pang LH, Suppl. 6. A51
Panizo A, Suppl. 6. A27
Pantelides P, Suppl. 6. A20
Pantelidis P, Suppl. 6. A21, A65
Pantin C, Suppl. 6. A4
Pantin CF, Suppl. 6. A28
Papacosta O, 628
Papavergos T, 299
Pardo OE, Suppl. 6. A27
Parkes SN, 171
Parry E, 589 (E)
Partlett J, Suppl. 6. A12
Pasquis P, 690
Pasteur M, Suppl. 6. A4, A84
Pastorino U, Suppl. 6. A65
Patel DB, Suppl. 6. A65
Patel KR, 625, Suppl. 6. A63
Paton J, 223
Pattison J, Suppl. 6. A27
Paul EA, 802, Suppl. 6. A6, A10, A15, A36
Paulus P, 187
Pavia D, 176
Pavord I, Suppl. 6. A14, A15
Pavord ID, 239, 498 (E)
Peacock A, 9 (E), Suppl. 6. A63
Peacock AJ, 1013
Peake MD, Suppl. 6. A11
Pearce N, 750 (L), Suppl. 6. A40
Pearce S, Suppl. 6. A46
Pearson M, Suppl. 6. A17
Pearson MG, 998, Suppl. 6. A23, A28, A47, A75
Pellegrini V, 998
Pendlebury ST, 872
Penson RT, 297
Pépin J-L, 872
Pepperell J, Suppl. 6. A2
Persson CGA, 213, 569, 964, 1010
Pescarmona EO, 289
Peters M, Suppl. 4. S1–24
Petkova DK, Suppl. 6. A52
Petros AJ, Suppl. 6. A55, A56
Petrou M, 813
Pfister R, 940
Pham QT, 1045
Phelan P, 557
Phelan PD, 770
Philippe F, 582
Phillips CR, 185
Phillips GE, Suppl. 6. A23
Phillips J, Suppl. 6. A3
Phillips L, Suppl. 6. A79
Phillips M, Suppl. 6. A18
Pickering CAC, 22
Piddock LJV, Suppl. 6. A26
Piitulainen E, 244
Pinnock H, Suppl. 6. A69
Piragino C, 494 (L)
Pitson DJ, 72
Pizzichini E, 498 (E), 929
Pizzichini MMM, 498 (E), 929
Plant PK, Suppl. 6. A25, A67
Playfor SD, 932 (L)
Polak JM, Suppl. 6. A53, A62
Polkey MI, Suppl. 6. A19, A29, A73, A74, A80
Pollard AJ, Suppl. 6. A22
Pollock S, Suppl. 6. A27
Polosa R, 494 (L), 775, 919
Ponce-de-León A, 760
Pond MN, 987
Pönka A, 760
Porteous DJ, 742
Postma DS, 535, 820
Poston RN, 407
Poundsford J, Suppl. 6. A5
Pounsford JC, Suppl. 2. S53
Pouria S, 313
Pozniak A, Suppl. 6. A33
Pozzi E, 76
Prathiba BV, Suppl. 6. A77
Prathibha BV, Suppl. 6. A71
Premaratne UN, Suppl. 6. A18
Prescott E, 287
Prescott R, Suppl. 6. A4
Prescott RJ, 38
Price JF, Suppl. 6. A18
Price PD, 1040
Pride NB, 472
Prigmore SE, Suppl. 6. A77
Prosperini G, 775
Prowse K, Suppl. 6. A72
Public Health Laboratory Service/BTS/Department of Health Collaborative Group, 1060
Pujet J-C, 523
Pujol JL, Suppl. 6. A27
Pulford EC, Suppl. 6. A75
Purewal TS, Suppl. 6. A81
Puscinska E, Suppl. 6. A21
Pye A, Suppl. 6. A26
Pye K, Suppl. 6. A34
Pyper S, Suppl. 6. A44

Quénel P, 760
Quinlan G, Suppl. 6. A61
Quinlan GJ, Suppl. 6. A29, A55

Radermecker MF, 187
Raeside D, 9 (E), Suppl. 6. A63
Rafferty G, Suppl. 6. A19
Rahman I, 565, Suppl. 6. A27, A56
Rahman SU, Suppl. 6. A49
Raijmakers PGHM, 866
Rajan S, 932 (L)
Rajek MA, 545
Rajesh PB, Suppl. 6. A66
Rampulla C, 249
Ramsay SG, 453, Suppl. 6. A53
Randle BJ, Suppl. 6. A55
Range SP, Suppl. 6. A52
Rauwerda JA, 866
Raven J, 816, Suppl. 6. A2, A47
Rayner CFJ, Suppl. 6. A77
Rea HH, 750 (L)
Read RC, Suppl. 6. A13
Redfern EJ, Suppl. 6. A66, A73
Redington A, Suppl. 6. A56
Redington AE, 310 (E)
Redman P, Suppl. 6. A25
Redmond AOB, Suppl. 6. A41, A44
Redondo J, Suppl. 6. A62
Rees PJ, Suppl. 6. A80
Reeves DS, 927
Reger RB, 399 (L)
Regnis JA, 900
Reich JM, 102 (L)
Reid D, Suppl. 6. A47
Reid KR, 702
Reidy J, Suppl. 4. S1–24
Reiss TF, 45, 1030, 1099 (L)
Remmington T, Suppl. 6. A34, A35
Rendina EA, 289
Rennalls CT, Suppl. 6. A77
Reske SN, 438
Rhodes CG, Suppl. 6. A49
Ricci C, 289
Richard J-C, 690
Richards J, Suppl. 6. A83
Richards K, Suppl. 6. A1
Richardson J, Suppl. 3. S35
Richter C, 377
Riemer H, 1014
Riemersma RA, 535
Rigg A, 831
Rigo P, 187
Rijcken B, 820
Rimington LD, Suppl. 6. A47
Rimmer SJ, 136
Ritz M, 369
Rivere A, Suppl. 6. A27
Roberts D, Suppl. 6. A8
Roberts KT, Suppl. 6. A41
Roberts L, Suppl. 6. A19
Robertson AS, 28
Robertson CF, 770, Suppl. 6. A24
Robertson R, Suppl. 6. A18
Robertson-Mackay F, Suppl. 6. A67
Robey HL, 987
Robinson BWS, 786
Robinson M, 900
Robinson P, Suppl. 4. S1–24
Robson AG, Suppl. 6. A76
Rocker GM, 841 (E)
Rodrigues J, Suppl. 6. A26
Rodriguez-Roisin R, 120
Rodwell LT, 59
Roelant C, 465
Rogers DF, Suppl. 6. A15
Rolland J, Suppl. 6. A2
Rollason J, Suppl. 6. A75
Rom WN, 303
Romano S, 731
Römling U, 318
Rona R, Suppl. 6. A7
Roncaglia R, Suppl. 6. A21
Ronchi MC, 494 (L)
Rook GAW, Suppl. 3. S41
Roomes D, 1099 (L)
Rosell R, Suppl. 6. A26
Rosenberg MA, 1074
Rosencher L, 398 (L)
Rosenthal M, Suppl. 6. A42
Rosi E, 494 (L)
Rosón B, 745
Ross SJ, 953
Rossel P, Suppl. 6. A48
Roth M, 1074
Rothery S, Suppl. 6. A83
Rothman LP, 422
Rowe AM, Suppl. 6. A81
Rowles R, Suppl. 6. A10, A37
Rubens MB, 260, 265
Rudd R, 306 (L)
Rudd RM, 38, 297
Rudkin ST, Suppl. 6. A5, A11
Rudolf M, 665 (L)
Ruffie P, Suppl. 6. A27
Ruprai M, Suppl. 6. A8
Rushby I, Suppl. 6. A1
Rushdy AR, Suppl. 6. A34
Russell I, Suppl. 6. A72

Russell KJ, 502, Suppl. 6. A54
Ryan CF, 5 (E)
Ryland I, Suppl. 6. A17, A70

Sabanathan S, Suppl. 3. S35
Sabharwal AJ, Suppl. 6. A63
Sadikot RT, 579, 805
Sakatani M, 333
Salama FD, 837 (L)
Sallenave J-M, 742
Salmi T, 829
Salome CM, 136
Sampson AP, 513
Sampson SE, 513
Samways JM, Suppl. 6. A78
Sanderson CJ, 483
Sanderson PJ, 926
Sapoval M, 714
Sapsford RJ, Suppl. 6. A14
Saunders M, Suppl. 6. A71
Saunders N, Suppl. 6. A33
Saydah S, Suppl. 6. A81
Scallan M, Suppl. 6. A3
Scano G, 355, 494 (L)
Schenk P, 1014
Schiraldi G, Suppl. 6. A58
Schmetterer L, 736
Schmitz-Schumann M, 940
Schnabel A, 377
Scholey S, Suppl. 6. A11
Schols AMWJ, 338, 780, 981
Schouten JP, 820
Schroeven M, 1097
Schürmann W, 318
Schutz Y, 130
Schwartz J, 760
Scriven N, Suppl. 6. A19, A32
Scullion J, Suppl. 6. A1
Seale JP, 59, 136
Sears MR, 535
Seaton A, 166, 203 (L)
Seckl JR, 476
Seemungal T, Suppl. 6. A6, A14, A15, A26, A36
Seersholm N, 892, Suppl. 6. A48, A49
Sekiguchi M, 33
Selby PL, Suppl. 6. A44
Semenzato G, 76
Sertl K, 1014
Sethi T, Suppl. 6. A27
Severs N, Suppl. 6. A83
Shah PL, Suppl. 6. A68
Shaheen SO, 895, Suppl. 6. A38
Shakur BH, 861, Suppl. 6. A50, A57
Shale DJ, 95, 309 (E), Suppl. 6. A4
Shale DJS, Suppl. 6. A84
Shamji FM, 702
Shanahan F, Suppl. 6. A85
Sharara AM, 975
Sharkey RA, 411
Sharples L, Suppl. 6. A84
Shaw J, Suppl. 6. A55
Shaw NJ, Suppl. 3. S3
Shaw RJ, 301, 588 (L), 888, Suppl. 6. A33
Sheedy W, Suppl. 6. A63
Shi-Wen X, Suppl. 6. A20
Shindo K, 1024
Shinebourne EA, 697
Shirai R, 431
Shneerson JM, 89, Suppl. 6. A20, A38, A64, A71, A73
Short C, Suppl. 6. A85
Shute JK, 662
Sihra BS, 447
Silkstone VL, Suppl. 6. A82
Silverman M, 932 (L), 936 (E)
Silvester IH, Suppl. 6. A26
Similowski T, 582
Simler NR, Suppl. 6. A32
Simonds AK, Suppl. 6. A11
Simpson A, Suppl. 6. A3, A39
Simpson B, Suppl. 6. A3
Simpson G, 1099 (L)
Simpson JCG, 22, Suppl. 6. A12
Sinclair AJ, Suppl. 6. A75
Singh AD, 483
Singh S, Suppl. 6. A30
Sissons G, Suppl. 4. S1–24
Skinner C, 994
Skwarska E, 565, Suppl. 6. A27
Slane PW, 766, Suppl. 6. A41
Slater T, Suppl. 6. A40
Slight J, 796
Sliwinski P, 674
Sly PD, 1 (E), 837 (L)
Small T, Suppl. 6. A53
Smiley A, 648
Smith A, Suppl. 6. A3, A63
Smith AP, Suppl. 6. A71
Smith APL, Suppl. 6. A61
Smith B, 153
Smith D, Suppl. 6. A76, A78
Smith E, Suppl. 6. A44
Smith EC, Suppl. 2. S92, S102, Suppl. 6. A76, A78, A79
Smith EG, Suppl. 6. A34
Smith H, 528
Smith IE, 89, Suppl. 6. A20, A38, A71, A73
Smith JA, Suppl. 6. A25
Smith M, Suppl. 6. A70
Smith PEM, Suppl. 6. A18
Smith PK, Suppl. 6. A14
Smith RP, Suppl. 6. A5
Smith S, Suppl. 6. A3, A6, A84
Smyth AR, 932 (L)
Snell GI, 322, 551
Snell N, Suppl. 6. A67
Sodeyama T, 33
Sohi DK, 587 (L)
Sont JK, 739
Soriano JB, 235
Sorkness CA, 45
Sousa AR, 407, 940
Soutar A, 166
Spanish Group of the European Study of Asthma, 235
Spencer DA, Suppl. 2. S89
Spiller PA, 298
Spinhoven P, 149
Spiro SG, 598
Spix C, 760, 938 (E)
Spring J, 59
Sridhar MK, 751 (L), Suppl. 6. A26
Srivastava V, Suppl. 6. A66
Staal-van den Brekel AJ, 338
Stableforth DE, Suppl. 6. A44, A47
Stack B, Suppl. 6. A4
Stack BHR, 1056
Stack M, Suppl. 6. A85
Stain Ch, 1014
Staniforth A, Suppl. 6. A12
Stapleton KW, Suppl. 6. A82
Stark J, Suppl. 6. A7, A38
Starling LJ, Suppl. 6. A61
Starling R, Suppl. 6. A12
Stedman JR, 958
Steel RM, Suppl. 6. A27
Stein CE, 895
Stein P, Suppl. 4. S1–24
Stein RT, 946
Stell IM, Suppl. 6. A80
Stenmark KR, Suppl. 6. A62
Stenton SC, 746, Suppl. 3. S52, Suppl. 6. A45
Sterk PJ, 149, 739
Stern M, Suppl. 6. A3
Sterne JAC, Suppl. 6. A6, A18, A38
Stewart L, Suppl. 6. A83
Stewart RJ, 932 (L)
Stewart S, Suppl. 6. A84
Stidolph PN, 507
Stocking J, Suppl. 6. A1, A46, A58
Stockley R, Suppl. 6. A13, A16, A48
Stockley RA, Suppl. 6. A6, A26, A49, A75
Stocks J, Suppl. 6. A24
Stone V, Suppl. 6. A54, A55
Storck M, 438
Strachan D, 680
Strachan DP, 398 (L), 618, 905, 1081
Stradling J, Suppl. 6. A8, A12
Stradling JR, 72, 103 (E), Suppl. 6. A9
Straus C, 582
Strenn K, 736
Stricker W, 45
Strickland DH, 786
Stringer M, 281
Subhedar NV, Suppl. 3. S3
Summers Y, 98
Sunder-Plassmann L, 438
Sundler F, 213
Sunyer J, 235, 669 (E), 760
Sutton M, Suppl. 6. A70
Suzuki S, 125
Svensson C, 964
Swan A, Suppl. 6. A33
Swinburn CR, Suppl. 6. A2
Swystun VA, 845
Syed N, Suppl. 6. A39
Syed Q, Suppl. 6. A34, A35
Szekeres-Bartho J, 375
Szereday L, 375

Taggart SCO, 161
Taguchi O, 563
Taira O, 577
Talamini G, 969
Tan KS, 608
Tanaka WK, 1030
Tattersall R, Suppl. 6. A43
Tattersfield AE, 239, 458, 853, Suppl. 6. A59, A65
Taule M, 276
Taussig L, 946
Taylor C, Suppl. 6. A84
Taylor DR, Suppl. 6. A1
Taylor G, Suppl. 6. A81
Taylor I, Suppl. 6. A37
Taylor IK, Suppl. 6. A27
Taylor R, Suppl. 6. A77
ten Velde GPM, 338
Terrioux PH, 398 (L)
Tetley TD, 495 (E), Suppl. 6. A53
Teule GJJ, 866
Thickett DR, Suppl. 6. A20, A32
Thickett KM, Suppl. 6. A44
Thien F, Suppl. 6. A2, A50
Thien FCK, Suppl. 3. S22
Thomas D, 582
Thomas PS, 1018 (L)
Thomas S, Suppl. 6. A23, A35
Thomas SHL, Suppl. 2. S56
Thomas SR, Suppl. 6. A4, A41
Thompson-Coon J, 239
Thompson CS, Suppl. 6. A31
Thomson L, 625
Thomson LJ, 453
Thomson NC, 453, 625, Suppl. 6. A53, A78
Thorens J-B, 369
Tikkanen HO, 157
Tisdale MJ, Suppl. 6. A28
Tobias A, 235
Tobiasz M, 674
Tocque K, Suppl. 6. A34, A35
Todd G, 665 (L)
Todorov PT, Suppl. 6. A28
Tolan MJ, 714
Tomlinson HS, Suppl. 6. A82
Toop LJ, 1040
Torgny J, Suppl. 6. A48
Tornling G, 244
Touloumi G, 760
Town GI, 528, 1040
Town I, Suppl. 6. A40
Traill ZC, 416, 581, Suppl. 6. A67
Trask CW, 203 (L)
Trentin L, 76
Trigg CJ, 407
Trogrlic S, 1097
Tschernig T, 723, 1078
Tschernko EM, 545
Tschopp JM, 329, 836 (L)
Tucker JS, Suppl. 6. A38
Tullis DE, 99
Tümmler B, 318, 723
Tunnicliffe W, Suppl. 6. A33
Tunnicliffe WS, Suppl. 6. A40
Turley AJ, 111
Turner MO, 404 (E), 535

Uchida O, 577
Udwadia Z, 587 (L)
Udwadia ZP, Suppl. 6. A65
Ueda E, 333
Ueki J, 472
Upham JW, 786
Upton PD, Suppl. 6. A53, A62
Usuda J, 577
Uttley A, Suppl. 6. A33

Valente M, 284
Vallieres E, 702
van Aalderen WMC, 398 (L), 634
Van Camp G, 492
Van der Does AJW, 149
van der Molen T, 535
van der Werf TS, 752 (L)
van Herwerden L, 816
van Klaveren RJ, 465
Van Muylem A, 643
van Peski-Oosterbaan AS, 149
van Toorenenbergen AW, 143
van Velzen E, 662
van Woensel JBM, 634
Veale D, 872
Velasquez DJ, Suppl. 6. A81
Velluti G, Suppl. 6. A21
Vennik PHW, 752 (L)
Venuta F, 289
Verma A, Suppl. 6. A44
Vervaart P, 557
Vestbo J, 287, 892
Vesterinen E, 49
Vickers MR, Suppl. 6. A18, A59
Viskum K, 892
Vizza D, 289
Voelkel NF, Suppl. 3. S63
Vogiatzis I, Suppl. 6. A37
von der Hardt H, 318, 723
Vonk J, 760
Vrugt B, 662

Wahbi Z, Suppl. 6. A42, A68
Walker LA, Suppl. 6. A6
Walker M, 628
Walker S, 447
Walker WS, 486
Wallace L, Suppl. 6. A10, A37
Waller DA, 307 (E), 836 (L), Suppl. 6. A66
Wallis C, Suppl. 6. A23
Walsh G, Suppl. 6. A64
Walsh LJ, Suppl. 6. A59
Walshaw MJ, Suppl. 6. A4, A42, A43, A68
Walter S, 318
Walters EH, 322, 551, 816, Suppl. 6. A2, A47, A50
Walters S, Suppl. 6. A41, A45, A69
Walters SJ, 879
Wang J-Y, 723
Wangoo A, 588 (L), 888
Wanke T, 545
Warburton CJ, 22, Suppl. 6. A23, A28, A70, A75
Warburton E, Suppl. 6. A47
Ward C, 322, 551
Ward DJ, Suppl. 6. A41
Ward JPT, 84
Ward MJ, Suppl. 2. S45, Suppl. 6. A1, A57
Ward R, Suppl. 6. A14, A15
Ward RJ, Suppl. 6. A58
Wardlaw A, Suppl. 6. A14, A15
Wardrope J, Suppl. 6. A22
Warner JA, Suppl. 6. A24
Warner JO, Suppl. 6. A24
Warren SJ, Suppl. 6. A81
Watanuki Y, 125
Watchorn T, Suppl. 6. A52, A56
Waterhouse JC, 879
Wathen CG, 1095
Watkin SW, Suppl. 6. A1, A32, A46, A58
Watson A, 472, 987, Suppl. 2. S64
Watson AC, Suppl. 6. A19, A29
Watson JM, 190, 1060, Suppl. 6. A12, A33, A34
Watson JP, 605, Suppl. 6. A11
Watson L, Suppl. 6. A71, A79
Watson RM, 348
Watt B, Suppl. 6. A34
Webb AK, 291, 656, 671 (E), Suppl. 2. S69, Suppl. 6. A5, A44, A45, A84
Webb J, Suppl. 6. A18
Webb JK, Suppl. 6. A79
Webb JR, Suppl. 6. A46
Wedzicha JA, Suppl. 6. A6, A10, A14, A15, A26, A36, A75
Wei SM, 1045
Weiss S, Suppl. 3. S58
Weiss ST, 904
Weissbrodt H, 318
Wells AU, 260, 265
Wells FC, 488, 755 (E)
Wells PS, 203 (L)
Welsh KI, Suppl. 6. A21, A64
Westaby D, 313
Westerterp KR, 780
Wharton J, Suppl. 6. A53, A62
Whincup PH, 628
White NW, 748
White RJ, Suppl. 6. A5, A11
Whitenburgh M, Suppl. 6. A70
Whittaker AR, Suppl. 6. A78
Whittle AT, 1068, Suppl. 6. A54
Whyte RI, 490
Wickremasinghe M, 390, 861
Wilcke R, Suppl. 6. A48
Wilding P, 239
Wilkins MR, Suppl. 6. A62
Willems LNA, 149
Williams CSD, Suppl. 6. A35
Williams EM, Suppl. 6. A28
Williams IP, Suppl. 6. A68
Williams P, Suppl. 6. A29
Williams R, Suppl. 6. A33, A34
Williams SGJ, 313
Williams TJ, 322, 551
Williamson A, Suppl. 6. A37
Williamson IJ, 229
Wilson A, Suppl. 6. A8
Wilson AM, Suppl. 6. A57
Wilson GE, 305 (L)
Wilson JW, 322, Suppl. 6. A50

Wilson N, 936 (E)
Wilson P, 975
Wilson RSE, Suppl. 2. S92, S104
Wilson S, 662
Wiltshire N, Suppl. 6. A9
Winlove CP, Suppl. 6. A30
Winning A, Suppl. 6. A75
Wise AE, 313
Wisniewski AF, 853
Wisser W, 545
Witherden IR, Suppl. 6. A53
Wodehouse T, Suppl. 6. A67
Wojtyniak B, 760
Wolfs TFW, 634
Woltmann G, Suppl. 6. A14, A15
Wolzt M, 736
Wong AG, 900
Wong CA, Suppl. 6. A59
Wong CS, Suppl. 6. A1
Wong ZYH, 816
Woodcock A, 161, Suppl. 6. A3, A39
Woodcock AA, 98
Woodhead M, Suppl. 6. A12
Woodhead MA, Suppl. 6. A25
Woolcock AJ, 136
Woolf DA, 96
Woollmer P, 964
Wouters EFM, 338, 780, 981
Wrench C, Suppl. 6. A46
Wright AL, 946
Wright CE, Suppl. 6. A73
Wright DJ, Suppl. 6. A70
Wyile G, 348

Yacoub MH, Suppl. 6. A53, A62
Yamaguchi S, 33
Yamamoto S, 333
Yasui H, 563
Yates D, 1018 (L)
Yates DH, 507
Yeung A, Suppl. 6. A74
Yoshida M, 563
Yoshike Y, 125
Yost BL, Suppl. 6. A50
Young P, Suppl. 6. A69
Yoxall CW, Suppl. 3. S3
Yüksel B, 181
Yung B, 98, Suppl. 6. A85

Zaman F, Suppl. 6. A71
Zanen P, 586 (L)
Zer M, 487
Zetterström O, 342
Zhang J, 45, 1030
Zielinski J, 674, Suppl. 6. A21
Zuberbuhler P, Suppl. 6. A82

VOLUME 52 · SUBJECT INDEX

Abdominal muscle recruitment, Abdominal muscle recruitment and PEEPi during bronchoconstriction in chronic obstructive pulmonary disease, **355**
Abdominal surgery, Prevention of respiratory complications after abdominal surgery, **Suppl. 3. S35**
Abrams punch, Comparative trial of Tru-cut biopsy needle vs Abrams punch for pleural biopsy, **Suppl. 6. A66**
Accessory cardiac bronchus, Accessory cardiac bronchus presenting with haemoptysis, **490**: commentary, **486**
Accident and emergency department
Accident and emergency department – a primary care facility for respiratory illness? **Suppl. 6. A70**
Care of the asthmatic begins in the ambulance, **Suppl. 6. A70**
Comparison of BTS and American treatment regimens for acute asthma presenting to an accident and emergency dept., **Suppl. 6. A1**
Improved documentation for the assessment of acute asthma in an A & E department, **Suppl. 6. A70**
Acid fast L forms, Mycobacteria and sarcoidosis, **Suppl. 3. S47**
Acidosis, Prevalence of acidosis in patients admitted to hospital with an exacerbation of COPD – implications for non-invasive ventilation, **Suppl. 6. A25**
Activhaler, Inspiratory flow rate generation through the Activhaler in elderly patients with obstructive airways disease, **Suppl. 6. A67**
Activity of daily living, Development of a standardised measure of activity of daily living in patients with COPD: the London Chest Activity of Daily Living scale, **Suppl. 6. A36**
Acute leukaemia, Pseudohypoxaemia in a patient with acute leukaemia, **394**: commentary, **390**
Acute respiratory distress syndrome see Adult (acute) respiratory distress syndrome
Addendum, **494**
Adenosine bronchoprovocation, Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? **919**
Adenosine monophosphate
Adenosine monophosphate and histamine induced bronchoconstriction: repeatability and protection by terbutaline, **239**
Loss of normal cyclical beta-2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients, **608**
Single high dose of budesonide rapidly reverses eformoterol induced desensitisation to bronchoprotection against adenosine monophosphate challenge, **Suppl. 6. A50**
Adenovirus, Gene therapy for lung inflammatory diseases: not so far away? **742**
Adhesion molecules
Analysis of T cell subsets and beta chemokines in patients with pulmonary sarcoidosis, **431**
Soluble and surface adhesion molecules in community acquired pneumonia, **Suppl. 6. A13**
Adjuvant Navelbine International Trialist Association, ANITA (Adjuvant Navelbine International Trialist Association) A possible solution to the unresolved issues in adjuvant therapy for resectable non-small cell lung cancer, **Suppl. 6. A26**
Adrenal activity, Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children, **686**
Adrenal suppression, Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients, **55**
Adult (acute) respiratory distress syndrome
Acute lung injury after aortic surgery: the relation between lung and leg microvascular permeability to ^{111}indium-labelled transferrin and circulating mediators, **866**
Gravitational gradient of perfusion persists in the prone position in ventilated normal subjects, **Suppl. 6. A81**
Influence of hypoxia in augmenting IL-8 generation from human monocytes and macrophages – potential role in the acute respiratory distress syndrome, **Suppl. 6. A30**
Investigation to determine whether the inflammatory response in ARDS degrades pulmonary surfactant specific protein A *in vivo*, **Suppl. 6. A55**
Relative production of tumour necrosis factor and interleukin 10 in adult respiratory distress syndrome, **442**
Surfactant medication for acute respiratory distress syndrome, **Suppl. 3. S9**
Surfactant replacement therapy in ARDS: white knight or noise in the system? **195**
Adult lung function, Pneumonia before two years of age and adult lung function, **Suppl. 6. A38**
Adults, British guidelines on asthma management. 1995 review and position statement, **Suppl. 1. S1–21**
Aeroallergen, Climate and aeroallergen levels in asthma: a 12 month prospective study, **528**
Aerosolized surfactant, Surfactant medication for acute respiratory distress syndrome, **Suppl. 3. S9**
Aerosols
Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask, **171**
Halolite: a novel liquid drug aerosol delivery system, **Suppl. 6. A83**
Optimal particle size for aerosols: *letter*, **586**
Age
Age and the treatment of lung cancer: *letter*, **203**
Decline of FEV_1 by age and smoking status: facts, figures, and fallacies, **820**
Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha-1-antitrypsin deficiency (PiZZ), **244**
Influence of age and gender on the incidence of drug resistance in tuberculosis, **Suppl. 6. A34**
AIDS, Nebulisers for patients with HIV infection and AIDS, **Suppl. 2. S60**
Air cleaner, Effect of high efficiency particulate air cleaner on airborne cat allergen, **Suppl. 6. A3**
Air pollution
Air pollution and respiratory health in schoolchildren in East London, **Suppl. 6. A6**
Emergency hospital admissions for respiratory disorders attributable to summer time ozone episodes in Great Britain, **958**
Respiratory effects of air pollution in chronic obstructive pulmonary disease: a three month prospective study, **1040**
System for the generation and head-only delivery of submicronic particles for the study of the health effects of particulate air pollution, **Suppl. 6. A40**
Urban air pollution and emergency admissions for asthma in four European cities: the APHEA Project, **760**
Airflow (airway) obstruction
Chronic bronchitis, shortness of breath and airways obstruction by occupation in New Zealand, **Suppl. 6. A40**
Diagnosis of airflow obstruction from analysis of tidal breathing, **Suppl. 6. A78**
Does influenza immunisation cause exacerbations of chronic airflow obstruction or asthma? **190**
Endoscopic laser therapy in malignant tracheobronchial obstruction using sequential Nd YAG laser and photodynamic therapy, **281**
Expired airflow patterns in obstructed airways, **Suppl. 6. A28**
Respiratory symptoms do not predict airways obstruction in an elderly hospital population, **Suppl. 6. A75**
Use of tidal breathing expiratory flow profiles to assess airflow obstruction, **Suppl. 6. A78**
Airspace epithelial cells, Regulation of nitric oxide release from airspace epithelial cells, **Suppl. 6. A52**
Airway calibre, Effects of airway calibre on lung delivery of nebulised salbutamol, **1036**
Airway cells, Immunocytochemical localisation of cyclo-oxygenase isoforms in cultured human airway cells, **Suppl. 6. A52**
Airway epithelial cells, The comparative ability of thiol compounds to protect against hydrogen peroxide-induced injury in airway epithelial cells, **Suppl. 6. A56**
Airway function, Does diminished airway function at birth persist to one year of age? **Suppl. 6. A24**
Airway hyperreactivity, Use of leukotriene C_4 for detection of airway hyperreactivity in asthma, **Suppl. 6. A51**

Airway inflammation
Bronchial hyperresponsiveness in lung transplant recipients: lack of correlation with airway inflammation, **551**
Effect of measurement conditions on measured levels of peak exhaled nitric oxide, **697**
Induced sputum to assess airway inflammation in asthma. Validity and repeatability of sputum differential cell counts, **Suppl. 6. A14**
Proteoglycans: the "Teflon" on the airways? **924**
Use of induced sputum to investigate airway inflammation: *editorial*, **498**: *letter*, **1018**
Airway irritants, Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha-1-antitrypsin deficiency (PiZZ), **244**
Airway remodelling, Proteoglycans: the "Teflon" on the airways? **924**
Airway resistance measurements, Airway resistance measurements: comparison between impulse oscillometry and constant volume body plethysmography, **Suppl. 6. A78**
Airway responsiveness
Airway responsiveness and the clinical diagnosis of asthma, **Suppl. 6. A45**
Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic non-asthmatic subjects, **136**
Randomised, double blind, parallel group study comparing the effects of fluticasone propionate 2000 μg daily with placebo over 6 weeks on airway responsiveness in steroid naive subjects, **Suppl. 6. A58**
Airway tumours, Underwater photography in the human airway. The use of saline to visualise peripheral tumours and evaluate airway rigidity, **Suppl. 6. A65**
Airway wall remodelling, Airway wall remodelling in asthma: editorial, **310**
Airway Wallstent, Airway Wallstent: *letters*, **664**
Allergen
Allergen avoidance with dog *in situ*: washing the dog reduces allergen levels, but only for two days, **Suppl. 6. A39**
Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005, **348**
Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005, **342**
Measures for achieving low allergen environment in pregnancy and in early life, **Suppl. 6. A3**
Parental collection of specimens to show mite allergen exposure, **Suppl. 6. A39**
Allergen exposures, Indoor allergen exposures are not related to current asthma in atopic adults, **Suppl. 6. A2**
Allergen-induced late asthmatic reactions, Effect of cyclosporin A on the allergen-induced late asthmatic reaction, **447**
Allergic inflammation, Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? **919**
Allergic respiratory disease, Allergic respiratory disease: strategic targets for primary prevention during childhood: *editorial*, **1**: *letters*, **837**
Allergic rhinitis, Nasal responsiveness to allergen and histamine in patients with perennial rhinitis with and without a late phase response, **143**
Allograft rejection, Immunopathological changes in the airways of stable lung transplant recipients, **322**
Alpha-1-antitrypsin
PI SZ phenotype in chronic obstructive pulmonary disease, **659**
Polymerisation of the I variant of alpha-1-antitrypsin results in plasma deficiency and liver cirrhosis, **Suppl. 6. A16**
Alpha-1-antitrypsin deficiency
Alpha-1-antitrypsin deficiency in severe cystic fibrosis lung disease, **Suppl. 6. A84**
Attitudes in the Danish population and affected families towards family testing for alpha-1-antitrypsin deficiency - a questionnaire study, **Suppl. 6. A48**
Bronchial inflammation during an acute exacerbation in patients homozygous for alpha-1-antitrypsin deficiency, **Suppl. 6. A16**
Bronchial inflammation in patients with chronic bronchitis with and without alpha-1-antitrypsin deficiency, and patients with bronchiectasis, **Suppl. 6. A48**
Bronchodilator reversibility in patients with homozygous alpha-1-antitrypsin deficiency, **Suppl. 6. A48**
Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha-1-antitrypsin deficiency (PiZZ), **244**
Lung function and survival in subjects with alpha-1-antitrypsin deficiency PiZZ who have never smoked, **Suppl. 6. A49**
Monitoring the progress of emphysema in patients with severe alpha-1-antitrypsin deficiency by computer tomography, **Suppl. 6. A16**
Nationwide programme for detection of alpha-1-antitrypsin deficiency in Italy, **Suppl. 6. A15**
Quantum proteolysis by neutrophils (PMN): implications for pulmonary emphysema in alpha-1-antitrypsin deficiency, **Suppl. 6. A16**
Sputum induction to assess bronchial inflammation in patients with homozygous alpha-1-antitrypsin deficiency, **Suppl. 6. A48**
Testing for alpha-1-antitrypsin deficiency using dried blood spots: feasibility and clinical applications, **Suppl. 6. A49**
Alpha-2-macroglobulin, Effects of inhaled histamine, methacholine and capsaicin on sputum levels of alpha-2-macroglobulin, **964**
Altitude
Changes in cough frequency and cough receptor sensitivity at simulated altitude are not due to changes in temperature or humidity, **Suppl. 6. A22**
Changes in lung function on ascent to altitude, **Suppl. 6. A22**
Effect of altitude on children with asthma: *letter*, **494**
Alveolar macrophage
Developmental changes in the alveolar macrophage differential and immune receptor expression in normal children, **Suppl. 6. A24**
Effect of growth hormone on human alveolar macrophage oxidative metabolism, **818**
Involvement of an NAD(P)H oxidase-like enzyme in superoxide anion and hydrogen peroxide generation by rat type II cells, **465**
Model of human alveolar macrophage interactions with *Streptococcus pneumoniae*, **Suppl. 6. A13**
Release of prostaglandin E_2 and leukotriene B_4 by alveolar macrophages from patients with sarcoidosis, **76**
Selective inhibition of T cell proliferation but not expression of effector function by human alveolar macrophages, **786**
Alveolar T-lymphocytes, Expression of Fas and its ligand by alveolar T-lymphocytes in pulmonary sarcoidosis, **Suppl. 6. A21**
Alveolitis, Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha, **33**
Ambulance, Care of the asthmatic begins in the ambulance, **Suppl. 6. A70**
American treatment regimens
Comparison of BTS and American treatment regimens for acute asthma presenting to an accident and emergency department, **Suppl. 6. A1**
Comparison of BTS and American treatment regimens for the treatment of inpatients with acute asthma, **Suppl. 6. A58**
Aminoglycoside, Are repeat aminoglycoside levels in adult cystic fibrosis patients necessary? **Suppl. 6. A42**
Amiodarone, Amiodarone and the lung: wide variations in clinical practice, **Suppl. 6. A74**
Ammonium bisulphate, A system for the generation and head-only delivery of submicronic particles for the study of the health effects of particulate air pollution, **Suppl. 6. A40**
Amniocentesis, Perinatal lung function and invasive antenatal procedures, **181**
Angiotensin converting enzyme
Angiotensin converting enzyme expression in children and adults with pulmonary hypertension, **Suppl. 6. A62**
Human ACE gene polymorphism and distilled water induced cough, **111**
Angiotensin II receptor subtypes
Differential distribution of angiotensin II receptor subtypes in human fetal and adult lung, **Suppl. 6. A53**
Localisation of angiotensin II receptor subtypes in human pulmonary artery and AT1 mediated smooth muscle cell growth responses in vitro, **Suppl. 6. A62**
Annual Report, Annual Report October 1996 to September 1997: *editorial*, **1023**
Antenatal procedures, Perinatal lung function and invasive antenatal procedures, **181**
Antibiotic sensitivity, Antibiotic sensitivity of bacterial isolates recovered from hospital-based and community-based patients with chronic obstructive pulmonary disease, **Suppl. 6. A26**
Antibiotics
Audit of antibiotic use in acute exacerbations of chronic obstructive pulmonary disease, **Suppl. 6. A25**

Comparison of the clinical outcome of symptomatic and elective regular intravenous antibiotics in the treatment of cystic fibrosis, **Suppl. 6. A4**

Microbial exposure in childhood and subsequent atopy: pertussis immunisation and oral antibiotics, **Suppl. 6. A8**

Nebulised antibiotics for adults with cystic fibrosis, **Suppl. 2. S69**

Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis, **Suppl. 2. S89**

Anticytokine, Anticytokine approaches in pulmonary fibrosis: bringing factors into focus, **294**

Antigen induced hyperreactivity, Antigen induced hyperreactivity to histamine is vagally mediated, **Suppl. 6. A50**

Antioxidant intake, Maternal smoking and infant health: reduced antioxidant intake and/or increased oxidant stress? **Suppl. 6. A24**

Antioxidants

Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease, **565**

Bronchial reactivity and dietary antioxidants, **166**

Anxiety

Association of anxiety with perception of histamine induced bronchoconstriction in patients with asthma, **149**

Relationship between asthma symptoms alongside anxiety and depression, **Suppl. 6. A47**

Aortic aneurysm, Unilateral hypertranslucency of the left hemithorax due to aneurysm of the thoracic aorta, **299**

Aortic surgery, Acute lung injury after aortic surgery: the relation between lung and leg microvascular permeability to ^{111}indium-labelled transferrin and circulating mediators, **866**

AP-1 (c-fos/c-jun), Characterisation of gamma-glutamylcysteine synthetase gene promoter: role of proximal AP-1 (c-fos/c-jun), **Suppl. 6. A56**

Apoptosis, Lymphocyte dynamics: caution in interpreting BAL numbers, **1078**

Appetite-suppressant drugs, Appetite suppressants and pulmonary hypertension, **Suppl. 3. S63**

Arachidonic acid metabolites, Release of prostaglandin E_2 and leukotriene B_4 by alveolar macrophages from patients with sarcoidosis, **76**

Arm position, Effect of arm position on the ability to withstand restriction of vital capacity by an external compressive force, **Suppl. 6. A22**

Arthritis, Role of heat shock proteins in the pathogenesis of cystic fibrosis arthritis, **1056**

Asbestos

Aetiology of mesothelioma: are risk factors other than asbestos exposure important? *editorial*, **496**

Asbestos, Simian virus 40 and malignant mesothelioma, **Suppl. 3. S52**

Asbestos and lung cancer: *letter*, **306**

Malignant mesothelioma in south east England: clinico-pathological experience of 272 cases, **507**: correction, **1018**

Pericardial effusion associated with asbestos exposure, **1097**

Ascent, Changes in lung function on ascent to altitude, **Suppl. 6. A22**

Aspergilloma

Indications and outcome of surgery for pulmonary aspergilloma, **813**

Surgical management of pulmonary aspergilloma: *editorial*, **753**

Surgical treatment for pulmonary aspergilloma: a 28 year experience, **810**

Aspergillus fumigatus, Diffusible component from the spore surface of the fungus *Aspergillus fumigatus* which inhibits the macrophage oxidative burst is distinct from gliotoxin and other hyphal toxins, **796**

Aspirin-sensitive asthma

Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma, **940**

Too many COX (cyclo-oxygenase) spoil the broth: aspirin-sensitive asthma and 5-lipoxygenase: *editorial*, **933**

Assist-control mode, Physiological effects and optimisation of nasal assist-control ventilation for patients with chronic obstructive pulmonary disease in respiratory failure, **690**

Asthma

Absence of genetic linkage of chromosome 5q31 with asthma and atopy in the general population, **816**

Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? **919**

Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients, **55**

Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children, **686**

Airway epithelial repair: breathtakingly quick and multi-potentially pathogenic, **1010**

Airway responsiveness and the clinical diagnosis of asthma, **Suppl. 6. A45**

Airway wall remodelling in asthma: *editorial*, **310**

Anti-interleukin 5 strategies as a potential treatment for asthma, **483**

Aspects of atopy among asthmatic patients presenting to a hospital in urban Zimbabwe, **Suppl. 6. A38**

Association of anxiety with perception of histamine induced bronchoconstriction in patients with asthma, **149**

Association between type of training and risk of asthma in elite athletes, **157**

Asthma mortality in Birmingham, Solihull and Shropshire: a confidential enquiry, **Suppl. 6. A47**

Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005, **348**

Attenuation of propranolol-induced bronchoconstriction by frusemide, **861**

Audit of acute asthma attacks, **Suppl. 6. A69**

Bambuterol versus salmeterol in asthma patients with nocturnal symptoms, **Suppl. 6. A58**

British guidelines on asthma management. 1995 review and position statement, **Suppl. 1. S1–21**: *letters*, **665**, **932**

Bronchial reactivity and dietary antioxidants, **166**

Bronchodilator effects on breath sound frequency in asthma, **Suppl. 6. A78**

Care of the asthmatic begins in the ambulance, **Suppl. 6. A70**

Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid, **372**

Changes in neurokinin A (NKA) airway responsiveness with inhaled frusemide in asthma, **775**

Climate and aeroallergen levels in asthma: a 12 month prospective study, **528**

Community based assessment of asthma prevalence, management strategies, compliance and treatment perspectives amongst young adults in Melbourne, Australia, **Suppl. 6. A47**

Comparison of BTS and American treatment regimens for acute asthma presenting to an accident and emergency depattment, **Suppl. 6. A1**

Comparison of BTS and American treatment regimens for the treatment of inpatients with acute asthma, **Suppl. 6. A58**

Comparison of a lower fixed dose of inhaled fluticasone propionate (FP) with a high dose step-down regimen of FP in the prevention of re-exacerbations after an acute severe attack of asthma requiring oral corticosteroid therapy, **Suppl. 6. A1**

Cough receptor sensitivity in children with acute and non-acute asthma, **770**

Damp housing and asthma: a case-control study, **229**

Does influenza immunisation cause exacerbations of chronic airflow obstruction or asthma? **190**

Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK, **612**

Effect of acute alterations in inspired oxygen tension on methacholine induced bronchoconstriction in patients with asthma, **453**

Effect of altitude on children with asthma: *letter*, **494**

Effect of the asthma management guidelines on recruitment to a RCT of early introduction of inhaled steroids in asthma, **Suppl. 6. A18**

Effect of gender on hospital admissions for asthma and prevalence of self-reported asthma: a prospective study based on a sample of the general population, **287**

Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects, **59**

Effect of inhaled glucocorticoids on IL-1β and IL-1 receptor antagonist (IL-1ra) expression in asthmatic bronchial epithelium, **407**

Effect of inhaled prostaglandin D_2 in normal and atopic subjects, and of pretreatment with leukotriene D_4, **513**

Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air, **1074**

Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyperresponsiveness in asthmatic patients, **969**

Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D_4 challenge in normal volunteers, **519**
Effect of thunderstorms and airborne grass pollen on the incidence of acute asthma in England, 1990–94, **680**
Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients, **662**
Effects of inhaled lipopolysaccharide on neutrophil numbers in induced sputum in normal and asthmatic subjects, **Suppl. 6. A15**
Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids, **535**
Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids, **45**: letter, **1099**
Efficacy of regular versus as-required nebulised salbutamol in patients admitted to hospital with acute asthma, **Suppl. 6. A1**
Efficacy and safety of beclomethasone dipropionate delivered via a novel dry powder inhaler (Clickhaler) in paediatric patients with asthma, **Suppl. 6. A57**
Endothelin-1 levels in induced sputum samples from asthmatic and normal subjects, **625**
Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma, **940**
Enhancement of leukotriene B_4 release in stimulated asthmatic neutrophils by platelet activating factor, **1024**
Evaluating the asthma education of white European and Indian subcontinent asthmatics, **Suppl. 6. A47**
Evaluation of a home based coping skills training programme for high risk asthma sufferers, **Suppl. 6. A46**
Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren, **161**
Fenoterol, asthma deaths, and asthma severity: confounding or confusion? *letter*, **750**
General practice based community intervention trial on the management of asthma, **Suppl. 6. A18**
Geographic variations in the prevalence of asthma symptoms and its association with poverty, **Suppl. 6. A7**
Geographical variation in the prevalence of asthma symptoms in New Zealand, **Suppl. 6. A40**
Health service accessibility and deaths from asthma in 401 local authority districts in England and Wales, 1988–92, **218**
Health service accessibility and deaths from asthma: *editorial*, **205**
Home environment and asthma symptoms in childhood: two population based case-control studies 13 years apart, **618**
Hospital management of asthma, 1990–7, **Suppl. 6. A17**
How general practitioners manage acute asthma attacks, **153**
How severe is asthma in patients presenting to hospital with an exacerbation? **Suppl. 6. A46**
Immunotherapy in asthma, **Suppl. 3. S22**
Impact of asthma education on quality of life in white European and Indian subcontinent groups, **Suppl. 6. A17**
Impact of a nurse-led home management training programme in children admitted to hospital with acute asthma: a randomised controlled study, **223**
Improved documentation for the assessment of acute asthma in an A & E department, **Suppl. 6. A70**
Increase in subepithelial blood vessels in asthmatic airways may have relevance to BHR and may be steroid responsive, **Suppl. 6. A50**
Indoor allergen exposures are not related to current asthma in atopic adults, **Suppl. 6. A2**
Induced sputum to assess airway inflammation in asthma. Validity and repeatability of sputum differential cell counts, **Suppl. 6. A14**
Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005, **342**
Inspiratory muscle strength in acute asthma measured by sniff nasal pressure, **Suppl. 6. A80**
Interaction between inhaled beta-agonists and inhaled corticosteroids in the control of asthma, **Suppl. 6. A1**
Intravenous immunoglobulin therapy for asthma: time for a closer look? *editorial*, **593**
Is asthma treatment affordable in developing countries? **605**
Local research ethics committees and a randomised controlled trial of regular versus as needed salbutamol in mild to moderate asthma: for the National Asthma Task Force, **Suppl. 6. A59**
Loss of normal cyclical beta-2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients, **608**
Low asthma prevalence in rural populations of developing countries – temporal relationship between urbanization and development of asthma, **Suppl. 6. A7**
Lung function characteristics of elderly people with a diagnostic label of asthma, **Suppl. 6. A75**
Mechanisms of virus induced exacerbations of asthma, **380**
Minimum dose of inhaled lactose sensed by asthmatic patients, **Suppl. 6. A57**
Mortality of adults with asthma: a prospective cohort study, **49**
Mould allergy is commoner than house dust mite allergy in Salford patients with multiple hospital admissions for asthma (and uncommon in mild asthma), **Suppl. 6. A2**
Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breath holding, **540**
Nebulisers for asthma, **Suppl. 2. S45**
Non-acute asthma review in general practice: does it improve patient quality of life? **Suppl. 6. A18**
Occupational asthma in an isothiazolinone manufacturing plant, **746**
Occupational asthma due to chrome and nickel electroplating, **28**
Occupational asthma due to triglycidyl isocyanurate (TGIC), **Suppl. 6. A74**
One week review after admission with acute severe asthma: is it worthwhile? **Suppl. 6. A17**
Outcome for children of parents with atopic asthma and transient childhood wheezy bronchitis, **953**
Parental smoking and prevalence of respiratory symptoms and asthma in school age children, **1081**
Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma, **523**
Premenstrual asthma: still poorly understood: *editorial*, **591**
Preventing readmissions to hospital for asthma: *editorial*, **207**
Proteoglycans: the "Teflon" on the airways?, **924**
Provision of asthma medications in developing countries: a view from the pharmaceutical industry: *editorial*, **590**
Recruitment of children into a study of primary care treatment of childhood asthma, **Suppl. 6. A45**
Relationship between asthma symptoms alongside anxiety and depression, **Suppl. 6. A47**
Sample size estimation in studies monitoring exercise-induced bronchoconstriction in asthmatic children, **739**
Seasonal distribution of episodes of acute severe asthma in adults, **Suppl. 6. A7**
Should we advise parents of asthmatic children to stop smoking to protect their child's health? **Suppl. 6. A41**
Systemic dose response relationships with oral and inhaled corticosteroids in asthmatics, **Suppl. 6. A57**
Thunderstorms: a risk factor for asthma attacks: *editorial*, **669**
Too many COX (cyclo-oxygenase) spoil the broth: aspirin-sensitive asthma and 5-lipoxygenase: *editorial*, **933**
Treating asthma in developing countries: a problem of inaccessible unavailable essential medication: *editorial*, **589**
Urban air pollution and emergency admissions for asthma in four European cities: the APHEA Project, **760**
Use of leukotriene C_4 for detection of airway hyperreactivity in asthma, **Suppl. 6. A51**
What determines levels of passive smoking in children with asthma? **766**
What do prophylactic to bronchodilator ratios mean? **Suppl. 6. A59**

Asthma nurse
Asthma nurse specialist intervention in the management of asthma: the Asthma Resource Centre project in Greenwich, **Suppl. 6. A46**
Effect of asthma nurse intervention on health outcomes following hospital admission, **Suppl. 6. A46**

Atopy
Aspects of atopy among asthmatic patients presenting to a hospital in urban Zimbabwe, **Suppl. 6. A38**
Atopy phenotype in subjects with variants of the β subunit of the high affinity IgE receptor, **654**
Effect of inhaled prostaglandin D_2 in normal and atopic subjects, and of pretreatment with leukotriene D_4, **513**
Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren, **161**
Indoor allergen exposures are not related to current asthma in atopic adults, **Suppl. 6. A2**

Microbial exposure in childhood and subsequent atopy: pertussis immunisation and oral antibiotics, **Suppl. 6. A8**
Outcome for children of parents with atopic asthma and transient childhood wheezy bronchitis, **953**
Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood, **946**
Smoking and bronchial responsiveness in non-atopic and atopic young adults, **235**

Attendance allowance, Disability living allowance, mobility allowance and attendance allowance in adults with cystic fibrosis in the United Kingdom, **Suppl. 6. A69**

Audit
Audit of acute asthma attacks, **Suppl. 6. A69**
Audit of bronchoscopy practice in the United Kingdom: a survey of adherence to national guidelines, **709**
Audit of sleep apnoea in Heartlands Hospital, **Suppl. 6. A8**
Audit of the timely management of patients with lung cancer, **Suppl. 6. A32**
Audit of tuberculosis notification in Liverpool, UK, **Suppl. 6. A35**
Audit of tuberculosis notifications, **Suppl. 6. A36**
Prospective audit of the investigation and treatment of snoring and obstructive sleep apnoea in the Nottingham health district, **Suppl. 6. A8**

Aurasperone-C, Diffusible component from the spore surface of the fungus *Aspergillus fumigatus* which inhibits the macrophage oxidative burst is distinct from gliotoxin and other hyphal toxins, **796**

Australia, A community based assessment of asthma prevalence, management strategies, compliance and treatment perspectives amongst young adults in Melbourne, Australia, **Suppl. 6. A47**

Automatic nasal continuous positive airway pressure, Automatic nasal continuous positive airway pressure titration in the laboratory: patient outcomes, **72**

Automobile accidents, Effects of nasal CPAP on simulated driving performance in patients with obstructive sleep apnoea, **648**

Autonomic dysfunction, Autonomic dysfunction in patients with chest wall deformity: relationship with presence and severity of nocturnal hypoxia, **Suppl. 6. A11**

Autonomic neuropathy, Autonomic neuropathy and LTOT in patients with COPD, **Suppl. 6. A11**

Azithromycin, Long term azithromycin improves lung function in children with cystic fibrosis, **Suppl. 6. A42**

Azygos lobe, Spontaneous pneumothorax in a patient with an azygos lobe, **579**: commentary, **575**

B cell leukaemia-2 gene, Expression of *bcl-2* and Epstein-Barr virus LMP1 in lymphocytic interstitial pneumonia, **12**

Bacille Calmette-Guérin infection, Intractable mycobacterial infections associated with genetic defects in the receptor for interferon gamma: what does this tell us about immunity to mycobacteria? **Suppl. 3. S41**

Ballooning, Oesophageal plastic repair for symptomatic ballooning following circular oesophageal myotomy and correction of oesophageal atresia, **487**: commentary, **486**

Bamako initiative, Treating asthma in developing countries: a problem of inaccessible unavailable essential medication: *editorial*, **589**

Bambuterol, Bambuterol versus salmeterol in asthma patients with nocturnal symptoms, **Suppl. 6. A58**

Barrier restitution, Epithelial barrier formation by airway basal cells, **213**

Basal cells, Epithelial barrier formation by airway basal cells, **213**

BAYx 1005
Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005, **348**
Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air, **1074**
Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005, **342**

bcl-2, Expression of *bcl-2* and Epstein-Barr virus LMP1 in lymphocytic interstitial pneumonia, **12**

Beclomethasone, Provision of asthma medications in developing countries: a view from the pharmaceutical industry: *editorial*, **590**

Beclomethasone dipropionate
Comparison of the lung deposition of radiolabelled beclomethasone dipropionate from a novel dry powder inhaler, conventional pressurised metered dose inhaler and MDI with a spacer attachment, **Suppl. 6. A81**
Efficacy and safety of beclomethasone dipropionate delivered via a novel dry powder inhaler (Clickhaler) in paediatric patients with asthma, **Suppl. 6. A57**
HFA-beclomethasone extrafine aerosol improves therapeutic index, **Suppl. 6. A58**
Reduced need for a spacer attachment with extrafine aerosol MDI, **Suppl. 6. A81**

Berylliosis, Diffuse lung disease: product of genetic susceptibility and environmental encounters, **92**

Beta adrenergic receptor density, Effect of corticosteroids on pulmonary beta adrenergic receptor density and function, **Suppl. 6. A49**

Beta-agonists
Fenoterol, asthma deaths, and asthma severity: confounding or confusion? *letter*, **750**
Interaction between inhaled beta-agonists and inhaled corticosteroids in the control of asthma, **Suppl. 6. A1**

Beta-cell dysfunction, Beta-cell dysfunction and insulin resistance in adult patients with cystic fibrosis, **Suppl. 6. A85**

Beta-2 adrenergic agonist, Effects of fenoterol on ventilatory response to hypercapnia and hypoxia in patients with chronic obstructive pulmonary disease, **125**

Beta-2 adrenoceptor agonist/antagonist activity, Beta-2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol: *letter*, **305**

Beta-2 adrenoceptors
Loss of normal cyclical beta-2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients, **608**
Pharmacokinetics and extrapulmonary beta-2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers, **849**

Beta-2 receptors, Bradykinin induces IL-8 production via the activation of β2 receptors in human airway smooth muscle cells: role of cyclooxygenase metabolites, **Suppl. 6. A51**

Bioactivity, Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids, **476**

Biocides, Occupational asthma in an isothiazolinone manufacturing plant, **746**

Birmingham, Asthma mortality in Birmingham, Solihull and Shropshire: a confidential enquiry, **Suppl. 6. A47**

Bismuth, Radio-opaque punctate opacities on the chest radiograph following intravenous injection of a bismuth compound, **303**

Blood pressure, Predictors of overnight blood pressure changes in normal subjects, **Suppl. 6. A12**

Body position, Effect of body position on tongue posture in awake patients with obstructive sleep apnoea, **255**

Bone densitometry scans, Bone densitometry scans in chest clinic patients receiving oral corticosteroids, **Suppl. 6. A2**

Bone marrow transplant recipients, Interleukin-8 in bronchoalveolar lavage fluid from bone marrow transplant recipients, **Suppl. 6. A54**

Bone marrow transplantation, Bronchiectasis in bone marrow transplantation, **392**: commentary, **390**

Bone metabolism, Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma, **853**

Bone mineral density, Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma, **853**

Book reviews
Ayres JG, Turpin PJ. Peak flow measurement: an illustrated guide, **932**
Fisherman AP. Pulmonary rehabilitation (Lung Biology in Health and Disease), **204**
Gibson GJ. Clinical tests of respiratory function, **204**
Harries A, Maher D. TB/HIV: a clinical manual, **1018**
Harries A, Maher D, Upkelar M. TB: a clinical manual for South-East Asia, **1018**
Hurt R. The history of cardiothoracic surgery from early times, **752**
Kerem E, Canny GL, Branski D, Levison H. Pediatric and adolescent medicine. Volume 7: Advances in pediatric pulmonology, **1099**
Macbeth F, Milroy R, Steward W, Burnett R. Lung cancer: a practical guide to management, **838**
McDonald J. Lung growth and development (Lung Biology in Health & Diseases Series), **666**

Myint S, Taylor-Robinson D. Viral and other infections of the respiratory tract, **838**
Shale DJ. Cystic fibrosis, **400**
Zumla A, Johnson M, Miller R. AIDS and respiratory medicine, **838**

Brachial plexus injury, Bilateral diaphragmatic weakness: a late complication of radiotherapy, **829**: commentary, **828**

Bradykinin
Bradykinin induces IL-8 production via the activation of B2 receptors in human airway smooth muscle cells: role of cyclooxygenase metabolites, **Suppl. 6. A51**
Differential regulation on short- and long-term PGE_2 release by bradykinin in human airway smooth muscle cells: involvement of β2 receptor-related cyclooxygenase-2 induction, **Suppl. 6. A51**

Breath sound frequency, Bronchodilator effects on breath sound frequency in asthma, **Suppl. 6. A78**

British Thoracic Society
1996 Scientific Meeting of the British Thoracic Society: Conference report, **109**
British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management, **38**
BTS Guidelines for the management of chronic obstructive pulmonary disease, **Suppl. 5. S1-S28**
BTS sarcoidosis study: *letter*, **102**
Comparison of BTS and American treatment regimens for acute asthma presenting to an accident and emergency dept., **Suppl. 6. A1**
Comparison of BTS and American treatment regimens for the treatment of inpatients with acute asthma, **Suppl. 6. A58**
Nebuliser Project Group: Current best practice for nebuliser treatment, **Suppl. 2. S1–106**
Winter Meeting, London, December 1997, abstracts, **Suppl. 6. A1–85**

Bronchial artery, Transverse myelitis: a reversible complication of bronchial artery embolisation in cystic fibrosis, **99**: commentary, **95**

Bronchial asthma, Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyperresponsiveness in asthmatic patients, **969**

Bronchial biopsy, Immunopathological changes in the airways of stable lung transplant recipients, **322**

Bronchial epithelium, Effect of inhaled glucocorticoids on IL-1β and IL-1 receptor antagonist (IL-1ra) expression in asthmatic bronchial epithelium, **407**

Bronchial hyperresponsiveness, Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyperresponsiveness in asthmatic patients, **969**

Bronchial inflammation
Bronchial inflammation during an acute exacerbation in patients homozygous for alpha-1-antitrypsin deficiency, **Suppl. 6. A16**
Bronchial inflammation in patients with chronic bronchitis with and without alpha-1-antitrypsin deficiency, and patients with bronchiectasis, **Suppl. 6. A48**
Bronchial inflammation in patients colonised with *Haemophilus parainfluenzae* and non-typeable *Haemophilus influenzae*, **Suppl. 6. A13**
Sputum induction to assess bronchial inflammation in patients with homozygous alpha-1-antitrypsin deficiency, **Suppl. 6. A48**

Bronchial provocation testing, Occupational asthma due to chrome and nickel electroplating, **28**

Bronchial reactivity, Bronchial reactivity and dietary antioxidants, **166**

Bronchial responsiveness
Adenosine monophosphate and histamine induced bronchoconstriction: repeatability and protection by terbutaline, **239**
Risk factors for bronchial responsiveness in young adults, **Suppl. 6. A38**
Smoking and bronchial responsiveness in non-atopic and atopic young adults, **235**

Bronchial reversibility, Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis, **176**

Bronchial washings, Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid, **372**

Bronchiectasis
Bronchial inflammation in patients with chronic bronchitis with and without alpha-1-antitrypsin deficiency, and patients with bronchiectasis, **Suppl. 6. A48**
Bronchiectasis in bone marrow transplantation, **392**: commentary, **390**
Effects of airway infection by *Pseudomonas aeruginosa*: a computed tomographic study, **260**
Metabolic rate and inflammatory markers in COPD and bronchiectasis, **Suppl. 6. A67**
Nebulisers for bronchiectasis, **Suppl. 2. S72**

Bronchiolitis
Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis, **634**
Role of corticosteroids in bronchiolitis and croup: *editorial*, **595**

Bronchiolitis obliterans, Bronchiolitis obliterans following the ingestion of an Asian shrub leaf, **Suppl. 3. S68**

Bronchiolitis obliterans syndrome, Immunopathological changes in the airways of stable lung transplant recipients, **322**

Bronchitis, Outcome for children of parents with atopic asthma and transient childhood wheezy bronchitis, **953**

Bronchoalveolar lavage
Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis, **377**
Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid, **372**
Effect of exposure to swine dust on levels of IL-8 in airway lavage fluid, **638**
Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients, **502**
Interleukin-8 in bronchoalveolar lavage fluid from bone marrow transplant recipients, **Suppl. 6. A54**
Is heme oxygenase present in plasma and BALF from patients with ARDS? **Suppl. 6. A55**
Lymphocyte dynamics: caution in interpreting BAL numbers, **1078**

Bronchoconstriction
Abdominal muscle recruitment and PEEPi during bronchoconstriction in chronic obstructive pulmonary disease, **355**
Changes in neurokinin A (NKA) airway responsiveness with inhaled frusemide in asthma, **775**
Effect of acute alterations in inspired oxygen tension on methacholine induced bronchoconstriction in patients with asthma, **453**
Increased urinary excretion of LTE_4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist, **1030**

Bronchodilation (bronchodilators)
Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask, **171**
Bronchodilator effects on breath sound frequency in asthma, **Suppl. 6. A78**
Bronchodilator reversibility in patients with homozygous alpha-1-antitrypsin deficiency, **Suppl. 6. A48**
Clinical and physiological characteristics of COPD patients responding to domiciliary nebulised bronchodilator, **Suppl. 6. A75**
Combination bronchodilators in the assessment of short-term reversibility in COPD, **Suppl. 6. A5**
Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine, **845**
Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids, **45**: *letter*, **1099**
Most patients with stable COPD prefer inhaled to nebulised bronchodilators, **Suppl. 6. A75**
Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis, **Suppl. 2. S89**
Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis, **Suppl. 2. S64**
Paradoxical airway responsiveness in children with primary ciliary dyskinesia: effects of exercise and bronchodilator therapy, **Suppl. 6. A23**
Thermogenic effect of bronchodilators in patients with chronic obstructive pulmonary disease, **130**: *letter*, **751**

Bronchoprotection, Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine, **845**

Bronchoscopy
Accssory cardiac bronchus presenting with haemoptysis, **490**: commentary, **486**
Audit of bronchoscopy practice in the United Kingdom: a survey of adherence to national guidelines, **709**

Does oxygen desaturation occur during bronchoscopy in patients receiving supplemental oxygen? **Suppl. 6. A66**
Role of bronchoscopy in an Indian critical care unit: an experience of 118 procedures, **Suppl. 6. A65**
Underwater photography in the human airway. The use of saline to visualise peripheral tumours and evaluate airway rigidity, **Suppl. 6. A65**
Bronchospasm, Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren, **161**
Budesonide
Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients, **55**
Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children, **686**
Single high dose of budesonide rapidly reverses eformoterol induced desensitisation to bronchoprotection against adenosine monophosphate challenge, **Suppl. 6. A50**
Bullous emphysema, Occult lung cancer in patients with bullous emphysema, **289**
Burkholderia cepacia
Clinical outcome after acquisition of *Burkholderia cepacia*, **Suppl. 6. A41**
Lung function and *Burkholderia cepacia* colonisation: case control study, **Suppl. 6. A41**
Pulmonary function, inflammatory markers and *Burkholderia cepacia* antibodies in cystic fibrosis adults preceeding and following pulmonary colonisation with *Burkholderia cepacia*, **Suppl. 6. A84**
Should patients with cystic fibrosis infected with *Burkholderia cepacia* undergo lung transplantation? *editorial*, **671**
Taurolidine in adult cystic fibrosis patients colonised with epidemic *Burkholderia cepacia*, **Suppl. 6. A4**

Cachectic factor, A study of a new cachectic factor in a group of patients with early lung cancer, **Suppl. 6. A28**
Calcium channel blockers, Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange, **369**
Cancer gene therapy, Cancer gene therapy with a heat shock protein gene, **Suppl. 6. A27**
Capsaicin, Effects of inhaled histamine, methacholine and capsaicin on sputum levels of alpha-2-macroglobulin, **964**
Carbon dioxide, Carbon dioxide sensitivity in idiopathic hyperventilators, **Suppl. 6. A23**
Carbon monoxide
Expired air carbon monoxide levels and smoking histories in patients newly referred to general and occupational chest clinics, **Suppl. 6. A72**
Relationship of serum elastin peptide level to single breath transfer factor for carbon monoxide in French coal miners, **1045**
Respiratory effects of air pollution in chronic obstructive pulmonary disease: a three month prospective study, **1040**
Cardiopulmonary bypass
Hydrogen peroxide and catalase are inversely related during cardiopulmonary bypass, **Suppl. 6. A55**
Iron overload during paediatric cardiopulmonary bypass, **Suppl. 6. A56**
Cat allergen, The effect of high efficiency particulate air cleaner on airborne cat allergen, **Suppl. 6. A3**
Catalase, Hydrogen peroxide and catalase are inversely related during cardiopulmonary bypass, **Suppl. 6. A55**
Cationic liposomes
Assessment of the barriers to cationic liposome-mediated pulmonary gene transfer, **Suppl. 6. A83**
Selection of novel cationic liposomes for respiratory gene therapy, **Suppl. 6. A83**
Cause of death, Necroscopic histology and the cause of death: letter, **397**
Cell adhesion, Proteoglycans: the "Teflon" on the airways?, **924**
Cell counts, Induced sputum to assess airway inflammation in asthma. Validity and repeatability of sputum differential cell counts, **Suppl. 6. A14**
Cell viability and counts
Between observer repeatability of sputum differential cell counts, influence of cell viability and squamous cell contamination, **Suppl. 6. A14**
Comparison of cell viability and counts in spontaneous and induced sputum in patients with COPD, **Suppl. 6. A14**
Central venous catheter, Right phrenic nerve palsy as a complication of indwelling central venous catheters, **831**: commentary, **828**
Cfegs, "Ultimate activation" of eosinophils in vivo: lysis and release of clusters of free eosinophil granules (Cfegs), **569**
***cfrm*1HGU/m1HGU mouse**, Lung surfactant in a cystic fibrosis animal model: increased alveolar phospholipid pool size without altered composition and surface tension function in *cfrm*1HGU/m1HGU mice, **723**
Chemokines, beta, Analysis of T cell subsets and β chemokines in patients with pulmonary sarcoidosis, **431**
Chemotherapy
Chemotherapy in non-small cell lung cancer: a viable cost effective option? **Suppl. 6. A27**
Survival in small cell lung cancer treated by chemotherapy alone using an inexpensive four drug combination, **Suppl. 6. A26**
Chernobyl disaster liquidators, Long-term observation in a group of Chernobyl disaster liquidators treated with N-acetylcystein, **Suppl. 6. A56**
Chest radiograph, Outcome of patients referred by general practitioners to a hospital radiology department for a chest radiograph, **Suppl. 6. A31**
Chest wall deformity, Autonomic dysfunction in patients with chest wall deformity: relationship with presence and severity of nocturnal hypoxia, **Suppl. 6. A11**
Chest wall disease, Comparison of outcome of pulmonary rehabilitation in obstructive lung disease, interstitial lung disease and chest wall disease, **Suppl. 6. A11**
Children
Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children, **686**
Allergic respiratory disease: strategic targets for primary prevention during childhood: *editorial*, **1**: *letters*, **837**
Angiotensin converting enzyme expression in children and adults with pulmonary hypertension, **Suppl. 6. A62**
British guidelines on asthma management. 1995 review and position statement, **Suppl. 1. S1–21**: letters, **665**, **932**
Cough receptor sensitivity in children with acute and non-acute asthma, **770**
Developmental changes in the alveolar macrophage differential and immune receptor expression in normal children, **Suppl. 6. A24**
Efficacy and safety of beclomethasone dipropionate delivered via a novel dry powder inhaler (Clickhaler) in paediatric patients with asthma, **Suppl. 6. A57**
Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren, **161**
Impact of a nurse-led home management training programme in children admitted to hospital with acute asthma: a randomised controlled study, **223**
Iron overload during paediatric cardiopulmonary bypass, **Suppl. 6. A56**
Management of childhood croup: *editorial*, **757**
Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis, **Suppl. 2. S89**
Nebuliser therapy in childhood, **Suppl. 2. S78**
Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood, **946**
Pneumonia before two years of age and adult lung function, **Suppl. 6. A38**
Recruitment of children into a study of primary care treatment of childhood asthma, **Suppl. 6. A45**
Sample size estimation in studies monitoring exercise-induced bronchoconstriction in asthmatic children, **739**
What determines levels of passive smoking in children with asthma?, **766**
Wheezing phenotypes in childhood: *editorial*, **936**
Chlamydia pneumoniae, Markers of inflammation in induced sputum in acute bronchitis caused by *Chlamydia pneumoniae*, **929**: commentary, **926**
Chloride, Cough responses to substance P, PGF_2 and low chloride in idiopathic persistent cough, **Suppl. 6. A50**
Chondroid syringoma, Malignant chondroid syringoma presenting as multiple pulmonary nodules, **395**
Chorion villus sampling, Perinatal lung function and invasive antenatal procedures, **181**
Chrome, Occupational asthma due to chrome and nickel electroplating, **28**
Chromosome 5q31, Absence of genetic linkage of chromosome 5q31 with asthma and atopy in the general population, **816**

Chronic airflow obstruction, Does influenza immunisation cause exacerbations of chronic airflow obstruction or asthma?, **190**
Chronic bronchitis
Bronchial inflammation in patients with chronic bronchitis with and without alpha-1-antitrypsin deficiency, and patients with bronchiectasis, **Suppl. 6. A48**
Chronic bronchitis, shortness of breath and airways obstruction by occupation in New Zealand, **Suppl. 6. A40**
Chronic bronchitis in textile workers, **22**
Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis, **176**
Chronic dosing, Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients, **55**
Chronic heart failure
Effect of nocturnal supplemental oxygen on sleep quality and daytime cognitive function in chronic heart failure, **Suppl. 6. A12**
Prevalence of nocturnal desaturation in chronic heart failure, **Suppl. 6. A12**
Randomised controlled trial of inspiratory muscle training in stable chronic heart failure, **Suppl. 6. A22**
Chronic hepatitis C, Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha, **33**
Chronic obstructive airways disease, Inspiratory flow rate generation through the Activhaler in elderly patients with obstructive airways disease, **Suppl. 6. A67**
Chronic obstructive pulmonary disease
Abdominal muscle recruitment and PEEPi during bronchoconstriction in chronic obstructive pulmonary disease, **355**
Antibiotic sensitivity of bacterial isolates recovered from hospital-based and community-based patients with chronic obstructive pulmonary disease, **Suppl. 6. A26**
Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease, **565**
Audit of antibiotic use in acute exacerbations of chronic obstructive pulmonary disease, **Suppl. 6. A25**
Autonomic neuropathy and LTOT in patients with COPD, **Suppl. 6. A11**
Benefits of a 12-week outpatient rehabilitation programme are independent of the degree of lung dysfunction in patients with COPD, **Suppl. 6. A37**
BTS Guidelines for the management of chronic obstructive pulmonary disease, **Suppl. 5. S1-S28**
Changes in ventilatory mechanics and diaphragmatic function after lung volume reduction surgery in patients with COPD, **545**
Chronic lung disease and pulmonary hypertension: yes or no to NO? *editorial*, **105**
Clinical and physiological characteristics of COPD patients responding to domiciliary nebulised bronchodilator, **Suppl. 6. A75**
Combination bronchodilators in the assessment of short-term reversibility in COPD, **Suppl. 6. A5**
Comparison of cell viability and counts in spontaneous and induced sputum in patients with COPD, **Suppl. 6. A14**
Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting, **879**
Comparison of outcome of pulmonary rehabilitation in obstructive lung disease, interstitial lung disease and chest wall disease, **Suppl. 6. A11**
Comparison of pulsed dose oxygen delivery and continuous oxygen delivery during exercise in patients with COPD, **Suppl. 6. A6**
Decreased mechanical efficiency in clinically stable patients with COPD, **981**
Development of a standardised measure of activity of daily living in patients with COPD: the London Chest Activity of Daily Living scale, **Suppl. 6. A36**
Does pulmonary rehabilitation produce a lasting benefit in patients with COPD? **Suppl. 6. A10**
Effect of cold exposure on lung function in COPD patients with exacerbation, **Suppl. 6. A6**
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease, **Suppl. 6. A36**
Effect of exercise and hypoxaemia on myocardial repolarisation in severe chronic obstructive pulmonary disease, **Suppl. 6. A5**
Effect of long term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia, **674**
Effects of a 12-week supervised outpatient rehabilitation programme on physical performance in patients with COPD in the north east of England, **Suppl. 6. A37**
Effects of fenoterol on ventilatory response to hypercapnia and hypoxia in patients with chronic obstructive pulmonary disease, **125**
Hand held notes for patients with chronic obstructive pulmonary disease, **Suppl. 6. A77**
Hippy ventilator: effects of a portable ventilator on exercise tolerance in COPD, **Suppl. 6. A38**
How well are recommendations on immunisation in patients with chronic obstructive pulmonary disease being met in East Yorkshire, **Suppl. 6. A76**
Impact of non-invasive ventilation on nursing workload – Yorkshire Non-invasive Ventilation Trial, **Suppl. 6. A25**
Impact of outreach respiratory nurse specialist service on secondary care in COPD, **Suppl. 6. A76**
Inhaled nitric oxide and arterial oxygen tension in patients with chronic obstructive pulmonary disease and severe pulmonary hypertension, **120**
Metabolic rate and inflammatory markers in COPD and bronchiectasis, **Suppl. 6. A67**
Monitoring and reporting of COPD exacerbations in the community, **Suppl. 6. A26**
Most patients with stable COPD prefer inhaled to nebulised bronchodilators, **Suppl. 6. A75**
Nature of exacerbations of COPD, **Suppl. 6. A6**
Nebulisers for chronic obstructive pulmonary disease, **Suppl. 2. S49**
NO: COPD and beyond, **Suppl. 3. S16**
Occupation and COPD: *letter*, **399**
Oedema and cor pulmonale revisited: *editorial*, **401**
Palliative care and anxiety and depression in end-stage chronic obstructive pulmonary disease: a comparison with lung cancer, **Suppl. 6. A77**
Perceptions and needs of chronic obstructive pulmonary disease patients, **Suppl. 6. A77**
Physiological effects of flow and pressure triggering during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease, **249**
Physiological effects and optimisation of nasal assist-control ventilation for patients with chronic obstructive pulmonary disease in respiratory failure, **690**
PI SZ phenotype in chronic obstructive pulmonary disease, **659**
Predicting maximal ventilation and dyspnoea during cycle exercise in COPD patients, **Suppl. 6. A37**
Preliminary results of the influence of guidelines on the management of acute exacerbations of chronic obstructive pulmonary disease, **Suppl. 6. A68**
Prevalence of acidosis in patients admitted to hospital with an exacerbation of COPD – implications for non-invasive ventilation, **Suppl. 6. A25**
Prolonged effects of pulmonary rehabilitation in patients with COPD, **Suppl. 6. A10**
Prospective, randomised, double-blind, placebo controlled study of oral corticosteroids in patients admitted with normocapnic acute exacerbations of chronic obstructive pulmonary disease, **Suppl. 6. A5**
Provision of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United Kingdom, **Suppl. 6. A68**
Quality of life in end-stage chronic obstructive pulmonary disease and lung cancer: a comparative study, **Suppl. 6. A10**
Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease, **67**
Randomised controlled trial of pulmonary rehabilitation in a district general hospital, **Suppl. 6. A10**
Randomised trial of hospital v home rehabilitation in severe chronic obstructive pulmonary disease, **Suppl. 6. A11**
Relationships between pulmonary function and the timed swallow test: a study in COPD, **Suppl. 6. A71**
Renal functional reserve in patients with severe chronic obstructive pulmonary disease, **411**
Respiratory effects of air pollution in chronic obstructive pulmonary disease: a three month prospective study, **1040**
Safety of sputum induction in patients with COPD, **Suppl. 6. A15**
Sputum differential cell counts: *letter*, **494**
Thermogenic effect of bronchodilators in patients with chronic obstructive pulmonary disease, **130**: *letter*, **751**
Total daily expenditure relative to resting energy expenditure in clinically stable patients with COPD, **780**

UK survey of the practice of non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease, **Suppl. 6. A25**

Chronic stable heart failure, Inspiratory muscle endurance and lung volumes in chronic stable heart failure, **Suppl. 6. A79**

Cibenzoline, Neuromuscular blockade with acute respiratory failure in a patient receiving cibenzoline, **582**

Circular oesophagomyotomy, Oesophageal plastic repair for symptomatic ballooning following circular oesophageal myotomy and correction of oesophageal atresia, **487**: commentary, **486**

Clickhaler

Clickhaler: a novel multidose dry powder inhaler has high acceptability in patients with asthma, **Suppl. 6. A57**

Efficacy and safety of beclomethasone dipropionate delivered via a novel dry powder inhaler (Clickhaler) in paediatric patients with asthma, **Suppl. 6. A57**

Climate, Climate and aeroallergen levels in asthma: a 12 month prospective study, **528**

Clusters of free eosinophil granules, "Ultimate activation" of eosinophils in vivo: lysis and release of clusters of free eosinophil granules (Cfegs), **569**

Coal miners, Relationship of serum elastin peptide level to single breath transfer factor for carbon monoxide in French coal miners, **1045**

Cognitive function, The effect of nocturnal supplemental oxygen on sleep quality and daytime cognitive function in chronic heart failure, **Suppl. 6. A12**

Cohort study, Mortality of adults with asthma: a prospective cohort study, **49**

Cold exposure, Effect of cold exposure on lung function in COPD patients with exacerbation, **Suppl. 6. A6**

Colistin, Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis, **987**

Colomycin, Four years experience on intravenous colomycin in an adult cystic fibrosis unit, **Suppl. 6. A42**

Community acquired pleural infection

Intrapleural streptokinase: the answer to community acquired pleural infection? *editorial*, **403**

Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection, **416**: *letters*, **932**, **1099**

Community acquired pneumonia

Impact of management guidelines on the outcome of severe community acquired pneumonia, **17**

Soluble and surface adhesion molecules in community acquired pneumonia, **Suppl. 6. A13**

Systemic IL-6 and IL-10 levels in community acquired pneumonia, **Suppl. 6. A13**

Community based assessment, A community based assessment of asthma prevalence, management strategies, compliance and treatment perspectives amongst young adults in Melbourne, Australia, **Suppl. 6. A47**

Community intervention trial, A general practice based community intervention trial on the management of asthma, **Suppl. 6. A18**

Compliance, The effect of perinatal exposure to chronic hypoxia, L-NAME and indomethacin upon vascular reactivity and vessel compliance in the rat, **Suppl. 6. A59**

Complicated pneumothorax, Treatment of complicated spontaneous pneumothorax by simple talc pleurodesis under thoracoscopy and local anaesthesia, **329**: letters, **836**

Computed tomography

Accssory cardiac bronchus presenting with haemoptysis, **490**: commentary, **486**

Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomographic scans, **265**

Effects of airway infection by *Pseudomonas aeruginosa*: a computed tomographic study, **260**

Monitoring the progress of emphysema in patients with severe alpha1-antitrypsin deficiency by computer tomography, **Suppl. 6. A16**

Serial computed tomographic evaluation in desquamative interstitial pneumonia, **333**

Congenital diaphragmatic hernia, Making the most out of the least: new insights into congenital diaphragmatic hernia: *editorial*, **209**

Connective tissue disease, Cardiopulmonary exercise testing assessment of the efficacy of oral vasodilators in patients with pulmonary hypertension secondary to connective tissue disease, **Suppl. 6. A63**

Connective tissue growth factor, Connective tissue growth factor in scleroderma-associated fibrotic lung disease, **Suppl. 6. A20**

Constant volume body plethysmography, Airway resistance measurements: comparison between impulse oscillometry and constant volume body plethysmography, **Suppl. 6. A78**

Contact tracing

Contact tracing smear negative and non-pulmonary tuberculosis in a high-incidence area, **Suppl. 6. A34**

Reaudit of tuberculosis contact tracing in South Glamorgan: 1992–1994, **Suppl. 6. A35**

Continuous positive airway pressure

Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask, **171**

Effect of CPAP therapy on daytime function in patients with mild sleep apnoea/hypopnoea syndrome, **114**, **114**

Patterns of continuous positive airways pressure use at the Scottish National Sleep Centre, **Suppl. 6. A9**

Provision of CPAP machines in Avon in the financial year 1996–1997, **Suppl. 6. A9**

Cooking, The association of respiratory symptoms and lung function with the use of gas for cooking: results from the European Community Respiratory Health Survey, **Suppl. 6. A40**

Cor pulmonale, Oedema and cor pulmonale revisited: *editorial*, **401**

Corrections, **294**, **400**, **838**, **1018**

Corticosteroids

Bone densitometry scans in chest clinic patients receiving oral corticosteroids, **Suppl. 6. A2**

BTS sarcoidosis study: *letter*, **102**

Comparison of a lower fixed dose of inhaled fluticasone propionate (FP) with a high dose step-down regimen of FP in the prevention of re-exacerbations after an acute severe attack of asthma requiring oral corticosteroid therapy, **Suppl. 6. A1**

Effect of corticosteroids on pulmonary β adrenergic receptor density and function, **Suppl. 6. A49**

Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids, **535**

Increase in subepithelial blood vessels in asthmatic airways may have relevance to BHR and may be steroid responsive, **Suppl. 6. A50**

Interaction between inhaled beta-agonists and inhaled corticosteroids in the control of asthma, **Suppl. 6. A1**

Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids, **476**

Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis, **Suppl. 2. S64**

Prospective, randomised, double-blind, placebo controlled study of oral corticosteroids in patients admitted with normocapnic acute exacerbations of chronic obstructive pulmonary disease, **Suppl. 6. A5**

Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis, **634**

Role of corticosteroids in bronchiolitis and croup: *editorial*, **595**

Systemic dose response relationships with oral and inhaled corticosteroids in asthmatics, **Suppl. 6. A57**

Costs

Chemotherapy in non-small cell lung cancer: a viable cost effective option? **Suppl. 6. A27**

Cost comparison of home versus hospital-based investigation of obstructive sleep apnoea, **Suppl. 6. A72**

Is asthma treatment affordable in developing countries?, **605**

Provision of asthma medications in developing countries: a view from the pharmaceutical industry: *editorial*, **590**

Smoking cessation counsellor – benefit and cost, **Suppl. 6. A77**

Treating asthma in developing countries: a problem of inaccessible unavailable essential medication: *editorial*, **589**

Who should pay and who does pay for nebuliser compressors? **Suppl. 6. A68**

Cotinine, Urinary cotinine concentrations, reported household smoking and respiratory symptoms in inner city primary school children, **Suppl. 6. A41**

Cotton, Chronic bronchitis in textile workers, **22**

Cough

Changes in cough frequency and cough receptor sensitivity at simulated altitude are not due to changes in temperature or humidity, **Suppl. 6. A22**

Cough function in motor neurone disease, **Suppl. 6. A73**

Cough receptor sensitivity in children with acute and non-acute asthma, **770**

Cough responses to substance P, PGF_2 and low chloride in idiopathic persistent cough, **Suppl. 6. A50**

Cough simulated by rapid rate magnetic stimulation of the thoracic nerve roots, **Suppl. 6. A80**
Human ACE gene polymorphism and distilled water induced cough, **111**
COX, Too many COX (cyclo-oxygenase) spoil the broth: aspirin-sensitive asthma and 5-lipoxygenase: *editorial*, **933**
Critical care unit, Diaphragm and limb muscle strength in the critical care unit, **Suppl. 6. A19**
Croup
Management of childhood croup: *editorial*, **757**
Role of corticosteroids in bronchiolitis and croup: *editorial*, **595**
Cryptogenic fibrosing alveolitis
British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management, **38**
Cryptogenic fibrosing alveolitis: lack of association with Epstein-Barr virus infection, **888**
Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomographic scans, **265**
Cryptogenic fibrosing alveolitis with preserved lung volumes, **998**
Cyclooxygenase-2
Differential regulation on short- and long-term PGE_2 release by bradykinin in human airway smooth muscle cells: involvement of β2 receptor-related cyclooxygenase-2 induction, **Suppl. 6. A51**
Role of cyclooxygenase-2 induction in IL-1β induced desensitisation of human airway smooth muscle cell responses to isoprenaline, **Suppl. 6. A51**
Cyclooxygenase
Bradykinin induces IL-8 production via the activation of β2 receptors in human airway smooth muscle cells: role of cyclooxygenase metabolites, **Suppl. 6. A51**
Co-induction of iNOS and COX-2 in PA smooth muscle cells: a comparison between rat and human, **Suppl. 6. A61**
Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma, **940**
Immunocytochemical localisation of cyclooxygenase isoforms in cultured human airway cells, **Suppl. 6. A52**
Too many COX (cyclo-oxygenase) spoil the broth: aspirin-sensitive asthma and 5-lipoxygenase: *editorial*, **933**
Cyclosporin A, Effect of cyclosporin A on the allergen-induced late asthmatic reaction, **447**
CYP2D6 polymorphism, CYP2D6 polymorphism and the anti-tussive effect of dextromethorphan in man, **Suppl. 6. A73**
Cysteinyl leukotriene receptor antagonist, Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids, **45**: *letter*, **1099**
Cystic fibrosis
Access to specialist care for adults with cystic fibrosis in the United Kingdom, **Suppl. 6. A69**
Alpha-1-antitrypsin deficiency in severe cystic fibrosis lung disease, **Suppl. 6. A84**
Are repeat aminoglycoside levels in adult cystic fibrosis patients necessary? **Suppl. 6. A42**
Assessment of fitness in patients with cystic fibrosis and mild lung disease, **425**
Beta-cell dysfunction and insulin resistance in adult patients with cystic fibrosis, **Suppl. 6. A85**
Clinical outcome after acquisition of *Burkholderia cepacia*, **Suppl. 6. A41**
Comparison of the clinical outcome of symptomatic and elective regular intravenous antibiotics in the treatment of cystic fibrosis, **Suppl. 6. A4**
Comparison of delayed hyper-sensitivity in adult cystic fibrosis with sarcoidosis and HIV infected patients, **Suppl. 6. A85**
Confidential study of awareness of infertility and sexual matters in males with cystic fibrosis, **Suppl. 6. A44**
Cystic fibrosis diagnosed by molecular genetic investigation in the mother of a patient with cystic fibrosis, **96**: commentary, **95**
Disability living allowance, mobility allowance and attendance allowance in adults with cystic fibrosis in the United Kingdom, **Suppl. 6. A69**
Double blind placebo controlled trial of pulmonary and nasal administration of liposome-mediated CFTR gene transfer in CF subjects, **Suppl. 6. A3**
Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients, **Suppl. 6. A43**
Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis, **900**
Effect of posture and physiotherapy on reflux in adult cystic fibrosis patients, **Suppl. 6. A43**
Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis, **656**
Epidemiology of chronic *Pseudomonas aeruginosa* infections in the airways of lung transplant recipients with cystic fibrosis, **318**
Exercise limitation and symptoms at peak cycle ergometry in adults with cystic fibrosis, **Suppl. 6. A5**
Exercise testing and prognosis in adult cystic fibrosis, **291**
Four years experience on intravenous colomycin in an adult cystic fibrosis unit, **Suppl. 6. A42**
Fracture prevalence in patients with cystic fibrosis, **Suppl. 6. A43**
Guidelines and funding for the use of recombinant DNAse in one regional adult cystic fibrosis unit, **Suppl. 6. A68**
Incidence and treatment of methicillin resistant *S. aureus* (MRSA) positive sputum cultures in an adult cystic fibrosis clinic, **Suppl. 6. A4**
Induction of sputum in cystic fibrosis by inhaled hypertonic saline, **Suppl. 6. A43**
Interleukin-10 promoter genotype in relation to pulmonary function, BMI and bacterial colonisation in cystic fibrosis, **Suppl. 6. A84**
Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis, **987**
Long term azithromycin improves lung function in children with cystic fibrosis, **Suppl. 6. A42**
Lung surfactant in a cystic fibrosis animal model: increased alveolar phospholipid pool size without altered composition and surface tension function in *cftr*m1HGU/m1HGU mice, **723**
Methicillin-resistant *Staphylococcus aureus*: impact at an adult cystic fibrosis centre, **Suppl. 6. A4**
Nebulised antibiotics for adults with cystic fibrosis, **Suppl. 2. S69**
Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: *letter*, **398**
Nebulised bronchodilators
antibiotics and rhDNase for children with cystic fibrosis, **Suppl. 2. S89**
corticosteroids, and rhDNase in adult patients with cystic fibrosis, **Suppl. 2. S64**
Nitrite levels in breath condensate of cystic fibrosis patients are raised in contrast to exhaled nitric oxide levels, **Suppl. 6. A84**
Predicting survival in cystic fibrosis: *editorial*, **309**
Prevalence of osteoporosis in adults with cystic fibrosis, **Suppl. 6. A44**
Prognostic model for the prediction of survival in cystic fibrosis, **313**
Providing recombinant DNAse according to local guidelines in a regional cystic fibrosis unit, **Suppl. 6. A42**
Pulmonary function, inflammatory markers and *Burkholderia cepacia* antibodies in cystic fibrosis adults preceeding and following pulmonary colonisation with *Burkholderia cepacia*, **Suppl. 6. A84**
Pulmonary oxidative stress response in young children with cystic fibrosis, **557**
Quality of life in adults with cystic fibrosis: *letter*, **397**
Role of heat shock proteins in the pathogenesis of cystic fibrosis arthritis, **1056**
Severe osteoporosis in cystic fibrosis patients post transplantation, **Suppl. 6. A44**
Sex differences in weight perception in cystic fibrosis, **Suppl. 6. A45**
Should patients with cystic fibrosis infected with *Burkholderia cepacia* undergo lung transplantation? *editorial*, **671**
Taurolidine in adult cystic fibrosis patients colonised with epidemic *Burkholderia cepacia*, **Suppl. 6. A4**
Thromboembolism related to a Port-a-Cath device in a patient with cystic fibrosis, **98**: commentary, **95**
Total energy expenditure in stable patients with cystic fibrosis, **Suppl. 6. A44**
Transverse myelitis: a reversible complication of bronchial artery embolisation in cystic fibrosis, **99**: commentary, **95**
Validity of a visual numerical general quality of life scale and chest scale in adults with cystic fibrosis, **Suppl. 6. A45**
What do adults with cystic fibrosis like and dislike about the medical care they receive in the United Kingdom? **Suppl. 6. A69**

D-dimer, Prognostic significance of plasma D-dimer levels in patients with lung cancer, **563**
Damp housing
Damp housing and asthma: a case-control study, **229**

Damp housing, sensitisation to house dust mite and respiratory symptoms, **Suppl. 6. A7**
Daytime sleepiness, The relationship between sleep fragmentation, daytime sleepiness and quality of life in OSA and predictors of improvement in quality of life on nCPAP, **Suppl. 6. A9**
Death certification, Necroscopic histology and the cause of death: *letter*, **397**
Death rates, Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK, **612**
Deaths
Health service accessibility and deaths from asthma in 401 local authority districts in England and Wales, 1988–92, **218**
Health service accessibility and deaths from asthma: *editorial*, **205**
Delayed hyper-sensitivity, Comparison of delayed hyper-sensitivity in adult cystic fibrosis with sarcoidosis and HIV infected patients, **Suppl. 6. A85**
Denmark, Attitudes in the Danish population and affected families towards family testing for alpha-1-antitrypsin deficiency – a questionnaire study, **Suppl. 6. A48**
Densa Pneumograph DMS100, Home investigation of suspected obstructive sleep apnoea, **Suppl. 6. A72**
Depression, The relationship between asthma symptoms alongside anxiety and depression, **Suppl. 6. A47**
Der p1, Inactivation of Der p1 demonstrated by skin-prick testing, **Suppl. 6. A39**
Descending necrotising mediastinitis, Optimal treatment of descending necrotising mediastinitis, **702**
Desquamative interstitial pneumonia, Serial computed tomographic evaluation in desquamative interstitial pneumonia, **333**
Developing countries
Is asthma treatment affordable in developing countries?, **605**
Low asthma prevalence in rural populations of developing countries - temporal relationship between urbanization and development of asthma, **Suppl. 6. A7**
Provision of asthma medications in developing countries: a view from the pharmaceutical industry: *editorial*, **590**
Treating asthma in developing countries: a problem of inaccessible unavailable essential medication: *editorial*, **589**
Dexfenfluramine
Effect of chronic dexfenfluramine on platelet function in the Wistar and the fawn-hooded rat, **Suppl. 6. A60**
Effect of dexfenfluramine on 5-hydroxytryptamine clearance in the porcine lung, **Suppl. 6. A60**
Dextromethorphan, CYP2D6 polymorphism and the anti-tussive effect of dextromethorphan in man, **Suppl. 6. A73**
Diaphragm, Right phrenic nerve palsy as a complication of indwelling central venous catheters, **831**: commentary, **828**
Diaphragm fatigue, Evaluation of diaphragmatic fatigue in obstructive sleep apnoeas during non-REM sleep, **731**
Diaphragm function, Assessment of neonatal diaphragm function by magnetic stimulation of the phrenic nerves, **Suppl. 6. A19**
Diaphragm hernia, Making the most out of the least: new insights into congenital diaphragmatic hernia: *editorial*, **209**
Diaphragm paralysis
Neuromuscular blockade with acute respiratory failure in a patient receiving cibenzoline, **582**
Recovery of strength in bilateral diaphragm paralysis due to neuralgic amyotrophy, **Suppl. 6. A74**
Diaphragm strength
Diaphragm and limb muscle strength in the critical care unit, **Suppl. 6. A19**
Diaphragm strength soon after the diagnosis of motor neurone disease, **Suppl. 6. A19**
Diaphragm thickness, Diaphragm thickness and inspiratory strength in patients with Duchenne muscular dystrophy, **472**
Diaphragm weakness, Bilateral diaphragmatic weakness: a late complication of radiotherapy, **829**: commentary, **828**
Diet, Bronchial reactivity and dietary antioxidants, **166**
Diffuse lung disease, Diffuse lung disease: product of genetic susceptibility and environmental encounters, **92**
Diffuse panbronchiolitis, Erythromycin and diffuse panbronchiolitis, **915**
Diminished airway function, Does diminished airway function at birth persist to one year of age? **Suppl. 6. A24**
Disability living allowance, Disability living allowance, mobility allowance and attendance allowance in adults with cystic fibrosis in the United Kingdom, **Suppl. 6. A69**
DNA polymorphism, Human ACE gene polymorphism and distilled water induced cough, **111**
Dogs, Allergen avoidance with dog in situ: washing the dog reduces allergen levels, but only for two days, **Suppl. 6. A39**
Domestic gas appliances, Domestic gas appliances and lung disease, **Suppl. 3. S58**
Domestic washing, Domestic washing, the effects on the house dust mite, **Suppl. 6. A39**
Domiciliary nebuliser service, Running a domiciliary nebuliser service, **Suppl. 2. S104**
Doppler ultrasound, Renal functional reserve in patients with severe chronic obstructive pulmonary disease, **411**
Dose equivalence, Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma, **975**
Dried blood spots, Testing for alpha-1-antitrypsin deficiency using dried blood spots: feasibility and clinical applications, **Suppl. 6. A49**
Driving, Effects of nasal CPAP on simulated driving performance in patients with obstructive sleep apnoea, **648**
'Drop-in' clinic, Effect of a daily 'drop-in' clinic upon delays in the diagnosis and management of lung cancer, **Suppl. 6. A32**
Drug combination
Six year follow up of the European multicentre randomised study comparing navelbine alone vs navelbine + cisplatin vs vindesine + cisplatin in 612 patients with advanced non-small cell lung cancer, **Suppl. 6. A27**
Survival in small cell lung cancer treated by chemotherapy alone using an inexpensive four drug combination, **Suppl. 6. A26**
Drug costs
Is asthma treatment affordable in developing countries?, **605**
Provision of asthma medications in developing countries: a view from the pharmaceutical industry: *editorial*, **590**
Treating asthma in developing countries: a problem of inaccessible unavailable essential medication: *editorial*, **589**
Drug delivery
Inhalation drug delivery from seven different spacer devices: *letter*, **585**
The science of nebulised drug delivery, **Suppl. 2. S31**
Drug resistance, The influence of age and gender on the incidence of drug resistance in tuberculosis, **Suppl. 6. A34**
Drug use, Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK, **612**
Dry powder inhaler
Clickhaler: a novel multidose dry powder inhaler has high acceptability in patients with asthma, **Suppl. 6. A57**
Comparison of the lung deposition of radiolabelled beclomethasone dipropionate from a novel dry powder inhaler, conventional pressurised metered dose inhaler and MDI with a spacer attachment, **Suppl. 6. A81**
Efficacy and safety of beclomethasone dipropionate delivered via a novel dry powder inhaler (Clickhaler) in paediatric patients with asthma, **Suppl. 6. A57**
Minimum dose of inhaled lactose sensed by asthmatic patients, **Suppl. 6. A57**
DTPA clearance, Clearance of inhaled 99mTc-DTPA as a clinical index of pure pulmonary vascular disease in systemic sclerosis, **Suppl. 6. A63**
Duchenne muscular dystrophy, Diaphragm thickness and inspiratory strength in patients with Duchenne muscular dystrophy, **472**
Dust, Pulmonary infiltration after exposure to home renovation dust: *letter*, **399**
Dyspnoea
Association of anxiety with perception of histamine induced bronchoconstriction in patients with asthma, **149**
Unilateral hypertranslucency of the left hemithorax due to aneurysm of the thoracic aorta, **299**

East London, Air pollution and respiratory health in schoolchildren in East London, **Suppl. 6. A6**
Eformoterol, A single high dose of budesonide rapidly reverses eformoterol induced desensitisation to bronchoprotection against adenosine monophosphate challenge, **Suppl. 6. A50**
Elafin, Neutrophil collagenase (MMP-8) does not exert serpinase activity against secretory leucocyte proteinase inhibitor or elafin, **Suppl. 6. A17**
Elastase, Gene therapy for lung inflammatory diseases: not so far away?, **742**
Elastin peptide, Relationship of serum elastin peptide level to single breath transfer factor for carbon monoxide in French coal miners, **1045**
Elderly
Inspiratory flow rate generation through the Activhaler in elderly patients with obstructive airways disease, **Suppl. 6. A67**

Lung function characteristics of elderly people with a diagnostic label of asthma, **Suppl. 6. A75**
Nebulisers for the elderly, **Suppl. 2. S53**
Respiratory symptoms do not predict airways obstruction in an elderly hospital population, **Suppl. 6. A75**
Electrical impedance tomography, Monitoring pulmonary oedema by electrical impedance tomography, **Suppl. 6. A79**
Electroplating, Occupational asthma due to chrome and nickel electroplating, **28**
Embolisation, Transverse myelitis: a reversible complication of bronchial artery embolisation in cystic fibrosis, **99**
Emergency hospital admissions, Emergency hospital admissions for respiratory disorders attributable to summer time ozone episodes in Great Britain, **958**
Emphysema
Changes in ventilatory mechanics and diaphragmatic function after lung volume reduction surgery in patients with COPD, **545**
Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients, **502**
Health technology assessment: time for a randomised controlled trial of the role of lung volume reduction surgery in the treatment of emphysema: *editorial*, **755**
Matrix metalloproteinases: a role in emphysema? *editorial*, **495**
Monitoring the progress of emphysema in patients with severe alpha1-antitrypsin deficiency by computer tomography, **Suppl. 6. A16**
Quantum proteolysis by neutrophils (PMN): implications for pulmonary emphysema in alpha1-antitrypsin deficiency, **Suppl. 6. A16**
Empyema, *Listeria monocytogenes* empyema in an HIV infected patient, **745**
Enantiomers
Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine, **845**
Pharmacokinetics and extrapulmonary beta-2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers, **849**
Salbutamol enantiomers: early clinical evidence in humans: *editorial*, **839**
End-stage chronic obstructive pulmonary disease, Palliative care and anxiety and depression in end-stage chronic obstructive pulmonary disease: a comparison with lung cancer, **Suppl. 6. A77**
End-tidal CO_2, Use of end-tidal CO_2 as a non-invasive estimate of arterial PCO_2, **Suppl. 6. A28**
Endothelin-1 receptor antagonist, The effect of the endothelin-1 receptor antagonist PD156707 in rats with established hypoxic pulmonary hypertension, **Suppl. 6. A63**
Endothelins
Effect of endothelin on protein synthesis in smooth muscle cells from rat pulmonary microvasculature, **Suppl. 6. A62**
Endothelin-1 levels in induced sputum samples from asthmatic and normal subjects, **625**
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease, **Suppl. 6. A20**
Plasma levels of Big endothelin-1 and endothelin-1 in neonates with pulmonary hypertension referred for potential extracorporeal membrane oxygenation support, **Suppl. 6. A63**
Endothelin B receptors, Evidence for two endothelin B receptors on rabbit pulmonary resistance arteries, **Suppl. 6. A62**
Endotoxaemia, Time dependent effects of L-NAME on pulmonary macromolecular transport in endotoxaemia, **Suppl. 6. A30**
Endotoxin, Effect of exposure to swine dust on levels of IL-8 in airway lavage fluid, **638**
Endotracheobronchial cancer, Endoscopic laser therapy in malignant tracheobronchial obstruction using sequential Nd YAG laser and photodynamic therapy, **281**
Energy expenditure, Thermogenic effect of bronchodilators in patients with chronic obstructive pulmonary disease, **130**: *letter*, **751**
England and Wales, Tuberculosis in England and Wales in 1993: results of a national survey, **1060**
Eosinophilia, Anti-interleukin 5 strategies as a potential treatment for asthma, **483**
Eosinophilic pneumonia, Recurrent post-partum pulmonary eosinophilia, **1095**
Eosinophils
Effect of cyclosporin A on the allergen-induced late asthmatic reaction, **447**
"Ultimate activation" of eosinophils in vivo: lysis and release of clusters of free eosinophil granules (Cfegs), **569**
Epithelial cells, Regulation of nitric oxide release from airspace epithelial cells, **Suppl. 6. A52**
Epithelial repair, Airway epithelial repair: breathtakingly quick and multipotentially pathogenic, **1010**
Epithelial shedding, Epithelial barrier formation by airway basal cells, **213**
Epithelium, Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma, **940**
Epstein-Barr virus
Cryptogenic fibrosing alveolitis: lack of association with Epstein-Barr virus infection, **888**
Expression of *bcl-2* and Epstein-Barr virus LMP1 in lymphocytic interstitial pneumonia, **12**
Erythromycin, Erythromycin and diffuse panbronchiolitis, **915**
Essential medication
Is asthma treatment affordable in developing countries?, **605**
Treating asthma in developing countries: a problem of inaccessible unavailable essential medication: *editorial*, **589**
Europe, Urban air pollution and emergency admissions for asthma in four European cities: the APHEA Project, **760**
Evolution, Natural evolution of moderate sleep apnoea syndrome: significant progression over a mean of 17 months, **872**
Exacerbations, Mechanisms of virus induced exacerbations of asthma, **380**
Exercise
Assessment of fitness in patients with cystic fibrosis and mild lung disease, **425**
Cardiopulmonary exercise testing assessment of the efficacy of oral vasodilators in patients with pulmonary hypertension secondary to connective tissue disease, **Suppl. 6. A63**
Comparison of pulsed dose oxygen delivery and continuous oxygen delivery during exercise in patients with COPD, **Suppl. 6. A6**
Decreased mechanical efficiency in clinically stable patients with COPD, **981**
Does pulmonary rehabilitation change exercise behaviour? **Suppl. 6. A37**
Effect of exercise and hypoxaemia on myocardial repolarisation in severe chronic obstructive pulmonary disease, **Suppl. 6. A5**
Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren, **161**
Exercise limitation and symptoms at peak cycle ergometry in adults with cystic fibrosis, **Suppl. 6. A5**
Exercise testing and prognosis in adult cystic fibrosis, **291**
Hippy ventilator: effects of a portable ventilator on exercise tolerance in COPD, **Suppl. 6. A38**
Hyperventilation syndrome. Classification based on exercise testing, **Suppl. 6. A71**
Increased urinary excretion of LTE_4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist, **1030**
Paradoxical airway responsiveness in children with primary ciliary dyskinesia: effects of exercise and bronchodilator therapy, **Suppl. 6. A23**
Predicting maximal ventilation and dyspnoea during cycle exercise in COPD patients, **Suppl. 6. A37**
Reproducibility of hypocapnia on exercise over time in idiopathic hyperventilation syndrome, **Suppl. 6. A23**
Sample size estimation in studies monitoring exercise-induced bronchoconstriction in asthmatic children, **739**
Exhalation, Effect of measurement conditions on measured levels of peak exhaled nitric oxide, **697**
Exhaled NO, Exhaled NO during graded changes in inhaled oxygen in man, **736**
Expired airflow patterns, Expired airflow patterns in obstructed airways, **Suppl. 6. A28**
Extracorporeal membrane oxygenation, Plasma levels of Big endothelin-1 and endothelin-1 in neonates with pulmonary hypertension referred for potential extracorporeal membrane oxygenation support, **Suppl. 6. A63**
Extrafine aerosol, HFA-beclomethasone extrafine aerosol improves therapeutic index, **Suppl. 6. A58**
Extrafine aerosol MDI, Reduced need for a spacer attachment with extrafine aerosol MDI, **Suppl. 6. A81**

Fas, Expression of Fas and its ligand by alveolar T-lymphocytes in pulmonary sarcoidosis, **Suppl. 6. A21**
FcRI, Atopy phenotype in subjects with variants of the ß subunit of the high affinity IgE receptor, **654**

FDG-PET, Lymph node staging in non-small cell lung cancer: evaluation by [^{18}F]FDG positron emission tomography, **438**
Feather pillow, The home environment and asthma symptoms in childhood: two population based case-control studies 13 years apart, **618**
Fenoterol
Effects of fenoterol on ventilatory response to hypercapnia and hypoxia in patients with chronic obstructive pulmonary disease, **125**
Fenoterol, asthma deaths, and asthma severity: confounding or confusion? *letter*, **750**
Fetal growth, Relation of fetal growth to adult lung function in South India, **895**
FEV_1
Auto-correlation limits the precision of estimates of annual decline in FEV_1 based on patient administered serial spirometry, **Suppl. 6. A49**
Decline of FEV_1 by age and smoking status: facts, figures, and fallacies, **820**
Fibreoptic bronchoscopy, Effect of posture on oxygen saturation during fibreoptic bronchoscopy, **Suppl. 6. A66**
Fibres, Hydroxyl radical generation by respirable industrial fibres, **Suppl. 6. A31**
Fibronectin gene polymorphisms, Fibronectin gene polymorphisms and scleroderma lung fibrosis, **Suppl. 6. A21**
Fibrosing alveolitis, Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension, **1051**
Fibrotic lung disease
Connective tissue growth factor in scleroderma-associated fibrotic lung disease, **Suppl. 6. A20**
Fibronectin gene polymorphisms and scleroderma lung fibrosis, **Suppl. 6. A21**
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease, **Suppl. 6. A20**
Flail chest, An unusual case of flail chest: surgical repair using Marlex mesh, **488**: commentary, **486**
Flavanoids, Dietary flavanoids cause relaxation of rat pulmonary arteries, **Suppl. 6. A61**
Flow cytometry, Markers of inflammation in induced sputum in acute bronchitis caused by *Chlamydia pneumoniae*, **929**: commentary, **926**
Flow triggering, Physiological effects of flow and pressure triggering during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease, **249**
Fluorodeoxyglucose, Evaluation of pleural diseases with FDG-PET imaging: preliminary report, **187**
Fluticasone propionate
Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients, **55**
Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children, **686**
Comparison of a lower fixed dose of inhaled fluticasone propionate (FP) with a high dose step-down regimen of FP in the prevention of re-exacerbations after an acute severe attack of asthma requiring oral corticosteroid therapy, **Suppl. 6. A1**
Randomised, double blind, parallel group study comparing the effects of fluticasone propionate 2000 μg daily with placebo over 6 weeks on airway responsiveness in steroid naive subjects, **Suppl. 6. A58**
Flutter valve drainage bags, Flutter valve drainage bags are more effective than underwater seal systems in postoperative air leaks, **Suppl. 6. A66**
Formoterol
Beta-2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol: *letter*, **305**
Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids, **535**
Fracture prevalence, Fracture prevalence in patients with cystic fibrosis, **Suppl. 6. A43**
Fresh fruit, Effect of fresh fruit consumption on lung function and wheeze in children, **628**
Frusemide
Attenuation of propranolol-induced bronchoconstriction by frusemide, **861**
Changes in neurokinin A (NKA) airway responsiveness with inhaled frusemide in asthma, **775**
Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects, **59**
Fumagillin and Fumigaclavine-C, Diffusible component from the spore surface of the fungus *Aspergillus fumigatus* which inhibits the macrophage oxidative burst is distinct from gliotoxin and other hyphal toxins, **796**
Fungal spores, Climate and aeroallergen levels in asthma: a 12 month prospective study, **528**

Gamma-glutamylcysteine synthetase, Characterisation of gamma-glutamylcysteine synthetase gene promoter: role of proximal AP-1 (c-fos/c-jun), **Suppl. 6. A56**
Gas appliances, Domestic gas appliances and lung disease, **Suppl. 3. S58**
Gas for cooking, The association of respiratory symptoms and lung function with the use of gas for cooking: results from the European Community Respiratory Health Survey, **Suppl. 6. A40**
Gas exchange threshold, Assessment of fitness in patients with cystic fibrosis and mild lung disease, **425**
Gender
Influence of age and gender on the incidence of drug resistance in tuberculosis, **Suppl. 6. A34**
Sex differences in weight perception in cystic fibrosis, **Suppl. 6. A45**
Gene therapy
Cancer gene therapy with a heat shock protein gene, **Suppl. 6. A27**
Gene therapy for lung inflammatory diseases: not so far away?, **742**
Selection of novel cationic liposomes for respiratory gene therapy, **Suppl. 6. A83**
Gene transfer
Assessment of the barriers to cationic liposome-mediated pulmonary gene transfer, **Suppl. 6. A83**
Effects of influenza virus on gene transfer *in vivo*, **Suppl. 6. A83**
General practice (practitioners)
General practice based community intervention trial on the management of asthma, **Suppl. 6. A18**
General practice spirometry in North Staffordshire, **Suppl. 6. A74**
How general practitioners manage acute asthma attacks, **153**
Generation and head-only delivery, A system for the generation and head-only delivery of submicronic particles for the study of the health effects of particulate air pollution, **Suppl. 6. A40**
Genetics
Absence of genetic linkage of chromosome 5q31 with asthma and atopy in the general population, **816**
Atopy phenotype in subjects with variants of the β subunit of the high affinity IgE receptor, **654**
Diffuse lung disease: product of genetic susceptibility and environmental encounters, **92**
Genetic predisposition to sarcoidosis: MHC and non-MHC polymorphisms, **Suppl. 6. A21**
Genetic predisposition to scleroderma, **Suppl. 6. A64**
Outcome for children of parents with atopic asthma and transient childhood wheezy bronchitis, **953**
Geographic variation
Geographic variations in the prevalence of asthma symptoms and its association with poverty, **Suppl. 6. A7**
Geographical variation in the prevalence of asthma symptoms in New Zealand, **Suppl. 6. A40**
Ghana, Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren, **161**
Gianturco stents, Gianturco stents in the tracheobronchial tree: *letter*, **400**
Gliotoxin, Diffusible component from the spore surface of the fungus *Aspergillus fumigatus* which inhibits the macrophage oxidative burst is distinct from gliotoxin and other hyphal toxins, **796**
Glutathione, Characterisation of gamma-glutamylcysteine synthetase gene promoter: role of proximal AP-1 (c-fos/c-jun), **Suppl. 6. A56**
Glycoprotein, A study of a new cachectic factor in a group of patients with early lung cancer, **Suppl. 6. A28**
Graft dysfunction, Exhaled nitric oxide measurements and graft dysfunction in pulmonary transplantation, **Suppl. 6. A53**
Graft versus host disease, Bronchiectasis in bone marrow transplantation, **392**: commentary, **390**
Granulomatous inflammation, Growth factors and granulomatous inflammation: *letter*, **588**
Granulomatous lymphadenopathy, Pulmonary artery occlusion by tuberculous mediastinal lymphadenopathy, **301**
Grass pollen, Effect of thunderstorms and airborne grass pollen on the incidence of acute asthma in England, 1990–94, **680**

Growth factors, Growth factors and granulomatous inflammation: *letter*, **588**
Growth hormone
Effect of growth hormone on human alveolar macrophage oxidative metabolism, **818**, **818**
Guanylyl cyclases, Homologous desensitisation of soluble and particulate guanylyl cyclases in cultured human airway smooth muscle, **Suppl. 6. A52**
Guidelines
British guidelines on asthma management. 1995 review and position statement, **Suppl. 1. S1–21**: *letters*, **665**, **932**
BTS Guidelines for the management of chronic obstructive pulmonary disease, **Suppl. 5. S1-S28**
Impact of management guidelines on the outcome of severe community acquired pneumonia, **17**

Haem oxygenase mRNA, Tissue distribution of constitutive and inducible haem oxygenase mRNA in normal and lipopolysaccharide treated rats, **Suppl. 6. A29**
Haemophilus influenzae, Bronchial inflammation in patients colonised with *Haemophilus parainfluenzae* and non-typeable *Haemophilus influenzae*, **Suppl. 6. A13**
Haemophilus parainfluenzae, Bronchial inflammation in patients colonised with *Haemophilus parainfluenzae* and non-typeable *Haemophilus influenzae*, **Suppl. 6. A13**
Haemoptysis, Accessory cardiac bronchus presenting with haemoptysis, **490**: commentary, **486**
Haemothorax, Spontaneous haemothorax associated with von Recklinghausen's disease: review of occurrence in Japan, **577**: commentary, **575**
Halolite, Halolite: a novel liquid drug aerosol delivery system, **Suppl. 6. A83**
Hamartoma, Malignant chondroid syringoma presenting as multiple pulmonary nodules, **395**
Hand held notes, Hand held notes for patients with chronic obstructive pulmonary disease, **Suppl. 6. A77**
Hay fever, Bronchial reactivity and dietary antioxidants, **166**
Health service accessibility
Health service accessibility and deaths from asthma in 401 local authority districts in England and Wales, 1988–92, **218**
Health service accessibility and deaths from asthma: *editorial*, **205**
Health technology, Health technology assessment: time for a randomised controlled trial of the role of lung volume reduction surgery in the treatment of emphysema: *editorial*, **755**
Healthcare workers
Opinions of some healthcare professionals on the training of inhalation technique, **Suppl. 6. A70**
Tuberculosis in healthcare workers. A survey of cases in England and Wales, **Suppl. 6. A34**
Heart-lung transplantation, Respiratory mechanics after heart-lung and bilateral lung transplantation, **718**
Heat shock protein, Role of heat shock proteins in the pathogenesis of cystic fibrosis arthritis, **1056**
Heat shock protein gene, Cancer gene therapy with a heat shock protein gene, **Suppl. 6. A27**
Helvolic acid, Diffusible component from the spore surface of the fungus *Aspergillus fumigatus* which inhibits the macrophage oxidative burst is distinct from gliotoxin and other hyphal toxins, **796**
Heme oxygenase, Is heme oxygenase present in plasma and BALF from patients with ARDS? **Suppl. 6. A55**
Heparin, Proteoglycans: the "Teflon" on the airways?, **924**
Hepatitis C, Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha, **33**
HFA-134a beclomethasone dipropionate, Reduced need for a spacer attachment with extrafine aerosol MDI, **Suppl. 6. A81**
HFA-134a propellant aerosol MDIs, Spray force and temperature of CFC and HFA-134a propellant aerosol MDIs, **Suppl. 6. A81**
HFA-beclomethasone extrafine aerosol, HFA-beclomethasone extrafine aerosol improves therapeutic index, **Suppl. 6. A58**
High resolution computerised tomography, HRCT diagnosed lung disease in patients with rheumatoid arthritis, **Suppl. 6. A64**
Hippy ventilator, The Hippy ventilator: effects of a portable ventilator on exercise tolerance in COPD, **Suppl. 6. A38**
Histamine
Adenosine monophosphate and histamine induced broncho-constriction: repeatability and protection by terbutaline, **239**
Antigen induced hyperreactivity to histamine is vagally mediated, **Suppl. 6. A50**
Effects of inhaled histamine, methacholine and capsaicin on sputum levels of alpha-2-macroglobulin, **964**
Histamine induced bronchoconstriction, Association of anxiety with perception of histamine induced bronchoconstriction in patients with asthma, **149**
Histology, Necroscopic histology and the cause of death: *letter*, **397**
HIV
Comparison of delayed hyper-sensitivity in adult cystic fibrosis with sarcoidosis and HIV infected patients, **Suppl. 6. A85**
Decreased exhaled nitric oxide in subjects with HIV infection, **185**
Listeria monocytogenes empyema in an HIV infected patient, **745**
Nebulisers for patients with HIV infection and AIDS, **Suppl. 2. S60**
HIV-1 and HIV-2, Dual infection with HIV-1 and HIV-2: *letter*, **587**
Home environment, The home environment and asthma symptoms in childhood: two population based case-control studies 13 years apart, **618**
Home investigation
Cost comparison of home versus hospital-based investigation of obstructive sleep apnoea, **Suppl. 6. A72**
Diagnostic comparison of home versus hospital-based investigation of obstructive sleep apnoea, **Suppl. 6. A72**
Home investigation of suspected obstructive sleep apnoea in 103 patients, **Suppl. 6. A72**
Use of home sleep studies for diagnosis of the sleep apnoea/hypopnoea syndrome, **1068**
Home renovation dust, Pulmonary infiltration after exposure to home renovation dust: *letter*, **399**
Home visits, What are the expectations of patients with TB when visited at home by a specialist TB nurse? **Suppl. 6. A36**
Hospital admission
Effect of asthma nurse intervention on health outcomes following hospital admission, **Suppl. 6. A46**
Effect of gender on hospital admissions for asthma and prevalence of self-reported asthma: a prospective study based on a sample of the general population, **287**
Emergency hospital admissions for respiratory disorders attributable to summer time ozone episodes in Great Britain, **958**
Quality of life and hospital readmission in patients with chronic obstructive pulmonary disease, **67**
Urban air pollution and emergency admissions for asthma in four European cities: the APHEA Project, **760**
Hospital discharge, Long term survival after hospital discharge from a progressive care programme for patients failing to wean from invasive ventilation on ICU, **Suppl. 6. A73**
Hospital management, Hospital management of asthma, 1990–7, **Suppl. 6. A17**
Hospital readmission, Preventing readmissions to hospital for asthma: *editorial*, **207**
Hospital staff
Transmission of *Pneumocystis carinii* from patients to hospital staff, **422**
Tuberculosis in National Health Service hospital staff in the West Midlands region of England, 1992–5, **994**
Hospital v home rehabilitation
Cost comparison of home versus hospital-based investigation of obstructive sleep apnoea, **Suppl. 6. A72**
Diagnostic comparison of home versus hospital-based investigation of obstructive sleep apnoea, **Suppl. 6. A72**
Randomised trial of hospital v home rehabilitation in severe chronic obstructive pulmonary disease, **Suppl. 6. A11**
House dust mite
Damp housing, sensitisation to house dust mite and respiratory symptoms, **Suppl. 6. A7**
Domestic washing, the effects on the house dust mite, **Suppl. 6. A39**
Effect of mite allergen avoidance on Der p 1 levels in settling dust in UK homes, **Suppl. 6. A3**
Nasal responsiveness to allergen and histamine in patients with perennial rhinitis with and without a late phase response, **143**
Human defensin-1, Down regulation of human defensin-1 (hBD-1) in respiratory syncytial virus infection, **Suppl. 6. A14**
Hydrogen peroxide
Hydrogen peroxide and catalase are inversely related during cardiopulmonary bypass, **Suppl. 6. A55**
Involvement of an NAD(P)H oxidase-like enzyme in superoxide anion and hydrogen peroxide generation by rat type II cells, **465**
Hydrogen peroxide-induced injury, The comparative ability of thiol compounds to protect against hydrogen peroxide-induced injury in airway epithelial cells, **Suppl. 6. A56**

Hydroxyl radical generation, Hydroxyl radical generation by respirable industrial fibres, **Suppl. 6. A31**
5-Hydroxytryptamine, The effect of dexfenfluramine on 5-hydroxytryptamine clearance in the porcine lung, **Suppl. 6. A60**
Hypercapnic respiratory failure, Predictors of hypercapnic respiratory failure in patients with motor neurone disease, **Suppl. 6. A19**
Hypercapnic ventilatory response, Effects of fenoterol on ventilatory response to hypercapnia and hypoxia in patients with chronic obstructive pulmonary disease, **125**
Hyperoxia
Effect of acute alterations in inspired oxygen tension on methacholine induced bronchoconstriction in patients with asthma, **453**
Exhaled NO during graded changes in inhaled oxygen in man, **736**
Hyperresponsiveness, Bronchial hyperresponsiveness in lung transplant recipients: lack of correlation with airway inflammation, **551**
Hypertonic saline
Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients, **Suppl. 6. A43**
Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis, **900**
Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects, **59**
Induction of sputum in cystic fibrosis by inhaled hypertonic saline, **Suppl. 6. A43**
Success rate and safety of sputum induction using hypertonic saline, **Suppl. 6. A15**
Hypertrophic osteoarthropathy, Superior vena cava syndrome associated with *Nocardia farcinica* infection, **492**
Hypertrophic pulmonary osteoarthropathy
Octreotide and hypertrophic pulmonary osteoarthropathy: commentary, **297**
Treatment of resistant pain in hypertrophic pulmonary osteoarthropathy with subcutaneous octreotide, **298**
Hyperventilation syndrome
Hyperventilation syndrome: a syndrome under threat? **Suppl. 3. S30**
Hyperventilation syndrome. Classification based on exercise testing, **Suppl. 6. A71**
Hyperventilators, Carbon dioxide sensitivity in idiopathic hyperventilators, **Suppl. 6. A23**
Hypnotherapy, Controlled trial of hypnotherapy for weight loss in patients with obstructive sleep apnoea, **Suppl. 6. A8**
Hypocapnia, The reproducibility of hypocapnia on exercise over time in idiopathic hyperventilation syndrome, **Suppl. 6. A23**
Hypoxaemia
Effect of exercise and hypoxaemia on myocardial repolarisation in severe chronic obstructive pulmonary disease, **Suppl. 6. A5**
Effect of long term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia, **674**
Long term oxygen therapy in moderate hypoxaemia: *editorial*, **667**
Vasopressin and oxytocin release during prolonged environmental hypoxia in the rat, **84**
Hypoxia
Autonomic dysfunction in patients with chest wall deformity: relationship with presence and severity of nocturnal hypoxia, **Suppl. 6. A11**
Effect of acute alterations in inspired oxygen tension on methacholine induced bronchoconstriction in patients with asthma, **453**
Effect of perinatal exposure to chronic hypoxia, L-NAME and indomethacin upon vascular reactivity and vessel compliance in the rat, **Suppl. 6. A59**
Exhaled NO during graded changes in inhaled oxygen in man, **736**
Influence of hypoxia in augmenting IL-8 generation from human monocytes and macrophages – potential role in the acute respiratory distress syndrome, **Suppl. 6. A30**
Hypoxic ventilatory response, Effects of fenoterol on ventilatory response to hypercapnia and hypoxia in patients with chronic obstructive pulmonary disease, **125**

Idiopathic hyperventilators, Carbon dioxide sensitivity in idiopathic hyperventilators, **Suppl. 6. A23**
Immigrant screening, Is new immigrant screening for tuberculosis still worthwhile? **Suppl. 6. A35**
Immune receptor, Developmental changes in the alveolar macrophage differential and immune receptor expression in normal children, **Suppl. 6. A24**
Immune regulation, Selective inhibition of T cell proliferation but not expression of effector function by human alveolar macrophages, **786**
Immunisation, How well are recommendations on immunisation in patients with chronic obstructive pulmonary disease being met in East Yorkshire, **Suppl. 6. A76**
Immunoglobulin therapy
Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients, **662**
Intravenous immunoglobulin therapy for asthma: time for a closer look? *editorial*, **593**
Immunotherapy, Immunotherapy in asthma, **Suppl. 3. S22**
Impulse oscillometry
Airway resistance measurements: comparison between impulse oscillometry and constant volume body plethysmography, **Suppl. 6. A78**
Impulse oscillometry: intrabreath variability of the respiratory impedence, central resistance and peripheral reactance, **Suppl. 6. A79**
Inaccessible unavailable essential medication
Is asthma treatment affordable in developing countries?, **605**
Treating asthma in developing countries: a problem of inaccessible unavailable essential medication: *editorial*, **589**
Increased permeability, Acute lung injury after aortic surgery: the relation between lung and leg microvascular permeability to ^{111}indium-labelled transferrin and circulating mediators, **866**
India, Relation of fetal growth to adult lung function in South India, **895**
Indian critical care unit, Role of bronchoscopy in an Indian critical care unit: an experience of 118 procedures, **Suppl. 6. A65**
Indian subcontinent, Changing pattern of respiratory tuberculosis in the UK in adult patients from the Indian subcontinent, **802**
Indomethacin
Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects, **59**
Effect of perinatal exposure to chronic hypoxia, L-NAME and indomethacin upon vascular reactivity and vessel compliance in the rat, **Suppl. 6. A59**
Indoor environmental exposures
Home environment and asthma symptoms in childhood: two population based case-control studies 13 years apart, **618**
Indoor allergen exposures are not related to current asthma in atopic adults, **Suppl. 6. A2**
Indoor environment changes and respiratory health, **Suppl. 6. A2**
Industrial fibres, Hydroxyl radical generation by respirable industrial fibres, **Suppl. 6. A31**
Infants
Does diminished airway function at birth persist to one year of age? **Suppl. 6. A24**
Effect of mite allergen avoidance on Der p 1 levels in settling dust in UK homes, **Suppl. 6. A3**
Maternal smoking and infant health: reduced antioxidant intake and/or increased oxidant stress? **Suppl. 6. A24**
Measures for achieving low allergen environment in pregnancy and in early life, **Suppl. 6. A3**
Prediction of persistent wheeze in infants, **Suppl. 6. A24**
Pulmonary oxidative stress response in young children with cystic fibrosis, **557**
Infertility, Confidential study of awareness of infertility and sexual matters in males with cystic fibrosis, **Suppl. 6. A44**
Inflammation, Bronchial hyperresponsiveness in lung transplant recipients: lack of correlation with airway inflammation, **551**
Inflammatory bowel disease, Clinical, physiological and radiological characteristics of pulmonary disease in patients with inflammatory bowel disease, **Suppl. 6. A64**
Inflammatory mediators, Differential effects of inflammatory mediators on PMN deformability and adhesion, **Suppl. 6. A30**
Inflammatory response, Ischaemia reperfusion, inflammatory responses and acute lung injury: *editorial*, **841**
Influenza immunisation, Does influenza immunisation cause exacerbations of chronic airflow obstruction or asthma?, **190**
Influenza virus, Effects of influenza virus on gene transfer in vivo, **Suppl. 6. A83**
Inhalation drug delivery, Inhalation drug delivery from seven different spacer devices: *letter*, **585**
Inhalation technique, The opinions of some healthcare professionals on the training of inhalation technique, **Suppl. 6. A70**

Inhaled corticosteroids
Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients, **55**
Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children, **686**
Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma, **853**
Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids, **535**
Provision of asthma medications in developing countries: a view from the pharmaceutical industry: *editorial*, **590**
Inhaled fluticasone propionate, Comparison of a lower fixed dose of inhaled fluticasone propionate (FP) with a high dose step-down regimen of FP in the prevention of re-exacerbations after an acute severe attack of asthma requiring oral corticosteroid therapy, **Suppl. 6. A1**
Inner city primary school children, Urinary cotinine concentrations, reported household smoking and respiratory symptoms in inner city primary school children, **Suppl. 6. A41**
Inspiratory muscle
Diaphragm thickness and inspiratory strength in patients with Duchenne muscular dystrophy, **472**
Inspiratory muscle endurance in adults with mild-to-moderate idiopathic scoliosis, **Suppl. 6. A79**
Inspiratory muscle endurance and lung volumes in chronic stable heart failure, **Suppl. 6. A79**
Inspiratory muscle performance using negative pressure inspiratory loading, **Suppl. 6. A29**
Inspiratory muscle strength in acute asthma measured by sniff nasal pressure, **Suppl. 6. A80**
Randomised controlled trial of inspiratory muscle training in stable chronic heart failure, **Suppl. 6. A22**
Insulin resistance, Beta-cell dysfunction and insulin resistance in adult patients with cystic fibrosis, **Suppl. 6. A85**
Intensive care unit
Nebuliser therapy in the intensive care unit, **Suppl. 2. S56**
Survival to discharge from hospital in a progressive care programme for patients failing to wean from ventilation on ICU, **Suppl. 6. A20**
Interferon-alpha, Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha, **33**
Interferon-gamma-receptor deficiency, Intractable mycobacterial infections associated with genetic defects in the receptor for interferon gamma: what does this tell us about immunity to mycobacteria? **Suppl. 3. S41**
Interferon-gamma-receptor gene, Intractable mycobacterial infections associated with genetic defects in the receptor for interferon gamma: what does this tell us about immunity to mycobacteria? **Suppl. 3. S41**
Interleukin-1β
Effect of inhaled glucocorticoids on IL-1β and IL-1 receptor antagonist (IL-1ra) expression in asthmatic bronchial epithelium, **407**
Role of cyclooxygenase-2 induction in IL-1β induced desensitisation of human airway smooth muscle cell responses to isoprenaline, **Suppl. 6. A51**
Interleukin-5 inhibitors, Anti-interleukin 5 strategies as a potential treatment for asthma, **483**
Interleukin-6, Systemic IL-6 and IL-10 levels in community acquired pneumonia, **Suppl. 6. A13**
Interleukin-8
Bradykinin induces IL-8 production via the activation of β2 receptors in human airway smooth muscle cells: role of cyclooxygenase metabolites, **Suppl. 6. A51**
Effect of exposure to swine dust on levels of IL-8 in airway lavage fluid, **638**
Induction of interleukin-8 and tumour necrosis factor alpha expression in lung epithelial cells following exposure to ultrafine particles and quartz, **Suppl. 6. A54**
Influence of hypoxia in augmenting IL-8 generation from human monocytes and macrophages – potential role in the acute respiratory distress syndrome, **Suppl. 6. A30**
Interleukin-8 in bronchoalveolar lavage fluid from bone marrow transplant recipients, **Suppl. 6. A54**
Interleukin-10
Interleukin-10 promoter genotype in relation to pulmonary function, BMI and bacterial colonisation in cystic fibrosis, **Suppl. 6. A84**
Relative production of tumour necrosis factor and interleukin 10 in adult respiratory distress syndrome, **442**
Systemic IL-6 and IL-10 levels in community acquired pneumonia, **Suppl. 6. A13**
Interstitial lung disease
Comparison of outcome of pulmonary rehabilitation in obstructive lung disease, interstitial lung disease and chest wall disease, **Suppl. 6. A11**
Does vascular permeability factor play a role in interstitial lung disease? **Suppl. 6. A20**
Lung function impairment does not follow video assisted thoracoscopic lung biopsy for the diagnosis of interstitial lung disease, **Suppl. 6. A65**
Intrapleural streptokinase, Intrapleural streptokinase in the drainage of malignant multiloculated pleural effusions, **Suppl. 6. A67**
Intravenous immunoglobulin
Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients, **662**
Intravenous immunoglobulin therapy for asthma: time for a closer look? *editorial*, **593**
Invasive antenatal procedures, Perinatal lung function and invasive antenatal procedures, **181**
Ipratropium bromide
Influence of order of administration on response to nebulised ipratropium bromide and salbutamol, **Suppl. 6. A76**
Thermogenic effect of bronchodilators in patients with chronic obstructive pulmonary disease, **130**: *letter*, **751**
Iron overload, Iron overload during paediatric cardiopulmonary bypass, **Suppl. 6. A56**
Ischaemia, Ischaemia reperfusion, inflammatory responses and acute lung injury: *editorial*, **841**
Isocapnic hyperventilation, Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air, **1074**
Isoprenaline, Role of cyclooxygenase-2 induction in IL-1β induced desensitisation of human airway smooth muscle cell responses to isoprenaline, **Suppl. 6. A51**
Isothiazolinone, Occupational asthma in an isothiazolinone manufacturing plant, **746**

Joint hypermobility, Joint hypermobility in patients with primary spontaneous pneumothorax, **Suppl. 6. A73**

L-NAME
Effect of perinatal exposure to chronic hypoxia, L-NAME and indomethacin upon vascular reactivity and vessel compliance in the rat, **Suppl. 6. A59**
Time dependent effects of L-NAME on pulmonary macromolecular transport in endotoxaemia, **Suppl. 6. A30**
Lactate threshold, Assessment of fitness in patients with cystic fibrosis and mild lung disease, **425**
Lactose, Minimum dose of inhaled lactose sensed by asthmatic patients, **Suppl. 6. A57**
Laser, Laser assisted uvulopalatoplasty in sleep disordered breathing: *editorial*, **5**
Late asthmatic reactions, Effect of cyclosporin A on the allergen-induced late asthmatic reaction, **447**
Launois-Bensaude syndrome, Surgical management of Launois-Bensaude syndrome, **834**
Leucocyte larceny, Pseudohypoxaemia in a patient with acute leukaemia, **394**: commentary, **390**
Leucocyte proteinase inhibitor, Neutrophil collagenase (MMP-8) does not exert serpinase activity against secretory leucocyte proteinase inhibitor or elafin, **Suppl. 6. A17**
Leukaemia, Pseudohypoxaemia in a patient with acute leukaemia, **394**: commentary, **390**
Leukotriene B_4
Enhancement of leukotriene B_4 release in stimulated asthmatic neutrophils by platelet activating factor, **1024**
Release of prostaglandin E_2 and leukotriene B_4 by alveolar macrophages from patients with sarcoidosis, **76**
Leukotriene C_4, Use of leukotriene C_4 for detection of airway hyperreactivity in asthma, **Suppl. 6. A51**
Leukotriene D_4
Effect of inhaled prostaglandin D_2 in normal and atopic subjects, and of pretreatment with leukotriene D_4, **513**
Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D_4 challenge in normal volunteers, **519**

Leukotriene receptor antagonist
Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D_4 challenge in normal volunteers, **519**
Increased urinary excretion of LTE_4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist, **1030**
Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma, **523**
Leukotriene synthesis inhibition
Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005, **348**
Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005, **342**
Leukotrienes, Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air, **1074**
Life-threatening respiratory disease, Information provision and patients' perceptions in life-threatening respiratory disease, **Suppl. 6. A33**
Lifestyle risk factors, Case-control study of lifestyle risk factors for tuberculosis in Liverpool, UK, **Suppl. 6. A34**
Limb muscle strength, Diaphragm and limb muscle strength in the critical care unit, **Suppl. 6. A19**
Linkage, Absence of genetic linkage of chromosome 5q31 with asthma and atopy in the general population, **816**
Lion Intoxilyzer 6000UK, Ability of subjects with respiratory diseases to activate the Lion Intoxilyzer 6000UK, **Suppl. 6. A29**
Lipid peroxides, Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease, **565**
Lipomatosis, Surgical management of Launois-Bensaude syndrome, **834**
Lipopolysaccharide, Effects of inhaled lipopolysaccharide on neutrophil numbers in induced sputum in normal and asthmatic subjects, **Suppl. 6. A15**
Lipopolysaccharide treated rats, Tissue distribution of constitutive and inducible haem oxygenase mRNA in normal and lipopolysaccharide treated rats, **Suppl. 6. A29**
Liposome-mediated CFTR gene transfer, A double blind placebo controlled trial of pulmonary and nasal administration of liposome-mediated CFTR gene transfer in CF subjects, **Suppl. 6. A3**
Liposomes, Gene therapy for lung inflammatory diseases: not so far away?, **742**
5-Lipoxygenase, Too many COX (cyclo-oxygenase) spoil the broth: aspirin-sensitive asthma and 5-lipoxygenase: *editorial*, **933**
5-Lipoxygenase activating protein inhibitor, Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air, **1074**
Liquid ventilation, Liquid ventilation in the preterm neonate, **Suppl. 3. S3**
Listeria monocytogenes, *Listeria monocytogenes* empyema in an HIV infected patient, **745**
Liver cirrhosis, Polymerisation of the I variant of alpha-1-antitrypsin results in plasma deficiency and liver cirrhosis, **Suppl. 6. A16**
Lobar transplantation, Experimental bilateral lobar lung transplantation and its application in humans, **714**
Long acting β agonists, Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids, **535**
Long term ex-smokers, The lung cancer risk of long term ex-smokers is much less than that of smokers but much higher than that of non-smokers, **Suppl. 6. A31**
Long-term oxygen therapy
Autonomic neuropathy and LTOT in patients with COPD, **Suppl. 6. A11**
Effect of long term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia, **674**
Long term oxygen therapy in moderate hypoxaemia: *editorial*, **667**
Long-term ventilatory support, A survey of UK children receiving long-term ventilatory support at home, **Suppl. 6. A23**
Low salt diet, Effect of endogenous activation of the renin-angiotensin system by low salt diet on rat airway remodelling, **Suppl. 6. A53**
Lower respiratory illness, Parental smoking and lower respiratory illness in infancy and early childhood, **905**
Lung biopsy, Delayed pneumothorax after CT-guided percutaneous fine needle aspiration lung biopsy, **581**: commentary, **575**
Lung cancer
Age and the treatment of lung cancer: *letter*, **203**
Asbestos and lung cancer: *letter*, **306**
Audit of the timely management of patients with lung cancer, **Suppl. 6. A32**
Clinical trials in lung cancer: nihilism versus enthusiasm: Altounyan address, **598**: *letter*, **1018**
Delays in the diagnosis and surgical treatment of lung cancer: *letter*, **837**
Delays in the diagnosis and treatment of lung cancer: *letter*, **398**
Delays in the management of lung cancer: *editorial*, **107**
Delays in the management of lung cancer – mostly the patients fault? **Suppl. 6. A31**
Effect of a daily 'drop-in' clinic upon delays in the diagnosis and management of lung cancer, **Suppl. 6. A32**
Histological confirmation rate of lung cancer in Salford in 1994, **Suppl. 6. A32**
Lung cancer in relation to exposure to silica dust, silicosis and uranium production in South African gold miners, **271**
Lung cancer risk of long term ex-smokers is much less than that of smokers but much higher than that of non-smokers, **Suppl. 6. A31**
Lymph node staging in non-small cell lung cancer: evaluation by [^{18}F]FDG positron emission tomography, **438**
Occult lung cancer in patients with bullous emphysema, **289**
Palliative care needs of patients with lung cancer following the breaking of bad news in an outpatient clinic, **Suppl. 6. A33**
Patient held records in lung cancer. A pilot study, **Suppl. 6. A33**
Prognostic significance of plasma D-dimer levels in patients with lung cancer, **563**
Quality of life in end-stage chronic obstructive pulmonary disease and lung cancer: a comparative study, **Suppl. 6. A10**
Risk of malignant neoplasms in patients with pulmonary sarcoidosis, **892**
Silica exposure and risk of cancer: *letter*, **203**
Study of a new cachectic factor in a group of patients with early lung cancer, **Suppl. 6. A28**
Transcutaneous abdominal ultrasonography in the staging of lung cancer, **276**
Lung delivery, Effects of airway calibre on lung delivery of nebulised salbutamol, **1036**
Lung disease
HRCT diagnosed lung disease in patients with rheumatoid arthritis, **Suppl. 6. A64**
Regression of polyvinylchloride polymer pneumoconiosis, **748**
Lung epithelial cells
Induction of interleukin-8 and tumour necrosis factor alpha expression in lung epithelial cells following exposure to ultrafine particles and quartz, **Suppl. 6. A54**
Ultrafine carbon particles: induction of oxidative stress in lung epithelial cells, **Suppl. 6. A55**
Lung fibrosis, Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomographic scans, **265**
Lung function
Changes in lung function on ascent to altitude, **Suppl. 6. A22**
Chronic bronchitis in textile workers, **22**
Clinical outcome after acquisition of *Burkholderia cepacia*, **Suppl. 6. A41**
Domestic gas appliances and lung disease, **Suppl. 3. S58**
Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha-1-antitrypsin deficiency (PiZZ), **244**
Effect of fresh fruit consumption on lung function and wheeze in children, **628**
Long term azithromycin improves lung function in children with cystic fibrosis, **Suppl. 6. A42**
Lung function and *Burkholderia cepacia* colonisation: case control study, **Suppl. 6. A41**
Lung function characteristics of elderly people with a diagnostic label of asthma, **Suppl. 6. A75**
Lung function impairment does not follow video assisted thoracoscopic lung biopsy for the diagnosis of interstitial lung disease, **Suppl. 6. A65**
Lung function and survival in subjects with alpha-1-antitrypsin deficiency PiZZ who have never smoked, **Suppl. 6. A49**
Relation of fetal growth to adult lung function in South India, **895**
Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation, **643**
Lung function services, A survey of lung function services offered by hospitals in the United Kingdom, **Suppl. 6. A29**

Lung function test, Comparison of standardised residuals and percent predicted in delineating normal from abnormal lung function test results, **Suppl. 6. A71**
Lung inflammation, Ultrafine particles, lung inflammation and oxidant stress, **Suppl. 6. A30**
Lung inflammatory diseases, Gene therapy for lung inflammatory diseases: not so far away? **742**
Lung injury
Acute lung injury after aortic surgery: the relation between lung and leg microvascular permeability to ^{111}indium-labelled transferrin and circulating mediators, **866**
Ischaemia reperfusion, inflammatory responses and acute lung injury: *editorial*, **841**
Lung transfer factor, Relationship of serum elastin peptide level to single breath transfer factor for carbon monoxide in French coal miners, **1045**
Lung transplantation
Bronchial hyperresponsiveness in lung transplant recipients: lack of correlation with airway inflammation, **551**
Epidemiology of chronic *Pseudomonas aeruginosa* infections in the airways of lung transplant recipients with cystic fibrosis, **318**
Exhaled nitric oxide measurements and graft dysfunction in pulmonary transplantation, **Suppl. 6. A53**
Experimental bilateral lobar lung transplantation and its application in humans, **714**
Immunopathological changes in the airways of stable lung transplant recipients, **322**
Respiratory mechanics after heart-lung and bilateral lung transplantation, **718**
Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation, **643**
Should patients with cystic fibrosis infected with *Burkholderia cepacia* undergo lung transplantation? *editorial*, **671**
Lung volume
Comparison of two new methods for the measurement of lung volumes with two gold standard methods, **Suppl. 6. A28**
Cryptogenic fibrosing alveolitis with preserved lung volumes, **998**
Inspiratory muscle endurance and lung volumes in chronic stable heart failure, **Suppl. 6. A79**
Lung volume reduction surgery
Changes in ventilatory mechanics and diaphragmatic function after lung volume reduction surgery in patients with COPD, **545**
Health technology assessment: time for a randomised controlled trial of the role of lung volume reduction surgery in the treatment of emphysema: *editorial*, **755**
Lymph node staging, Lymph node staging in non-small cell lung cancer: evaluation by [^{18}F]FDG positron emission tomography, **438**
Lymphangioleiomyomatosis, Pregnancy in lymphangioleiomyomatosis, **Suppl. 6. A65**
Lymphocytes, Lymphocyte dynamics: caution in interpreting BAL numbers, **1078**
Lymphocytic interstitial pneumonia, Expression of bcl-2 and Epstein-Barr virus LMP1 in lymphocytic interstitial pneumonia, **12**
Lymphoma, Risk of malignant neoplasms in patients with pulmonary sarcoidosis, **892**
Lymphotoxin-alpha, TNF-alpha and lymphotoxin-alpha polymorphisms in sarcoidosis - no association, **Suppl. 6. A64**

Macrophage, Diffusible component from the spore surface of the fungus *Aspergillus fumigatus* which inhibits the macrophage oxidative burst is distinct from gliotoxin and other hyphal toxins, **796**
Madelung's disease, Surgical management of Launois-Bensaude syndrome, **834**
Magnetic stimulation
Assessment of neonatal diaphragm function by magnetic stimulation of the phrenic nerves, **Suppl. 6. A19**
Cough simulated by rapid rate magnetic stimulation of the thoracic nerve roots, **Suppl. 6. A80**
Measuring phrenic nerve conduction time with magnetic stimulation, **Suppl. 6. A80**
Major histocompatibility complex, Genetic predisposition to sarcoidosis: MHC and non-MHC polymorphisms, **Suppl. 6. A21**
Malignant airway obstruction, Endoscopic laser therapy in malignant tracheobronchial obstruction using sequential Nd YAG laser and photodynamic therapy, **281**
Malignant chondroid syringoma, Malignant chondroid syringoma presenting as multiple pulmonary nodules, **395**
Malignant multiloculated pleural effusions, Intrapleural streptokinase in the drainage of malignant multiloculated pleural effusions, **Suppl. 6. A67**
Man-made fibre, Chronic bronchitis in textile workers, **22**
Markers, Metabolic rate and inflammatory markers in COPD and bronchiectasis, **Suppl. 6. A67**
Marlex mesh, An unusual case of flail chest: surgical repair using Marlex mesh, **488**: commentary, **486**
Mass lesion, Pleural sarcoidosis: a rare presentation, **200**: commentary, **198**: *letter*, **752**
Mass median aerodynamic diameter
Inhalation drug delivery from seven different spacer devices: *letter*, **585**
Optimal particle size for aerosols: *letter*, **586**
Mast cells, Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma, **940**
Maternal smoking, Maternal smoking and infant health: reduced antioxidant intake and/or increased oxidant stress? **Suppl. 6. A24**
Matrix metalloproteinases
Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients, **502**
Matrix metalloproteinases: a role in emphysema? *editorial*, **495**
Migration of neutrophils through human pulmonary endothelial monolayers is not inhibited by inhibitors of matrix metalloproteinases, **Suppl. 6. A54**
Mechanical efficiency, Decreased mechanical efficiency in clinically stable patients with COPD, **981**
Mediastinitis, Optimal treatment of descending necrotising mediastinitis, **702**
Medical audit, Assessing peak flow charts: calculation versus by eye estimation. An audit of Yorkshire physicians, **Suppl. 6. A71**
Meningococcal disease, Three cases of meningococcal pneumonia, **927**: commentary, **926**
Mesothelioma
Aetiology of mesothelioma: are risk factors other than asbestos exposure important? *editorial*, **496**
Asbestos, Simian virus 40 and malignant mesothelioma, **Suppl. 3. S52**
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases, **507**: correction, **1018**
Metallic opacities, Radio-opaque punctate opacities on the chest radiograph following intravenous injection of a bismuth compound, **303**
Metered dose inhalers
Comparison of the lung deposition of radiolabelled beclomethasone dipropionate from a novel dry powder inhaler, conventional pressurised metered dose inhaler and MDI with a spacer attachment, **Suppl. 6. A81**
Further validation on the use of urinary salbutamol excretion to evaluate the relative bioavailability of salbutamol to the lung following inhalation, **Suppl. 6. A82**
Reduced need for a spacer attachment with extrafine aerosol MDI, **Suppl. 6. A81**
Relative lung bioavailability of salbutamol following administration by metered dose inhaler and nebuliser, **Suppl. 6. A82**
Spray force and temperature of CFC and HFA-134a propellant aerosol MDIs, **Suppl. 6. A81**
Methacholine
Effect of acute alterations in inspired oxygen tension on methacholine induced bronchoconstriction in patients with asthma, **453**
Effects of inhaled histamine, methacholine and capsaicin on sputum levels of alpha-2-macroglobulin, **964**
Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood, **946**
Methicillin resistant *Staphylococcus aureus*
Incidence and treatment of methicillin resistant *S. aureus* (MRSA) positive sputum cultures in an adult cystic fibrosis clinic, **Suppl. 6. A4**
Methicillin-resistant *Staphylococcus aureus*: impact at an adult cystic fibrosis centre, **Suppl. 6. A4**
Methotrexate, Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis, **377**
Microbial exposure, Microbial exposure in childhood and subsequent atopy: pertussis immunisation and oral antibiotics, **Suppl. 6. A8**
Mite allergen, Parental collection of specimens to show mite allergen exposure, **Suppl. 6. A39**

MK-0476, Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids, **45**: *letter*, **1099**
Mobility allowance, Disability living allowance, mobility allowance and attendance allowance in adults with cystic fibrosis in the United Kingdom, **Suppl. 6. A69**
Molecular epidemiology, Molecular epidemiology of tuberculosis in inner London, **Suppl. 6. A33**
Molecular genetic analysis, Cystic fibrosis diagnosed by molecular genetic investigation in the mother of a patient with cystic fibrosis, **96**: commentary, **95**
Monnal D ventilator, Secondary failure of nasal intermittent positive pressure ventilation using the Monnal D: effects of changing ventilator, **89**
Montelukast
Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids, **45**: *letter*, **1099**
Increased urinary excretion of LTE_4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist, **1030**
Mortality
Asthma mortality in Birmingham, Solihull and Shropshire: a confidential enquiry, **Suppl. 6. A47**
Health service accessibility and deaths from asthma in 401 local authority districts in England and Wales, 1988–92, **218**
Health service accessibility and deaths from asthma: *editorial*, **205**
Impact of management guidelines on the outcome of severe community acquired pneumonia, **17**
Mortality of adults with asthma: a prospective cohort study, **49**
Optimal treatment of descending necrotising mediastinitis, **702**
Motor neurone disease
Cough function in motor neurone disease, **Suppl. 6. A73**
Diaphragm strength soon after the diagnosis of motor neurone disease, **Suppl. 6. A19**
Predictors of hypercapnic respiratory failure in patients with motor neurone disease, **Suppl. 6. A19**
Mould allergy, Mould allergy is commoner than house dust mite allergy in Salford patients with multiple hospital admissions for asthma (and uncommon in mild asthma), **Suppl. 6. A2**
Mucociliary clearance, Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis, **900**
Mucosal barrier, Airway epithelial repair: breathtakingly quick and multipotentially pathogenic, **1010**
Muscle strength, Diaphragm and limb muscle strength in the critical care unit, **Suppl. 6. A19**
Muscle training, Randomised controlled trial of inspiratory muscle training in stable chronic heart failure, **Suppl. 6. A22**
Muscular dystrophy, Does nocturnal oxygen desaturation predict survival in childhood onset muscular dystrophy, **Suppl. 6. A18**
Mycobacteria, Mycobacteria and sarcoidosis, **Suppl. 3. S47**
Mycobacterial infection, Intractable mycobacterial infections associated with genetic defects in the receptor for interferon gamma: what does this tell us about immunity to mycobacteria? **Suppl. 3. S41**
Mycobacterium tuberculosis, gamma/delta T lymphocytes in *Mycobacterium tuberculosis* infection, **375**
Myocardial repolarisation, The effect of exercise and hypoxaemia on myocardial repolarisation in severe chronic obstructive pulmonary disease, **Suppl. 6. A5**
Myositis, Sarcoidosis and primary biliary cirrhosis with co-existing myositis, **201**: commentary, **198**

N-acetylcystein, Long-term observation in a group of Chernobyl disaster liquidators treated with N-acetylcystein, **Suppl. 6. A56**
NAD(P)H oxidase-like enzyme, Involvement of an NAD(P)H oxidase-like enzyme in superoxide anion and hydrogen peroxide generation by rat type II cells, **465**
Nasal continuous positive airway pressure
Automatic nasal continuous positive airway pressure titration in the laboratory: patient outcomes, **72**
Can autonomic arousals and neural net EEG analysis predict daytime sleepiness and its response to nCPAP in OSA? **Suppl. 6. A9**
Effects of nasal CPAP on simulated driving performance in patients with obstructive sleep apnoea, **648**
Relationship between sleep fragmentation, daytime sleepiness and quality of life in OSA and predictors of improvement in quality of life on nCPAP, **Suppl. 6. A9**
Short term controlled trial of an adjustable oral appliance for the treatment of mild to moderate obstructive sleep apnoea, **362**
Nasal hyperreactivity, Nasal responsiveness to allergen and histamine in patients with perennial rhinitis with and without a late phase response, **143**
Nasal intermittent positive pressure ventilation, Secondary failure of nasal intermittent positive pressure ventilation using the Monnal D: effects of changing ventilator, **89**
Nasal lavage, Effect of exposure to swine dust on levels of IL-8 in airway lavage fluid, **638**
Nasal provocation, Nasal responsiveness to allergen and histamine in patients with perennial rhinitis with and without a late phase response, **143**
National Health Service hospital staff
Opinions of some healthcare professionals on the training of inhalation technique, **Suppl. 6. A70**
Tuberculosis in National Health Service hospital staff in the West Midlands region of England, 1992–5, **994**
Navelbine
ANITA (Adjuvant Navelbine International Trialist Association) A possible solution to the unresolved issues in adjuvant therapy for resectable non-small cell lung cancer, **Suppl. 6. A26**
Six year follow up of the European multicentre randomised study comparing navelbine alone vs navelbine + cisplatin vs vindesine + cisplatin in 612 patients with advanced non-small cell lung cancer, **Suppl. 6. A27**
Nd YAG laser, Endoscopic laser therapy in malignant tracheobronchial obstruction using sequential Nd YAG laser and photodynamic therapy, **281**
Nebulised antipseudomonal antibiotic therapy, Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: *letter*, **398**
Nebulised bronchodilators
Clinical and physiological characteristics of COPD patients responding to domiciliary nebulised bronchodilator, **Suppl. 6. A75**
Most patients with stable COPD prefer inhaled to nebulised bronchodilators, **Suppl. 6. A75**
Nebulised colistin, Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis, **656**
Nebulised ipratropium bromide, Influence of order of administration on response to nebulised ipratropium bromide and salbutamol, **Suppl. 6. A76**
Nebulised salbutamol
Effects of airway calibre on lung delivery of nebulised salbutamol, **1036**
Efficacy of regular versus as-required nebulised salbutamol in patients admitted to hospital with acute asthma, **Suppl. 6. A1**
Estimates of the dosages of salbutamol sulphate delivered to the respiratory tract from three nebulizers, **Suppl. 6. A82**
Influence of order of administration on response to nebulised ipratropium bromide and salbutamol, **Suppl. 6. A76**
Output of salbutamol from nebulisers at different breathing patterns, **Suppl. 6. A82**
Relative lung bioavailability of salbutamol following administration by metered dose inhaler and nebuliser, **Suppl. 6. A82**
Nebuliser chambers, Contamination of nebulizer chambers in domiciliary use, **Suppl. 6. A76**
Nebuliser compressors, Who should pay and who does pay for nebuliser compressors? **Suppl. 6. A68**
Nebuliser treatment, current best practice
Current best practice for nebuliser treatment, **Suppl. 2. S1–106**: introduction, **Suppl. 2. S1**
Guidelines, **Suppl. 2. S4–24**
Nebulised antibiotics for adults with cystic fibrosis, **Suppl. 2. S69**
Nebulised bronchodilators
antibiotics and rhDNase for children with cystic fibrosis, **Suppl. 2. S89**
corticosteroids, and rhDNase in adult patients with cystic fibrosis, **Suppl. 2. S64**
Nebulised drugs in palliative care, **Suppl. 2. S75**
Nebuliser therapy in childhood, **Suppl. 2. S78**
Nebuliser therapy in the intensive care unit, **Suppl. 2. S56**
Nebulisers for asthma, **Suppl. 2. S45**
Nebulisers for bronchiectasis, **Suppl. 2. S72**
Nebulisers for chronic obstructive pulmonary disease, **Suppl. 2. S49**
Nebulisers for the elderly, **Suppl. 2. S53**
Nebulisers for patients with HIV infection and AIDS, **Suppl. 2. S60**
Overview of nebuliser treatment, **Suppl. 2. S25**
Running a domiciliary nebuliser service, **Suppl. 2. S104**

Selecting and using nebuliser equipment, **Suppl. 2. S92**
Staff education, **Suppl. 2. S102**
Summary of guidelines, **Suppl. 2. S2**
Suppliers of nebulisers and compressors, **Suppl. 2. S101**
The science of nebulised drug delivery, **Suppl. 2. S31**

Necroscopic histology, Necroscopic histology and the cause of death: *letter*, **397**

Negative pressure inspiratory loading, Inspiratory muscle performance using negative pressure inspiratory loading, **Suppl. 6. A29**

Neisseria meningitidis, Three cases of meningococcal pneumonia, **927**: commentary, **926**

Neonate, Liquid ventilation in the preterm neonate, **Suppl. 3. S3**

Nephrotoxicity, Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis, **987**

Neuralgic amyotrophy, Recovery of strength in bilateral diaphragm paralysis due to neuralgic amyotrophy, **Suppl. 6. A74**

Neurofibromatosis
Spontaneous haemothorax associated with von Recklinghausen's disease: review of occurrence in Japan, **577**: commentary, **575**
Unusual case of flail chest: surgical repair using Marlex mesh, **488**: commentary, **486**

Neurokinin A, Changes in neurokinin A (NKA) airway responsiveness with inhaled frusemide in asthma, **775**

Neuromuscular blockade, Neuromuscular blockade with acute respiratory failure in a patient receiving cibenzoline, **582**

Neurotoxicity, Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis, **987**

Neutrophil collagenase, Neutrophil collagenase (MMP-8) does not exert serpinase activity against secretory leucocyte proteinase inhibitor or elafin, **Suppl. 6. A17**

Neutrophils
Differential effects of inflammatory mediators on PMN deformability and adhesion, **Suppl. 6. A30**
Effects of inhaled lipopolysaccharide on neutrophil numbers in induced sputum in normal and asthmatic subjects, **Suppl. 6. A15**
Enhancement of leukotriene B_4 release in stimulated asthmatic neutrophils by platelet activating factor, **1024**
Migration of neutrophils through human pulmonary endothelial monolayers is not inhibited by inhibitors of matrix metalloproteinases, **Suppl. 6. A54**
Neutrophil migration across human pulmonary endothelial monolayers, **Suppl. 6. A54**
Quantum proteolysis by neutrophils (PMN): implications for pulmonary emphysema in alpha1-antitrypsin deficiency, **Suppl. 6. A16**

Nickel, Occupational asthma due to chrome and nickel electroplating, **28**

Nippy ventilator, Secondary failure of nasal intermittent positive pressure ventilation using the Monnal D: effects of changing ventilator, **89**

Nitric oxide
Chronic lung disease and pulmonary hypertension: yes or no to NO? *editorial*, **105**
Decreased exhaled nitric oxide in subjects with HIV infection, **185**
Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension, **1051**
Effect of measurement conditions on measured levels of peak exhaled nitric oxide, **697**
Exhaled nitric oxide measurements and graft dysfunction in pulmonary transplantation, **Suppl. 6. A53**
Exhaled NO during graded changes in inhaled oxygen in man, **736**
Inhaled nitric oxide and arterial oxygen tension in patients with chronic obstructive pulmonary disease and severe pulmonary hypertension, **120**
Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breath holding, **540**
Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange, **369**
Nitrite levels in breath condensate of cystic fibrosis patients are raised in contrast to exhaled nitric oxide levels, **Suppl. 6. A84**
NO: COPD and beyond, **Suppl. 3. S16**
Regulation of nitric oxide release from airspace epithelial cells, **Suppl. 6. A52**

Nitric oxide synthase, Co-induction of iNOS and COX-2 in PA smooth muscle cells: a comparison between rat and human, **Suppl. 6. A61**

Nitrite levels, Nitrite levels in breath condensate of cystic fibrosis patients are raised in contrast to exhaled nitric oxide levels, **Suppl. 6. A84**

Nitrogen dioxide, Respiratory effects of air pollution in chronic obstructive pulmonary disease: a three month prospective study, **1040**

Nocardia farcinica, Superior vena cava syndrome associated with *Nocardia farcinica* infection, **492**

Nocturnal desaturation, The prevalence of nocturnal desaturation in chronic heart failure, **Suppl. 6. A12**

Nocturnal hypoxia, Autonomic dysfunction in patients with chest wall deformity: relationship with presence and severity of nocturnal hypoxia, **Suppl. 6. A11**

Nocturnal oxygen desaturation, Does nocturnal oxygen desaturation predict survival in childhood onset muscular dystrophy, **Suppl. 6. A18**

Nocturnal supplemental oxygen, Effect of nocturnal supplemental oxygen on sleep quality and daytime cognitive function in chronic heart failure, **Suppl. 6. A12**

Nocturnal symptoms, Bambuterol versus salmeterol in asthma patients with nocturnal symptoms, **Suppl. 6. A58**

Non-invasive ventilation
Impact of non-invasive ventilation on nursing workload – Yorkshire Non-invasive Ventilation Trial, **Suppl. 6. A25**
Physiological effects and optimisation of nasal assist-control ventilation for patients with chronic obstructive pulmonary disease in respiratory failure, **690**
Prevalence of acidosis in patients admitted to hospital with an exacerbation of COPD - implications for non-invasive ventilation, **Suppl. 6. A25**
Provision of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United Kingdom, **Suppl. 6. A68**
UK survey of the practice of non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease, **Suppl. 6. A25**

Non-small cell lung cancer
ANITA (Adjuvant Navelbine International Trialist Association) A possible solution to the unresolved issues in adjuvant therapy for resectable non-small cell lung cancer, **Suppl. 6. A26**
Chemotherapy in non-small cell lung cancer: a viable cost effective option? **Suppl. 6. A27**
Six year follow up of the European multicentre randomised study comparing navelbine alone vs navelbine + cisplatin vs vindesine + cisplatin in 612 patients with advanced non-small cell lung cancer, **Suppl. 6. A27**

Notices, **102**, **204**, **306**, **588**, **666**, **838**, **932**, **1018**

Nurse-led home management, Impact of a nurse-led home management training programme in children admitted to hospital with acute asthma: a randomised controlled study, **223**

Obstructive sleep apnoea
Automatic nasal continuous positive airway pressure titration in the laboratory: patient outcomes, **72**
Can autonomic arousals and neural net EEG analysis predict daytime sleepiness and its response to nCPAP in OSA? **Suppl. 6. A9**
Controlled trial of hypnotherapy for weight loss in patients with obstructive sleep apnoea, **Suppl. 6. A8**
Cost comparison of home versus hospital-based investigation of obstructive sleep apnoea, **Suppl. 6. A72**
Diagnostic comparison of home versus hospital-based investigation of obstructive sleep apnoea, **Suppl. 6. A72**
Does obstructive sleep apnoea have a training effect on the inspiratory muscles? **Suppl. 6. A80**
Effect of body position on tongue posture in awake patients with obstructive sleep apnoea, **255**
Effects of nasal CPAP on simulated driving performance in patients with obstructive sleep apnoea, **648**
Evaluation of diaphragmatic fatigue in obstructive sleep apnoeas during non-REM sleep, **731**
Home investigation of suspected obstructive sleep apnoea in 103 patients, **Suppl. 6. A72**
Natural evolution of moderate sleep apnoea syndrome: significant progression over a mean of 17 months, **872**
Obstructive sleep apnoea: a progressive disorder? *editorial*, **843**
Patterns of continuous positive airways pressure use at the Scottish National Sleep Centre, **Suppl. 6. A9**
Predictors of overnight blood pressure changes in normal subjects, **Suppl. 6. A12**

Prospective audit of the investigation and treatment of snoring and obstructive sleep apnoea in the Nottingham health district, **Suppl. 6. A8**
Provision of CPAP machines in Avon in the financial year 1996–1997, **Suppl. 6. A9**
Relationship between sleep fragmentation, daytime sleepiness and quality of life in OSA and predictors of improvement in quality of life on nCPAP, **Suppl. 6. A9**
Short term controlled trial of an adjustable oral appliance for the treatment of mild to moderate obstructive sleep apnoea, **362**
Who should receive treatment for sleep apnoea? *editorial*, **103**
see also Sleep apnoea/hypopnoea syndrome
Obstructive spirometry, Respiratory symptoms to not predict airways obstruction in an elderly hospital population, **Suppl. 6. A75**
Occupation, Occupation and COPD: *letter*, **399**
Occupational asthma
Occupational asthma in an isothiazolinone manufacturing plant, **746**
Occupational asthma due to chrome and nickel electroplating, **28**
Occupational exposure, Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha-1-antitrypsin deficiency (PiZZ), **244**
Occupational surveillance, Tuberculosis in National Health Service hospital staff in the West Midlands region of England, 1992–5, **994**
Octreotide
Octreotide and hypertrophic pulmonary osteoarthropathy: commentary, **297**
Treatment of resistant pain in hypertrophic pulmonary osteoarthropathy with subcutaneous octreotide, **298**
Oedema, Oedema and cor pulmonale revisited: *editorial*, **401**
Oesophageal ballooning, Oesophageal plastic repair for symptomatic ballooning following circular oesophageal myotomy and correction of oesophageal atresia, **487**: commentary, **486**
Oesophagoplasty, Oesophageal plastic repair for symptomatic ballooning following circular oesophageal myotomy and correction of oesophageal atresia, **487**: commentary, **486**
ONO-1078
Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D_4 challenge in normal volunteers, **519**
Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma, **523**
Optimal particle size, Optimal particle size for aerosols: *letter*, **586**
Oral appliances, Short term controlled trial of an adjustable oral appliance for the treatment of mild to moderate obstructive sleep apnoea, **362**
Oral vasodilators, Cardiopulmonary exercise testing assessment of the efficacy of oral vasodilators in patients with pulmonary hypertension secondary to connective tissue disease, **Suppl. 6. A63**
Organic dust, Effect of exposure to swine dust on levels of IL-8 in airway lavage fluid, **638**
Osteoporosis
Prevalence of osteoporosis in adults with cystic fibrosis, **Suppl. 6. A44**
Severe osteoporosis in cystic fibrosis patients post transplantation, **Suppl. 6. A44**
Outcome
Indications and outcome of surgery for pulmonary aspergilloma, **813**
Outcome of patients referred by general practitioners to a hospital radiology department for a chest radiograph, **Suppl. 6. A31**
Outpatient rehabilitation programme
Benefits of a 12-week outpatient rehabilitation programme are independent of the degree of lung dysfunction in patients with COPD, **Suppl. 6. A37**
Effects of a 12-week supervised outpatient rehabilitation programme on physical performance in patients with COPD in the north east of England, **Suppl. 6. A37**
Overlap syndrome, Sarcoidosis and primary biliary cirrhosis with co-existing myositis, **201**: commentary, **198**
Oxidant stress
Maternal smoking and infant health: reduced antioxidant intake and/or increased oxidant stress? **Suppl. 6. A24**
Oxidant stress induces the release of both PGE_2 and 8-iso PGF_2 by a COX-2 dependent pathway, **Suppl. 6. A61**
Ultrafine particles, lung inflammation and oxidant stress, **Suppl. 6. A30**
Oxidants, Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease, **565**
Oxidation, Effect of growth hormone on human alveolar macrophage oxidative metabolism, **818**
Oxidative stress
Systemic oxidative stress in patients with small cell lung cancer, **Suppl. 6. A27**
Ultrafine carbon particles: induction of oxidative stress in lung epithelial cells, **Suppl. 6. A55**
Oxygen
Does nocturnal oxygen desaturation predict survival in childhood onset muscular dystrophy, **Suppl. 6. A18**
Does oxygen desaturation occur during bronchoscopy in patients receiving supplemental oxygen? **Suppl. 6. A66**
Effect of nocturnal supplemental oxygen on sleep quality and daytime cognitive function in chronic heart failure, **Suppl. 6. A12**
Haemodynamic effects of increasing inspired oxygen concentration, **Suppl. 6. A67**
Oxygen delivery, Comparison of pulsed dose oxygen delivery and continuous oxygen delivery during exercise in patients with COPD, **Suppl. 6. A6**
Oxygen saturation
Effect of posture on oxygen saturation during fibreoptic bronchoscopy, **Suppl. 6. A66**
Prevalence of nocturnal desaturation in chronic heart failure, **Suppl. 6. A12**
Oxygen therapy
Effect of long term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia, **674**
Long term oxygen therapy in moderate hypoxaemia: editorial, **667**
Oxytocin, Vasopressin and oxytocin release during prolonged environmental hypoxia in the rat, **84**
Ozone
Emergency hospital admissions for respiratory disorders attributable to summer time ozone episodes in Great Britain, **958**
Ozone is bad for health - but only for some? *editorial*, **938**

Palliative care
Nebulised drugs in palliative care, **Suppl. 2. S75**
Palliative care and anxiety and depression in end-stage chronic obstructive pulmonary disease: a comparison with lung cancer, **Suppl. 6. A77**
Palliative care needs of patients with lung cancer following the breaking of bad news in an outpatient clinic, **Suppl. 6. A33**
Panbronchiolitis, Erythromycin and diffuse panbronchiolitis, **915**
Pancoast tumours, Pancoast tumours: clinical assessment and long term results of combined radiosurgical treatment, **284**
Paraquat poisoning, Treatment of paraquat poisoning: *letter*, **588**
Parental smoking
Parental smoking and lower respiratory illness in infancy and early childhood, **905**
Parental smoking and prevalence of respiratory symptoms and asthma in school age children, **1081**
Particle size, Optimal particle size for aerosols: *letter*, **586**
Particulate air pollution, A system for the generation and head-only delivery of submicronic particles for the study of the health effects of particulate air pollution, **Suppl. 6. A40**
Particulates, Respiratory effects of air pollution in chronic obstructive pulmonary disease: a three month prospective study, **1040**
Passive smoking
Health effects of passive smoking: introduction, **904**
Parental smoking and lower respiratory illness in infancy and early childhood, **905**
Passive smoking and sudden infant death syndrome: review of the epidemiological evidence, **1003**
What determines levels of passive smoking in children with asthma? **766**
Patients' perceptions, Information provision and patients' perceptions in life-threatening respiratory disease, **Suppl. 6. A33**
PCO_2, Use of end-tidal CO_2 as a non-invasive estimate of arterial PCO_2, **Suppl. 6. A28**
PD156707, The effect of the endothelin-1 receptor antagonist PD156707 in rats with established hypoxic pulmonary hypertension, **Suppl. 6. A63**
Peak cycle ergometry, Exercise limitation and symptoms at peak cycle ergometry in adults with cystic fibrosis, **Suppl. 6. A5**
Peak flow, Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood, **946**

Peak flow charts, Assessing peak flow charts: calculation versus by eye estimation. An audit of Yorkshire physicians, **Suppl. 6. A71**
Percutaneous fine needle aspiration, Delayed pneumothorax after CT-guided percutaneous fine needle aspiration lung biopsy, **581**: commentary, **575**
Perflubron, Liquid ventilation in the preterm neonate, **Suppl. 3. S3**
Pericardial effusion
Pericardial effusion associated with asbestos exposure, **1097**
Severe pulmonary hypertension reversed by antibiotics in a patient with Whipple's disease, **1014**: commentary, **1013**
Pericarditis, Superior vena cava syndrome associated with *Nocardia farcinica* infection, **492**
Perinatal intervention, Adverse perinatal intervention and indices of pulmonary hypertension in adult rat, **Suppl. 6. A59**
Perinatal lung function, Perinatal lung function and invasive antenatal procedures, **181**
Pertussis immunisation, Microbial exposure in childhood and subsequent atopy: pertussis immunisation and oral antibiotics, **Suppl. 6. A8**
Pharmaceutical economics, Is asthma treatment affordable in developing countries?, **605**
Pharmaceutical industry, Provision of asthma medications in developing countries: a view from the pharmaceutical industry: *editorial*, **590**
Pharmacokinetics, Pharmacokinetics and extrapulmonary beta-2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers, **849**
Photodynamic therapy, Endoscopic laser therapy in malignant tracheobronchial obstruction using sequential Nd YAG laser and photodynamic therapy, **281**
Phrenic nerve conduction time, Measuring phrenic nerve conduction time with magnetic stimulation, **Suppl. 6. A80**
Phrenic nerve palsy
Bilateral diaphragmatic weakness: a late complications of radiotherapy, **829**: commentary, **828**
Right phrenic nerve palsy as a complication of indwelling central venous catheters, **831**: commentary, **828**
Phrenic nerve stimulation, Neuromuscular blockade with acute respiratory failure in a patient receiving cibenzoline, **582**
Phrenic nerves, Assessment of neonatal diaphragm function by magnetic stimulation of the phrenic nerves, **Suppl. 6. A19**
Physiotherapy, The effect of posture and physiotherapy on reflux in adult cystic fibrosis patients, **Suppl. 6. A43**
PI SZ phenotype, PI SZ phenotype in chronic obstructive pulmonary disease, **659**
Platelet activating factor
Enhancement of leukotriene B_4 release in stimulated asthmatic neutrophils by platelet activating factor, **1024**
Platelet activating factor revisited: *editorial*, **1019**
Platelets, The effect of chronic dexfenfluramine on platelet function in the Wistar and the fawn-hooded rat, **Suppl. 6. A60**
Pleural biopsy, Comparative trial of Tru-cut biopsy needle vs Abrams punch for pleural biopsy, **Suppl. 6. A66**
Pleural disease
Evaluation of pleural diseases with FDG-PET imaging: preliminary report, **187**
Pleural sarcoidosis: a rare presentation, **200**: commentary, **198**: *letter*, **752**
Pleural effusion
Intrapleural streptokinase in the drainage of malignant multiloculated pleural effusions, **Suppl. 6. A67**
Severe pulmonary hypertension reversed by antibiotics in a patient with Whipple's disease, **1014**: commentary, **1013**
Pleural empyema, Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection, **416**: *letters*, **932, 1099**
Pleural infection, Intrapleural streptokinase: the answer to community acquired pleural infection? *editorial*, **403**
Pleural mesothelioma tissue
Asbestos, Simian virus 40 and malignant mesothelioma, **Suppl. 3. S52**
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases, **507**: correction, **1018**
Pneumoconiosis, Regression of polyvinylchloride polymer pneumoconiosis, **748**
Pneumocystis carinii, Transmission of *Pneumocystis carinii* from patients to hospital staff, **422**
Pneumonia
Pneumonia before two years of age and adult lung function, **Suppl. 6. A38**
Pneumonia deaths in young adults in England and Wales – incidence, pre-existing disease and death certificates, **Suppl. 6. A12**
Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection, **416**: *letters*, **932, 1099**
Serial computed tomographic evaluation in desquamative interstitial pneumonia, **333**
Three cases of meningococcal pneumonia, **927**: commentary, **926**
Pneumonitis, Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis, **377**
Pneumothorax
Delayed pneumothorax after CT-guided percutaneous fine needle aspiration lung biopsy, **581**: commentary, **575**
Joint hypermobility in patients with primary spontaneous pneumothorax, **Suppl. 6. A73**
Recurrence of primary spontaneous pneumothorax, **805**
Short wave diathermy for small spontaneous pneumothorax, **561**
Spontaneous pneumothorax in a patient with an azygos lobe, **579**: commentary, **575**
Treatment of complicated spontaneous pneumothorax by simple talc pleurodesis under thoracoscopy and local anaesthesia, **329**: *letters*, **836**
Video-assisted thoracoscopic surgery (VATS) in the management of spontaneous pneumothorax: *editorial*, **307**: *letters*, **836**
Pollen, Effect of thunderstorms and airborne grass pollen on the incidence of acute asthma in England, 1990–94, **680**
Pollen counts, Climate and aeroallergen levels in asthma: a 12 month prospective study, **528**
Polymerase chain reaction, Transmission of *Pneumocystis carinii* from patients to hospital staff, **422**
Polysomnography, Use of home sleep studies for diagnosis of the sleep apnoea/hypopnoea syndrome, **1068**
Polyvinylchloride, Regression of polyvinylchloride polymer pneumoconiosis, **748**
Population study, Effect of gender on hospital admissions for asthma and prevalence of self-reported asthma: a prospective study based on a sample of the general population, **287**
Port-a-Cath device, Thromboembolism related to a Port-a-Cath device in a patient with cystic fibrosis, **98**: commentary, **95**
Position, prone, Gravitational gradient of perfusion persists in the prone position in ventilated normal subjects, **Suppl. 6. A81**
Positive end expiratory alveolar pressure (PEEPi), Abdominal muscle recruitment and PEEPi during bronchoconstriction in chronic obstructive pulmonary disease, **355**
Positron emission tomography, Evaluation of pleural diseases with FDG-PET imaging: preliminary report, **187**
Post-partum pulmonary eosinophilia, Recurrent post-partum pulmonary eosinophilia, **1095**
Post transplantation, Severe osteoporosis in cystic fibrosis patients post transplantation, **Suppl. 6. A44**
Postoperative air leaks, Flutter valve drainage bags are more effective than underwater seal systems in postoperative air leaks, **Suppl. 6. A66**
Posture
Effect of posture on oxygen saturation during fibreoptic bronchoscopy, **Suppl. 6. A66**
Effect of posture and physiotherapy on reflux in adult cystic fibrosis patients, **Suppl. 6. A43**
Poverty, Geographic variations in the prevalence of asthma symptoms and its association with poverty, **Suppl. 6. A7**
Pranlukast
Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D_4 challenge in normal volunteers, **519**
Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma, **523**
Prednisolone, Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis, **634**
Pregnancy
Measures for achieving low allergen environment in pregnancy and in early life, **Suppl. 6. A3**
Pregnancy in lymphangioleiomyomatosis, **Suppl. 6. A65**
Premenstrual asthma, Premenstrual asthma: still poorly understood: *editorial*, **591**
Preterm neonate, Liquid ventilation in the preterm neonate, **Suppl. 3. S3**
Primary biliary cirrhosis, Sarcoidosis and primary biliary cirrhosis with co-existing myositis, **201**: commentary, **198**
Primary care treatment, Recruitment of children into a study of primary care treatment of childhood asthma, **Suppl. 6. A45**

Primary ciliary dyskinesia, Paradoxical airway responsiveness in children with primary ciliary dyskinesia: effects of exercise and bronchodilator therapy, **Suppl. 6. A23**
Primary pulmonary hypertension
Altered breathing pattern in the fawn hooded rat: a model of primary pulmonary hypertension, **Suppl. 6. A60**
Appetite suppressants and pulmonary hypertension, **Suppl. 3. S63**
Making measurements in the pulmonary circulation: when and how? *editorial*, **9**
Primary spontaneous pneumothorax, Recurrence of primary spontaneous pneumothorax, **805**
Prognosis
Exercise testing and prognosis in adult cystic fibrosis, **291**
Prognostic significance of plasma D-dimer levels in patients with lung cancer, **563**
Prognostic model, A prognostic model for the prediction of survival in cystic fibrosis, **313**
Progressive care programme
Long term survival after hospital discharge from a progressive care programme for patients failing to wean from invasive ventilation on ICU, **Suppl. 6. A73**
Survival to discharge from hospital in a progressive care programme for patients failing to wean from ventilation on ICU, **Suppl. 6. A20**
Proliferation, Lymphocyte dynamics: caution in interpreting BAL numbers, **1078**
Prone position, Gravitational gradient of perfusion persists in the prone position in ventilated normal subjects, **Suppl. 6. A81**
Prophylactic to bronchodilator ratios, What do prophylactic to bronchodilator ratios mean? **Suppl. 6. A59**
Propranolol, Attenuation of propranolol-induced bronchoconstriction by frusemide, **861**
Prostacyclin, Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange, **369**
Prostaglandins
Cough responses to substance P, PGF_2 and low chloride in idiopathic persistent cough, **Suppl. 6. A50**
Differential regulation on short- and long-term PGE_2 release by bradykinin in human airway smooth muscle cells: involvement of B2 receptor-related cyclooxygenase-2 induction, **Suppl. 6. A51**
Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects, **59**
Effect of inhaled prostaglandin D_2 in normal and atopic subjects, and of pretreatment with leukotriene D_4, **513**
Oxidant stress induces the release of both PGE_2 and 8-iso PGF_2 by a COX-2 dependent pathway, **Suppl. 6. A61**
Release of prostaglandin E_2 and leukotriene B_4 by alveolar macrophages from patients with sarcoidosis, **76**
Protease inhibitors, Protease inhibitors modulate human airway smooth muscle cell proliferation in culture, **Suppl. 6. A52**
Protein kinase C, Involvement of an NAD(P)H oxidase-like enzyme in superoxide anion and hydrogen peroxide generation by rat type II cells, **465**
Protein synthesis, Effect of endothelin on protein synthesis in smooth muscle cells from rat pulmonary microvasculature, **Suppl. 6. A62**
Proteoglycans, Proteoglycans: the "Teflon" on the airways?, **924**
Pseudohypoxaemia, Pseudohypoxaemia in a patient with acute leukaemia, **394**: commentary, **390**
Pseudomonas aeruginosa
Effects of airway infection by *Pseudomonas aeruginosa*: a computed tomographic study, **260**
Epidemiology of chronic *Pseudomonas aeruginosa* infections in the airways of lung transplant recipients with cystic fibrosis, **318**
Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis, **987**
Psychomotor performance, Effect of CPAP therapy on daytime function in patients with mild sleep apnoea/hypopnoea syndrome, **114**
Pulmonary artery
Dietary flavanoids cause relaxation of rat pulmonary arteries, **Suppl. 6. A61**
Localisation of angiotensin II receptor subtypes in human pulmonary artery and AT1 mediated smooth muscle cell growth responses in vitro, **Suppl. 6. A62**
Pulmonary artery occlusion, Pulmonary artery occlusion by tuberculous mediastinal lymphadenopathy, **301**
Pulmonary aspergilloma
Indications and outcome of surgery for pulmonary aspergilloma, **813**
Surgical management of pulmonary aspergilloma: *editorial*, **753**
Surgical treatment for pulmonary aspergilloma: a 28 year experience, **810**
Pulmonary beta adrenergic receptor density, Effect of corticosteroids on pulmonary beta adrenergic receptor density and function, **Suppl. 6. A49**
Pulmonary disease, Clinical, physiological and radiological characteristics of pulmonary disease in patients with inflammatory bowel disease, **Suppl. 6. A64**
Pulmonary embolism
Spiral volumetric CT scanning: *letter*, **203**
Suspected acute pulmonary embolism: a practical approach, **Suppl. 4. S1–24**
Pulmonary endothelial monolayers
Migration of neutrophils through human pulmonary endothelial monolayers is not inhibited by inhibitors of matrix metalloproteinases, **Suppl. 6. A54**
Neutrophil migration across human pulmonary endothelial monolayers, **Suppl. 6. A54**
Pulmonary fibrosis, Anticytokine approaches in pulmonary fibrosis: bringing factors into focus, **294**
Pulmonary gas exchange, NO: COPD and beyond, **Suppl. 3. S16**
Pulmonary hypertension
Adverse perinatal intervention and indices of pulmonary hypertension in adult rat, **Suppl. 6. A59**
Angiotensin converting enzyme expression in children and adults with pulmonary hypertension, **Suppl. 6. A62**
Cardiopulmonary exercise testing assessment of the efficacy of oral vasodilators in patients with pulmonary hypertension secondary to connective tissue disease, **Suppl. 6. A63**
Chronic lung disease and pulmonary hypertension: yes or no to NO? *editorial*, **105**
Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension, **1051**
Effect of the endothelin-1 receptor antagonist PD156707 in rats with established hypoxic pulmonary hypertension, **Suppl. 6. A63**
Inhaled nitric oxide and arterial oxygen tension in patients with chronic obstructive pulmonary disease and severe pulmonary hypertension, **120**
Making measurements in the pulmonary circulation: when and how? *editorial*, **9**
Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange, **369**
Plasma levels of Big endothelin-1 and endothelin-1 in neonates with pulmonary hypertension referred for potential extracorporeal membrane oxygenation support, **Suppl. 6. A63**
Pulmonary hypertensive fawn-hooded rat has a normal serotonin transporter coding sequence, **Suppl. 6. A61**
Severe pulmonary hypertension reversed by antibiotics in a patient with Whipple's disease, **1014**: commentary, **1013**
Tumour microembolism presenting as "primary pulmonary hypertension", **1016**: commentary, **1013**
Pulmonary infiltration, Pulmonary infiltration after exposure to home renovation dust: *letter*, **399**
Pulmonary interstitiopathies, What's the meaning of the impaired phagocytosis and intracellular killing in some pulmonary interstitiopathies? **Suppl. 6. A21**
Pulmonary lobar transplantation, Experimental bilateral lobar lung transplantation and its application in humans, **714**
Pulmonary macromolecular transport, Time dependent effects of L-NAME on pulmonary macromolecular transport in endotoxaemia, **Suppl. 6. A30**
Pulmonary metastases, Malignant chondroid syringoma presenting as multiple pulmonary nodules, **395**
Pulmonary microvasculature, Effect of endothelin on protein synthesis in smooth muscle cells from rat pulmonary microvasculature, **Suppl. 6. A62**
Pulmonary oedema, Monitoring pulmonary oedema by electrical impedance tomography, **Suppl. 6. A79**
Pulmonary oxidative stress, Pulmonary oxidative stress response in young children with cystic fibrosis, **557**
Pulmonary rehabilitation
Benefits of a 12-week outpatient rehabilitation programme are independent of the degree of lung dysfunction in patients with COPD, **Suppl. 6. A37**

Comparison of outcome of pulmonary rehabilitation in obstructive lung disease, interstitial lung disease and chest wall disease, **Suppl. 6. A11**
Does pulmonary rehabilitation change exercise behaviour? **Suppl. 6. A37**
Does pulmonary rehabilitation produce a lasting benefit in patients with COPD?, **Suppl. 6. A10**
Effects of a 12-week supervised outpatient rehabilitation programme on physical performance in patients with COPD in the north east of England, **Suppl. 6. A37**
Prolonged effects of pulmonary rehabilitation in patients with COPD, **Suppl. 6. A10**
Randomised controlled trial of pulmonary rehabilitation in a district general hospital, **Suppl. 6. A10**
Randomised trial of hospital v home rehabilitation in severe chronic obstructive pulmonary disease, **Suppl. 6. A11**
Pulmonary resistance arteries, Evidence for two endothelin B receptors on rabbit pulmonary resistance arteries, **Suppl. 6. A62**
Pulmonary sarcoidosis
Analysis of T cell subsets and β chemokines in patients with pulmonary sarcoidosis, **431**
Expression of Fas and its ligand by alveolar T-lymphocytes in pulmonary sarcoidosis, **Suppl. 6. A21**
Release of prostaglandin E_2 and leukotriene B_4 by alveolar macrophages from patients with sarcoidosis, **76**
Pulmonary toxicity, Amiodarone and the lung: wide variations in clinical practice, **Suppl. 6. A74**
Pulmonary vascular disease, Clearance of inhaled 99mTc-DTPA as a clinical index of pure pulmonary vascular disease in systemic sclerosis, **Suppl. 6. A63**
Pulmonary vasoreactivity, Enhanced pulmonary vasoreactivity to serotonin in the fawn hooded rat, **Suppl. 6. A60**
Pulsed dose oxygen delivery, Comparison of pulsed dose oxygen delivery and continuous oxygen delivery during exercise in patients with COPD, **Suppl. 6. A6**

Quality of life
Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting, **879**
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease, **Suppl. 6. A36**
Impact of asthma education on quality of life in white European and Indian subcontinent groups, **Suppl. 6. A17**
Non-acute asthma review in general practice: does it improve patient quality of life? **Suppl. 6. A18**
Quality of life in adults with cystic fibrosis: *letter*, **397**
Quality of life in end-stage chronic obstructive pulmonary disease and lung cancer: a comparative study, **Suppl. 6. A10**
Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease, **67**
Relationship between sleep fragmentation, daytime sleepiness and quality of life in OSA and predictors of improvement in quality of life on nCPAP, **Suppl. 6. A9**
Validity of a visual numerical general quality of life scale and chest scale in adults with cystic fibrosis, **Suppl. 6. A45**
Quantum proteolysis, Quantum proteolysis by neutrophils (PMN): implications for pulmonary emphysema in alpha1-antitrypsin deficiency, **Suppl. 6. A16**
Quartz, Induction of interleukin-8 and tumour necrosis factor alpha expression in lung epithelial cells following exposure to ultrafine particles and quartz, **Suppl. 6. A54**
Questionnaires, Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting, **879**

Radiation-induced neuropathy, Bilateral diaphragmatic weakness: a late complication of radiotherapy, **829**: commentary, **828**
Radiotherapy, Pancoast tumours: clinical assessment and long term results of combined radiosurgical treatment, **284**
Ragweed, Immunotherapy in asthma, **Suppl. 3. S22**
Readmissions, Preventing readmissions to hospital for asthma: *editorial*, **207**
Recombinant DNAse
Guidelines and funding for the use of recombinant DNAse in one regional adult cystic fibrosis unit, **Suppl. 6. A68**
Providing recombinant DNAse according to local guidelines in a regional cystic fibrosis unit, **Suppl. 6. A42**
Rehabilitation
Benefits of a 12-week outpatient rehabilitation programme are independent of the degree of lung dysfunction in patients with COPD, **Suppl. 6. A37**
Effects of a 12-week supervised outpatient rehabilitation programme on physical performance in patients with COPD in the north east of England, **Suppl. 6. A37**
Rejection, Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation, **643**
Renal blood flow, Renal functional reserve in patients with severe chronic obstructive pulmonary disease, **411**
Renal functional reserve, Renal functional reserve in patients with severe chronic obstructive pulmonary disease, **411**
Renin-angiotensin system
Effect of endogenous activation of the renin-angiotensin system by low salt diet on rat airway remodelling, **Suppl. 6. A53**
Is there a local renin-angiotensin system in the lungs? **Suppl. 6. A53**
Reperfusion, Ischaemia reperfusion, inflammatory responses and acute lung injury: *editorial*, **841**
Reproducibility, Sample size estimation in studies monitoring exercise-induced bronchoconstriction in asthmatic children, **739**
Respiratory admissions, Emergency hospital admissions for respiratory disorders attributable to summer time ozone episodes in Great Britain, **958**
Respiratory complications, Prevention of respiratory complications after abdominal surgery, **Suppl. 3. S35**
Respiratory disease
Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK, **612**
Information provision and patients' perceptions in life-threatening respiratory disease, **Suppl. 6. A33**
Respiratory distress syndrome, Liquid ventilation in the preterm neonate, **Suppl. 3. S3**
Respiratory failure
Neuromuscular blockade with acute respiratory failure in a patient receiving cibenzoline, **582**
Physiological effects and optimisation of nasal assist-control ventilation for patients with chronic obstructive pulmonary disease in respiratory failure, **690**
Respiratory health
Air pollution and respiratory health in schoolchildren in East London, **Suppl. 6. A6**
Indoor environment changes and respiratory health, **Suppl. 6. A2**
Respiratory illness, Accident and emergency department - a primary care facility for respiratory illness? **Suppl. 6. A70**
Respiratory nurse specialist, The impact of outreach respiratory nurse specialist service on secondary care in COPD, **Suppl. 6. A76**
Respiratory symptoms
Damp housing, sensitisation to house dust mite and respiratory symptoms, **Suppl. 6. A7**
Domestic gas appliances and lung disease, **Suppl. 3. S58**
Parental smoking and prevalence of respiratory symptoms and asthma in school age children, **1081**
Respiratory symptoms to not predict airways obstruction in an elderly hospital population, **Suppl. 6. A75**
Urinary cotinine concentrations, reported household smoking and respiratory symptoms in inner city primary school children, **Suppl. 6. A41**
Respiratory syncytial virus
Down regulation of human defensin-1 (hBD-1) in respiratory syncytial virus infection, **Suppl. 6. A14**
Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis, **634**
Resting energy expenditure
Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls, **338**
Total daily expenditure relative to resting energy expenditure in clinically stable patients with COPD, **780**
rhDNase
Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis, **Suppl. 2. S89**
Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis, **Suppl. 2. S64**
Rheumatoid arthritis
Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis, **377**

HRCT diagnosed lung disease in patients with rheumatoid arthritis, **Suppl. 6. A64**
Rhinitic non-asthmatic subjects, Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic non-asthmatic subjects, **136**
Rural, Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren, **161**
Rural populations, Low asthma prevalence in rural populations of developing countries – temporal relationship between urbanization and development of asthma, **Suppl. 6. A7**

Salbutamol
Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma, **975**
Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic non-asthmatic subjects, **136**
Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine, **845**
Effects of airway calibre on lung delivery of nebulised salbutamol, **1036**
Efficacy of regular versus as-required nebulised salbutamol in patients admitted to hospital with acute asthma, **Suppl. 6. A1**
Estimates of the dosages of salbutamol sulphate delivered to the respiratory tract from three nebulizers, **Suppl. 6. A82**
Further validation on the use of urinary salbutamol excretion to evaluate the relative bioavailability of salbutamol to the lung following inhalation, **Suppl. 6. A82**
Influence of order of administration on response to nebulised ipratropium bromide and salbutamol, **Suppl. 6. A76**
Local research ethics committees and a randomised controlled trial of regular versus as needed salbutamol in mild to moderate asthma: for the National Asthma Task Force, **Suppl. 6. A59**
Output of salbutamol from nebulisers at different breathing patterns, **Suppl. 6. A82**
Pharmacokinetics and extrapulmonary beta-2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers, **849**
Relative lung bioavailability of salbutamol following administration by metered dose inhaler and nebuliser, **Suppl. 6. A82**
Salbutamol enantiomers: early clinical evidence in humans: *editorial*, **839**
Thermogenic effect of bronchodilators in patients with chronic obstructive pulmonary disease, **130**: *letter*, **751**
Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects, **458**
Salford, Histological confirmation rate of lung cancer in Salford in 1994, **Suppl. 6. A32**
Saline
Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients, **Suppl. 6. A43**
Induction of sputum in cystic fibrosis by inhaled hypertonic saline, **Suppl. 6. A43**
Underwater photography in the human airway. The use of saline to visualise peripheral tumours and evaluate airway rigidity, **Suppl. 6. A65**
Salmeterol
Bambuterol versus salmeterol in asthma patients with nocturnal symptoms, **Suppl. 6. A58**
Beta-2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol: *letter*, **305**
Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma, **975**
Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK, **612**
Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects, **458**
Sarcoidosis
Analysis of T cell subsets and β chemokines in patients with pulmonary sarcoidosis, **431**
BTS sarcoidosis study: *letter*, **102**
Comparison of delayed hyper-sensitivity in adult cystic fibrosis with sarcoidosis and HIV infected patients, **Suppl. 6. A85**
Diffuse lung disease: product of genetic susceptibility and environmental encounters, **92**
Expression of Fas and its ligand by alveolar T-lymphocytes in pulmonary sarcoidosis, **Suppl. 6. A21**
Genetic predisposition to sarcoidosis: MHC and non-MHC polymorphisms, **Suppl. 6. A21**
Mycobacteria and sarcoidosis, **Suppl. 3. S47**
Pleural sarcoidosis: a rare presentation, **200**: commentary, **198**: *letter*, **752**
Release of prostaglandin E_2 and leukotriene B_4 by alveolar macrophages from patients with sarcoidosis, **76**
Risk of malignant neoplasms in patients with pulmonary sarcoidosis, **892**
Sarcoidosis and primary biliary cirrhosis with co-existing myositis, **201**: commentary, **198**
TNF-alpha and lymphotoxin-alpha polymorphisms in sarcoidosis - no association, **Suppl. 6. A64**
Sauropus androgynus, Bronchiolitis obliterans following the ingestion of an Asian shrub leaf, **Suppl. 3. S68**
SB 205312
Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D_4 challenge in normal volunteers, **519**
Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma, **523**
Schoolchildren
Air pollution and respiratory health in schoolchildren in East London, **Suppl. 6. A6**
British guidelines on asthma management. 1995 review and position statement, **Suppl. 1. S1–21**: *letters*, **665**, **932**
Science, The science of nebulised drug delivery, **Suppl. 2. S31**
Scientific Meeting, 1996 Scientific Meeting of the British Thoracic Society: Conference report, **109**
Scleroderma (systemic sclerosis)
Clearance of inhaled 99mTc-DTPA as a clinical index of pure pulmonary vascular disease in systemic sclerosis, **Suppl. 6. A63**
Connective tissue growth factor in scleroderma-associated fibrotic lung disease, **Suppl. 6. A20**
Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomographic scans, **265**
Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension, **1051**
Diffuse lung disease: product of genetic susceptibility and environmental encounters, **92**
Fibronectin gene polymorphisms and scleroderma lung fibrosis, **Suppl. 6. A21**
Genetic predisposition to scleroderma, **Suppl. 6. A64**
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease, **Suppl. 6. A20**
Scoliosis, Inspiratory muscle endurance in adults with mild-to-moderate idiopathic scoliosis, **Suppl. 6. A79**
Scottish National Sleep Centre, Patterns of continuous positive airways pressure use at the Scottish National Sleep Centre, **Suppl. 6. A9**
Seasonal distribution, Seasonal distribution of episodes of acute severe asthma in adults, **Suppl. 6. A7**
Seasonality, Seasonality of tuberculosis: *letter*, **398**
Secondary pulmonary hypertension, Making measurements in the pulmonary circulation: when and how? *editorial*, **9**
Self-management, Impact of a nurse-led home management training programme in children admitted to hospital with acute asthma: a randomised controlled study, **223**
Sepsis, Surfactant medication for acute respiratory distress syndrome, **Suppl. 3. S9**
Serotonin
Enhanced pulmonary vasoreactivity to serotonin in the fawn hooded rat, **Suppl. 6. A60**
The pulmonary hypertensive fawn-hooded rat has a normal serotonin transporter coding sequence, **Suppl. 6. A61**
Serpinase activity, Neutrophil collagenase (MMP-8) does not exert serpinase activity against secretory leucocyte proteinase inhibitor or elafin, **Suppl. 6. A17**
Severe community acquired pneumonia, Impact of management guidelines on the outcome of severe community acquired pneumonia, **17**
Sexual matters, Confidential study of awareness of infertility and sexual matters in males with cystic fibrosis, **Suppl. 6. A44**
Short wave diathermy, Short wave diathermy for small spontaneous pneumothorax, **561**
Shortness of breath, Chronic bronchitis, shortness of breath and airways obstruction by occupation in New Zealand, **Suppl. 6. A40**
Silica exposure, Silica exposure and risk of cancer: *letter*, **203**
Silicosis, Lung cancer in relation to exposure to silica dust, silicosis and uranium production in South African gold miners, **271**
Simian virus 40 large T antigen, Asbestos, Simian virus 40 and malignant mesothelioma, **Suppl. 3. S52**

Skin-prick testing, Inactivation of Der p1 demonstrated by skin-prick testing, **Suppl. 6. A39**
Sleep, Effect of nocturnal supplemental oxygen on sleep quality and daytime cognitive function in chronic heart failure, **Suppl. 6. A12**
Sleep apnoea/hypopnoea syndrome
Audit of sleep apnoea in Heartlands Hospital, **Suppl. 6. A8**
Effect of CPAP therapy on daytime function in patients with mild sleep apnoea/hypopnoea syndrome, **114**
Use of home sleep studies for diagnosis of the sleep apnoea/hypopnoea syndrome, **1068**
see also Obstructive sleep apnoea
Sleep disordered breathing, Laser assisted uvulopalatoplasty in sleep disordered breathing: *editorial*, **5**
Sleep fragmentation, The relationship between sleep fragmentation, daytime sleepiness and quality of life in OSA and predictors of improvement in quality of life on nCPAP, **Suppl. 6. A9**
Small cell lung cancer
Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls, **338**
Survival in small cell lung cancer treated by chemotherapy alone using an inexpensive four drug combination, **Suppl. 6. A26**
Systemic oxidative stress in patients with small cell lung cancer, **Suppl. 6. A27**
Smoking
Chronic bronchitis in textile workers, **22**
Cryptogenic fibrosing alveolitis with preserved lung volumes, **998**
Decline of FEV_1 by age and smoking status: facts, figures, and fallacies, **820**
Expired air carbon monoxide levels and smoking histories in patients newly referred to general and occupational chest clinics, **Suppl. 6. A72**
Health effects of passive smoking: introduction, **904**
Lung cancer risk of long term ex-smokers is much less than that of smokers but much higher than that of non-smokers, **Suppl. 6. A31**
Lung function and survival in subjects with alpha-1-antitrypsin deficiency PiZZ who have never smoked, **Suppl. 6. A49**
Maternal smoking and infant health: reduced antioxidant intake and/or increased oxidant stress? **Suppl. 6. A24**
Parental smoking and lower respiratory illness in infancy and early childhood, **905**
Parental smoking and prevalence of respiratory symptoms and asthma in school age children, **1081**
Passive smoking and sudden infant death syndrome: review of the epidemiological evidence, **1003**
Should we advise parents of asthmatic children to stop smoking to protect their child's health? **Suppl. 6. A41**
Smoking and bronchial responsiveness in non-atopic and atopic young adults, **235**
Tobacco: the epidemic we could all avoid: *editorial*, **1021**
Urinary cotinine concentrations, reported household smoking and respiratory symptoms in inner city primary school children, **Suppl. 6. A41**
What determines levels of passive smoking in children with asthma?, **766**
Smoking cessation counsellor, Smoking cessation counsellor - benefit and cost, **Suppl. 6. A77**
Smooth muscle cells
Bradykinin induces IL-8 production via the activation of β2 receptors in human airway smooth muscle cells: role of cyclooxygenase metabolites, **Suppl. 6. A51**
Co-induction of iNOS and COX-2 in PA smooth muscle cells: a comparison between rat and human, **Suppl. 6. A61**
Differential regulation on short- and long-term PGE_2 release by bradykinin in human airway smooth muscle cells: involvement of β2 receptor-related cyclooxygenase-2 induction, **Suppl. 6. A51**
Effect of endothelin on protein synthesis in smooth muscle cells from rat pulmonary microvasculature, **Suppl. 6. A62**
Homologous desensitisation of soluble and particulate guanylyl cyclases in cultured human airway smooth muscle, **Suppl. 6. A52**
Localisation of angiotensin II receptor subtypes in human pulmonary artery and AT1 mediated smooth muscle cell growth responses in vitro, **Suppl. 6. A62**
Protease inhibitors modulate human airway smooth muscle cell proliferation in culture, **Suppl. 6. A52**
Role of cyclooxygenase-2 induction in IL-1β induced desensitisation of human airway smooth muscle cell responses to isoprenaline, **Suppl. 6. A51**
Sniff nasal pressure, Inspiratory muscle strength in acute asthma measured by sniff nasal pressure, **Suppl. 6. A80**
Snoring, Prospective audit of the investigation and treatment of snoring and obstructive sleep apnoea in the Nottingham health district, **Suppl. 6. A8**
South Glamorgan, Reaudit of tuberculosis contact tracing in South Glamorgan: 1992–1994, **Suppl. 6. A35**
Spacer devices, Inhalation drug delivery from seven different spacer devices: *letter*, **585**
Spiral volumetric CT scanning, Spiral volumetric CT scanning: *letter*, **203**
Spirometry
Auto-correlation limits the precision of estimates of annual decline in FEV_1 based on patient administered serial spirometry, **Suppl. 6. A49**
General practice spirometry in North Staffordshire, **Suppl. 6. A74**
Respiratory symptoms to not predict airways obstruction in an elderly hospital population, **Suppl. 6. A75**
Spontaneous pneumothorax
Short wave diathermy for small spontaneous pneumothorax, **561**
Spontaneous pneumothorax in a patient with an azygos lobe, **579**: commentary, **575**
Video-assisted thoracoscopic surgery (VATS) in the management of spontaneous pneumothorax: *editorial*, **307**: *letters*, **836**
Sports, Association between type of training and risk of asthma in elite athletes, **157**
Spray force, Spray force and temperature of CFC and HFA-134a propellant aerosol MDIs, **Suppl. 6. A81**
Sputum
Between observer repeatability of sputum differential cell counts, influence of cell viability and squamous cell contamination, **Suppl. 6. A14**
Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid, **372**
Comparison of cell viability and counts in spontaneous and induced sputum in patients with COPD, **Suppl. 6. A14**
Comparison of the use of sputum cytology by respiratory physicians and other clinicians, **Suppl. 6. A32**
Effects of inhaled histamine, methacholine and capsaicin on sputum levels of alpha-2-macroglobulin, **964**
Effects of inhaled lipopolysaccharide on neutrophil numbers in induced sputum in normal and asthmatic subjects, **Suppl. 6. A15**
Endothelin-1 levels in induced sputum samples from asthmatic and normal subjects, **625**
Induced sputum to assess airway inflammation in asthma. Validity and repeatability of sputum differential cell counts, **Suppl. 6. A14**
Markers of inflammation in induced sputum in acute bronchitis caused by *Chlamydia pneumoniae*, **929**: commentary, **926**
Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis, **176**
Safety of sputum induction in patients with COPD, **Suppl. 6. A15**
Sputum differential cell counts: *letter*, **494**
Sputum induction to assess bronchial inflammation in patients with homozygous alpha-1-antitrypsin deficiency, **Suppl. 6. A48**
Success rate and safety of sputum induction using hypertonic saline, **Suppl. 6. A15**
Use of induced sputum to investigate airway inflammation: *editorial*, **498**: *letter*, **1018**
Sputum cells, Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic non-asthmatic subjects, **136**
Squamous cell contamination, Between observer repeatability of sputum differential cell counts, influence of cell viability and squamous cell contamination, **Suppl. 6. A14**
Staff education, Staff education, nebuliser treatment, **Suppl. 2. S102**
Standardised residuals, Comparison of standardised residuals and percent predicted in delineating normal from abnormal lung function test results, **Suppl. 6. A71**
Stents, Gianturco stents in the tracheobronchial tree: *letter*, **400**
Sternocostoclavicular hyperostosis, Sternocostoclavicular hyperostosis: *letter*, **305**
Steroids
Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma, **853**

Effect of the asthma management guidelines on recruitment to a RCT of early introduction of inhaled steroids in asthma, **Suppl. 6. A18**

Effect of inhaled glucocorticoids on IL-1β and IL-1 receptor antagonist (IL-1ra) expression in asthmatic bronchial epithelium, **407**

Streptococcus pneumoniae, A model of human alveolar macrophage interactions with *Streptococcus pneumoniae*, **Suppl. 6. A13**

Streptokinase

Intrapleural streptokinase: the answer to community acquired pleural infection? *editorial*, **403**

Intrapleural streptokinase in the drainage of malignant multiloculated pleural effusions, **Suppl. 6. A67**

Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection, **416**: *letters*, **932**, **1099**

Subepithelial blood vessels, The increase in subepithelial blood vessels in asthmatic airways may have relevance to BHR and may be steroid responsive, **Suppl. 6. A50**

Submicronic particles, A system for the generation and head-only delivery of submicronic particles for the study of the health effects of particulate air pollution, **Suppl. 6. A40**

Substance P, Cough responses to substance P, PGF_2 and low chloride in idiopathic persistent cough, **Suppl. 6. A50**

Sudden infant death syndrome, Passive smoking and sudden infant death syndrome: review of the epidemiological evidence, **1003**

Sulphuric acid, A system for the generation and head-only delivery of submicronic particles for the study of the health effects of particulate air pollution, **Suppl. 6. A40**

Superior vena cava syndrome, Superior vena cava syndrome associated with *Nocardia farcinica* infection, **492**

Superoxide anion, Involvement of an NAD(P)H oxidase-like enzyme in superoxide anion and hydrogen peroxide generation by rat type II cells, **465**

Surfactant, Surfactant medication for acute respiratory distress syndrome, **Suppl. 3. S9**

Surfactant pool size, Lung surfactant in a cystic fibrosis animal model: increased alveolar phospholipid pool size without altered composition and surface tension function in *cftr*m1HGU/m1HGU mice, **723**

Surfactant replacement therapy, Surfactant replacement therapy in ARDS: white knight or noise in the system?, **195**

Surfactant specific protein A, Investigation to determine whether the inflammatory response in ARDS degrades pulmonary surfactant specific protein A *in vivo*, **Suppl. 6. A55**

Surgery, Pancoast tumours: clinical assessment and long term results of combined radiosurgical treatment, **284**

Swine dust, Effect of exposure to swine dust on levels of IL-8 in airway lavage fluid, **638**

Syncytial virus infection, Down regulation of human defensin-1 (hBD-1) in respiratory syncytial virus infection, **Suppl. 6. A14**

Systemic activity, Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects, **458**

T cell subsets, Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha, **33**

T cells

gamma/delta T lymphocytes in *Mycobacterium tuberculosis* infection, **375**

Selective inhibition of T cell proliferation but not expression of effector function by human alveolar macrophages, **786**

Taiwan Bronchiolitis obliterans following the ingestion of an Asian shrub leaf, **Suppl. 3. S68**

Talc pleurodesis, Treatment of complicated spontaneous pneumothorax by simple talc pleurodesis under thoracoscopy and local anaesthesia, **329**: *letters*, **836**

Taurolidine, Taurolidine in adult cystic fibrosis patients colonised with epidemic *Burkholderia cepacia*, **Suppl. 6. A4**

Textile workers, Chronic bronchitis in textile workers, **22**

Theophylline, Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyperresponsiveness in asthmatic patients, **969**

Thin section CT scanning, Effects of airway infection by *Pseudomonas aeruginosa*: a computed tomographic study, **260**

Thiol compounds, The comparative ability of thiol compounds to protect against hydrogen peroxide-induced injury in airway epithelial cells, **Suppl. 6. A56**

Thoracic CT scanning, Measuring the clinical impact of thoracic computed tomographic scanning: *editorial*, **404**

Thoracic nerve roots, Cough simulated by rapid rate magnetic stimulation of the thoracic nerve roots, **Suppl. 6. A80**

Thoracoscopic lung biopsy, Lung function impairment does not follow video assisted thoracoscopic lung biopsy for the diagnosis of interstitial lung disease, **Suppl. 6. A65**

Thorax, Annual Report October 1996 to September 1997: *editorial*, **1023**

Thromboembolism, Thromboembolism related to a Port-a-Cath device in a patient with cystic fibrosis, **98**: commentary, **95**

Thrombosis, Right phrenic nerve palsy as a complication of indwelling central venous catheters, **831**: commentary, **828**

Thunderstorms

Climate and aeroallergen levels in asthma: a 12 month prospective study, **528**

Effect of thunderstorms and airborne grass pollen on the incidence of acute asthma in England, 1990–94, **680**

Thunderstorms: a risk factor for asthma attacks: *editorial*, **669**

Tidal breathing, Diagnosis of airflow obstruction from analysis of tidal breathing, **Suppl. 6. A78**

Tidal breathing expiratory flow, Use of tidal breathing expiratory flow profiles to assess airflow obstruction, **Suppl. 6. A78**

Timed swallow test, Relationships between pulmonary function and the timed swallow test: a study in COPD, **Suppl. 6. A71**

Tobacco, Tobacco: the epidemic we could all avoid: *editorial*, **1021**

Tongue, Effect of body position on tongue posture in awake patients with obstructive sleep apnoea, **255**

Tonicity, Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis, **656**

Total daily energy expenditure, Total daily expenditure relative to resting energy expenditure in clinically stable patients with COPD, **780**

Total energy expenditure, Total energy expenditure in stable patients with cystic fibrosis, **Suppl. 6. A44**

Totally implantable venous access devices, Thromboembolism related to a Port-a-Cath device in a patient with cystic fibrosis, **98**: commentary, **95**

Toxicity, Amiodarone and the lung: wide variations in clinical practice, **Suppl. 6. A74**

Tracheobronchial clearance, Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis, **176**

Tracheobronchial tree, Gianturco stents in the tracheobronchial tree: *letter*, **400**

Training, Association between type of training and risk of asthma in elite athletes, **157**

Transverse myelitis, Transverse myelitis: a reversible complication of bronchial artery embolisation in cystic fibrosis, **99**: commentary, **95**

Treatment

Is asthma treatment affordable in developing countries?, **605**

Treating asthma in developing countries: a problem of inaccessible unavailable essential medication: *editorial*, **589**

Triglycidyl isocyanurate (TGIC), Occupational asthma due to triglycidyl isocyanurate (TGIC), **Suppl. 6. A74**

Tropheryma whippelii, Severe pulmonary hypertension reversed by antibiotics in a patient with Whipple's disease, **1014**: commentary, **1013**

Tru-cut biopsy needle, Comparative trial of Tru-cut biopsy needle vs Abrams punch for pleural biopsy, **Suppl. 6. A66**

Tuberculin anergy, gamma/delta T lymphocytes in *Mycobacterium tuberculosis* infection, **375**

Tuberculin skin tests, Interpreting tuberculin skin tests: the need for background data from the general population, **Suppl. 6. A35**

Tuberculosis

Audit of tuberculosis notification in Liverpool, UK, **Suppl. 6. A35**

Audit of tuberculosis notifications, **Suppl. 6. A36**

Case-control study of lifestyle risk factors for tuberculosis in Liverpool, UK, **Suppl. 6. A34**

Changing pattern of respiratory tuberculosis in the UK in adult patients from the Indian subcontinent, **802**

Contact tracing smear negative and non-pulmonary tuberculosis in a high-incidence area, **Suppl. 6. A34**

Influence of age and gender on the incidence of drug resistance in tuberculosis, **Suppl. 6. A34**

Is new immigrant screening for tuberculosis still worthwhile? **Suppl. 6. A35**

Molecular epidemiology of tuberculosis in inner London, **Suppl. 6. A33**

Reaudit of tuberculosis contact tracing in South Glamorgan: 1992–1994, **Suppl. 6. A35**

Seasonality of tuberculosis: *letter*, **398**

Surgical treatment for pulmonary aspergilloma: a 28 year experience, **810**
Tuberculosis in England and Wales in 1993: results of a national survey, **1060**
Tuberculosis in healthcare workers. A survey of cases in England and Wales, **Suppl. 6. A34**
Tuberculosis in National Health Service hospital staff in the West Midlands region of England, 1992–5, **994**
What are the expectations of patients with TB when visited at home by a specialist TB nurse? **Suppl. 6. A36**
Tuberculous mediastinal lymphadenopathy, Pulmonary artery occlusion by tuberculous mediastinal lymphadenopathy, **301**
Tumour microemboli, Tumour microembolism presenting as "primary pulmonary hypertension", **1016**: commentary, **1013**
Tumour necrosis factor-alpha
Induction of interleukin-8 and tumour necrosis factor expression in lung epithelial cells following exposure to ultrafine particles and quartz, **Suppl. 6. A54**
Relative production of tumour necrosis factor alpha and interleukin 10 in adult respiratory distress syndrome, **442**
TNF-alpha and lymphotoxin-alpha polymorphisms in sarcoidosis – no association, **Suppl. 6. A64**

Ultrafine particles
Induction of interleukin-8 and tumour necrosis factor alpha expression in lung epithelial cells following exposure to ultrafine particles and quartz, **Suppl. 6. A54**
Ultrafine carbon particles: induction of oxidative stress in lung epithelial cells, **Suppl. 6. A55**
Ultrafine particles, lung inflammation and oxidant stress, **Suppl. 6. A30**
Ultrasonography
Diaphragm thickness and inspiratory strength in patients with Duchenne muscular dystrophy, **472**
Transcutaneous abdominal ultrasonography in the staging of lung cancer, **276**
Underwater photography, Underwater photography in the human airway. The use of saline to visualise peripheral tumours and evaluate airway rigidity, **Suppl. 6. A65**
Underwater seal systems, Flutter valve drainage bags are more effective than underwater seal systems in postoperative air leaks, **Suppl. 6. A66**
Unilateral hypertranslucency, Unilateral hypertranslucency of the left hemithorax due to aneurysm of the thoracic aorta, **299**
Upper airway imaging, Natural evolution of moderate sleep apnoea syndrome: significant progression over a mean of 17 months, **872**
Upper respiratory tract, Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breath holding, **540**
Uranium, Lung cancer in relation to exposure to silica dust, silicosis and uranium production in South African gold miners, **271**
Urban, Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren, **161**
US regimen, Comparison of BTS and American treatment regimens for acute asthma presenting to an accident and emergency dept., **Suppl. 6. A1**
Uvulopalatoplasty, Laser assisted uvulopalatoplasty in sleep disordered breathing: *editorial*, **5**

Vascular permeability factor, Does vascular permeability factor play a role in interstitial lung disease? **Suppl. 6. A20**
Vasodilators, Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange, **369**
Vasopressin, Vasopressin and oxytocin release during prolonged environmental hypoxia in the rat, **84**
Ventilation
Gravitational gradient of perfusion persists in the prone position in ventilated normal subjects, **Suppl. 6. A81**
Impact of non-invasive ventilation on nursing workload – Yorkshire Non-invasive Ventilation Trial, **Suppl. 6. A25**
Liquid ventilation in the preterm neonate, **Suppl. 3. S3**
Long term survival after hospital discharge from a progressive care programme for patients failing to wean from invasive ventilation on ICU, **Suppl. 6. A73**
Physiological effects of flow and pressure triggering during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease, **249**
Prevalence of acidosis in patients admitted to hospital with an exacerbation of COPD – implications for non-invasive ventilation, **Suppl. 6. A25**
Provision of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United Kingdom, **Suppl. 6. A68**
Survey of UK children receiving long-term ventilatory support at home, **Suppl. 6. A23**
Survival to discharge from hospital in a progressive care programme for patients failing to wean from ventilation on ICU, **Suppl. 6. A20**
UK survey of the practice of non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease, **Suppl. 6. A25**
Ventilatory mechanics, Changes in ventilatory mechanics and diaphragmatic function after lung volume reduction surgery in patients with COPD, **545**
Video-assisted thoracoscopic lung biopsy, Lung function impairment does not follow video assisted thoracoscopic lung biopsy for the diagnosis of interstitial lung disease, **Suppl. 6. A65**
Video-assisted thoracoscopic surgery, Video-assisted thoracoscopic surgery (VATS) in the management of spontaneous pneumothorax: *editorial*, **307**: *letters*, **836**
Video-assisted thoracoscopy, Treatment of complicated spontaneous pneumothorax by simple talc pleurodesis under thoracoscopy and local anaesthesia, **329**: *letters*, **836**
Virus, Mechanisms of virus induced exacerbations of asthma, **380**
Vital capacity, Effect of arm position on the ability to withstand restriction of vital capacity by an external compressive force, **Suppl. 6. A22**
Vitamin C, Effect of fresh fruit consumption on lung function and wheeze in children, **628**
von Recklinghausen's disease, Spontaneous haemothorax associated with von Recklinghausen's disease: review of occurrence in Japan, **577**: commentary, **575**

Wallstent, Airway Wallstent: *letters*, **664**
Washing, Domestic washing, the effects on the house dust mite, **Suppl. 6. A39**
Weight loss, Controlled trial of hypnotherapy for weight loss in patients with obstructive sleep apnoea, **Suppl. 6. A8**
Weight perception, Sex differences in weight perception in cystic fibrosis, **Suppl. 6. A45**
Wheeze (wheezing)
Effect of fresh fruit consumption on lung function and wheeze in children, **628**
Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood, **946**
Prediction of persistent wheeze in infants, **Suppl. 6. A24**
Wheezing phenotypes in childhood: *editorial*, **936**
Wheezy bronchitis, Outcome for children of parents with atopic asthma and transient childhood wheezy bronchitis, **953**
Whipple's disease, Severe pulmonary hypertension reversed by antibiotics in a patient with Whipple's disease, **1014**: commentary, **1013**
Women
Effect of gender on hospital admissions for asthma and prevalence of self-reported asthma: a prospective study based on a sample of the general population, **287**
Loss of normal cyclical beta-2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients, **608**

Young adults
Domestic gas appliances and lung disease, **Suppl. 3. S58**
Pneumonia deaths in young adults in England and Wales – incidence, pre-existing disease and death certificates, **Suppl. 6. A12**
Risk factors for bronchial responsiveness in young adults, **Suppl. 6. A38**

Zimbabwe, Aspects of atopy among asthmatic patients presenting to a hospital in urban Zimbabwe, **Suppl. 6. A38**